学术周报 · IF≥10

心血管科领域文献阅读汇编

2026年第39周 (2026-09-24) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
收录论文
64
临床研究
38
基础研究
26
IF≥20
23
IF 10-20
41
子领域
23
期刊种类
26
数据日期
2026-09-24

★本周 Top 10 高影响力文献

#论文期刊IF
1Targeting super elongation complex-driven RNA polymerase II elongation reduces plaque vulnerability.Signal transduction and targeted therapyIF 81.2
2Targeting trafficking defects in long QT syndrome type 2: a phase 2 clinical study with patient-spec...European heart journalIF 45.3
3Arrhythmogenic right ventricular cardiomyopathy.European heart journalIF 45.3
4Direct oral anticoagulants vs warfarin in Asian vs non-Asian patients with atrial fibrillation: a pa...European heart journalIF 45.3
5Cardiac resynchronization therapy with or without atrioventricular node ablation in atrial fibrillat...European heart journalIF 45.3
6Ultrasound-guided vs conventional venous puncture for atrial fibrillation ablation: the ULYSSES tria...European heart journalIF 45.3
7Stroke and systemic embolism following atrial fibrillation ablation: the EMBOL-AF Global Registry.European heart journalIF 45.3
8Atrial fibrillation density as a biomarker for ischaemic stroke risk prediction.European heart journalIF 45.3
9Intracranial haemorrhage following tenecteplase fibrinolysis for acute myocardial infarction.European heart journalIF 45.3
10Spatial atlas of the human brain vasculature reveals specialized cell ensembles.CellIF 45.1

Ŧ期刊分布统计

期刊篇数IF
European journal of preventive cardiology11IF 10.0
European heart journal8IF 45.3
Circulation8IF 41.3
Cardiovascular research6IF 12.5
Acta pharmacologica Sinica3IF 10.4
British journal of sports medicine3IF 15.5
Stroke3IF 11.1
Pharmacological research2IF 12.2
Diabetes care2IF 22.6
Redox biology2IF 16.2

1心肌梗死/ACS (12篇)

临床研究 (8篇)

NEJM evidence IF 11.6 2026-9-22 PMID: 42770784
Beta-blockers are a cornerstone of therapy following myocardial infarction. The effect of different β-blockers on the outcomes of patients without heart failure after myocardial infarction is not well-studied. This observational cohort study used administrative data from French National Health Data System. Eligible patients were 18 years of age or older, hospitalized in the Paris area between January 1, 2008, and December 31, 2018, with a new myocardial infarction, and were dispensed either atenolol or bisoprolol within 2 days of hospital discharge. Patients prescribed β-blockers or loop diuretics or with a recorded diagnosis of heart failure (based on International Classification of Diseases, 10th Revision codes) during the 2 years preceding hospital discharge were excluded. Outcomes were followed for up to 2 years following hospital discharge and included major adverse cardiovascular events (cardiac arrest, all-cause mortality, reinfarction, stroke, or hospitalization for heart failure) (primary outcome) and all-cause mortality (secondary outcome). Targeted maximum likelihood estimation was used to estimate the average treatment effects (ATEs) comparing patients initiated on atenolol versus bisoprolol. Among 11,558 patients, 1523 (13.2%) initiated atenolol and 10,035 (86.8%) initiated bisoprolol within 2 days of discharge. Comparing the atenolol group to the bisoprolol group, the ATE was 2.9 percentage points (95% confidence interval [CI], 1.1-4.7) for major adverse cardiovascular events and 0.6 percentage points (95% CI, -0.2 to 1.3) for all-cause mortality. The weighted proportions of patients experiencing major adverse cardiovascular events were 10.8% and 14.1% in the atenolol and bisoprolol groups, respectively. The weighted proportions of patients experiencing all-cause mortality were 1.4% and 2.2% in the atenolol and bisoprolol groups, respectively. Among patients without recorded characteristics in an administrative database suggesting the presence of heart failure, initiation of atenolol after myocardial infarction was associated with a lower risk of major adverse cardiovascular events, but not all-cause mortality, at 2 years compared with bisoprolol. (Funded by PRAIRIE and others.).
中文摘要:β受体阻滞剂是心肌梗死后治疗的基石。不同β受体阻滞剂对心肌梗死后无心力衰竭患者结局的影响尚未得到充分研究。这项观察性队列研究使用了法国国家健康数据系统的行政数据。纳入患者为18岁及以上,在2008年1月1日至2018年12月31日期间于巴黎地区住院,发生新发心肌梗死,并在出院后2天内被配发阿替洛尔或比索洛尔。排除在出院前2年内被处方β受体阻滞剂或袢利尿剂,或根据国际疾病分类第10版编码记录有心力衰竭诊断的患者。出院后随访至2年,结局包括主要不良心血管事件(心脏骤停、全因死亡、再发心肌梗死、卒中或心力衰竭住院)(主要结局)和全因死亡(次要结局)。使用靶向最大似然估计来估计平均治疗效应(ATE),比较启动阿替洛尔与比索洛尔的患者。在11558例患者中,1523例(13.2%)在出院后2天内启动阿替洛尔,10035例(86.8%)启动比索洛尔。比较阿替洛尔组与比索洛尔组,主要不良心血管事件的ATE为2.9个百分点(95%置信区间[CI],1.1-4.7),全因死亡的ATE为0.6个百分点(95% CI,-0.2至1.3)。阿替洛尔组和比索洛尔组发生主要不良心血管事件的加权比例分别为10.8%和14.1%。阿替洛尔组和比索洛尔组发生全因死亡的加权比例分别为1.4%和2.2%。在行政数据库中未记录提示存在心力衰竭特征的患者中,与比索洛尔相比,心肌梗死后启动阿替洛尔与2年时较低的主要不良心血管事件风险相关,但与全因死亡无关。(由PRAIRIE等资助。)
Progress in cardiovascular diseases IF 10.6 2026-9-22 PMID: 42772537
The risk of recurrent cardiovascular events remains high in acute myocardial infarction (AMI) patients even after revascularization. Coronary residual inflammation plays a promoting role in this process. This study aimed to address the clinical impact of pancoronary inflammation at long-term follow-up in AMI patients. Between January 2017 and December 2021, 1312 AMI patients underwent three-vessel optical coherence tomography (OCT) imaging following successful percutaneous coronary intervention. Patients were stratified by the median number (3) of inflammatory plaques (defined as macrophage-containing non-culprit lesions) into low-inflammation (≤3 lesions) and high-inflammation (>3 lesions) groups. The primary endpoint was major adverse cardiovascular events (MACE), defined as a composite of cardiac mortality, non-fatal MI, and unplanned revascularization, assessed over a 5-year follow-up period. The number of inflammatory plaques (i.e. pancoronary inflammation) had a significant correlation with hs-CRP level (i.e. systemic inflammation) (r = 0.109; P < 0.001). OCT features of plaque vulnerability were significantly more common in patients with high pancoronary inflammation level, compared to those with low pancoronary inflammation level. During a median 4.1-year follow-up, non-culprit lesion-related MACEs occurred more frequently in patients with more inflammatory plaques (8.1% versus 3.1% [hazard ratio, 2.71 (95% CI, 1.52-4.84)]), primarily attributable to increased risk of unplanned coronary revascularization. In multivariable models, higher pancoronary inflammation, rather than higher systemic inflammation, was the independent predictor of non-culprit lesion-related MACEs. The high pancoronary inflammation was found to be associated with more vulnerable plaque characteristics and increased risk of long-term adverse cardiovascular events in AMI patients.
中文摘要:急性心肌梗死(AMI)患者即使在血运重建后,复发性心血管事件风险仍然较高。冠状动脉残余炎症在这一过程中起促进作用。本研究旨在探讨AMI患者长期随访中全冠状动脉炎症的临床影响。2017年1月至2021年12月期间,1312例AMI患者在成功经皮冠状动脉介入治疗后接受了三支血管光学相干断层扫描(OCT)成像。根据炎症斑块(定义为含巨噬细胞的非罪犯病变)数量的中位数(3个),患者被分为低炎症组(≤3个病变)和高炎症组(>3个病变)。主要终点为主要不良心血管事件(MACE),定义为心源性死亡、非致死性心肌梗死和非计划血运重建的复合终点,在5年随访期内进行评估。炎症斑块数量(即全冠状动脉炎症)与hs-CRP水平(即全身炎症)显著相关(r=0.109;P<0.001)。与低全冠状动脉炎症水平患者相比,高全冠状动脉炎症水平患者中OCT斑块易损性特征显著更常见。在中位4.1年随访期间,炎症斑块较多的患者中非罪犯病变相关MACE发生更频繁(8.1%对3.1%[风险比,2.71(95%CI,1.52-4.84)]),主要归因于非计划冠状动脉血运重建风险增加。在多变量模型中,较高的全冠状动脉炎症而非较高的全身炎症是非罪犯病变相关MACE的独立预测因素。研究发现,高全冠状动脉炎症与AMI患者更易损的斑块特征及长期不良心血管事件风险增加相关。
Circulation IF 41.3 2026-9-21 PMID: 42766690
Acute coronary syndrome (ACS) remains underrecognized in patients with Kawasaki disease (KD). The population at risk for KD-associated ACS is increasing, yet current ACS guidelines are largely derived from atherosclerotic disease and do not adequately address the distinctive mechanisms, anatomy, and thrombosis risk associated with KD. Because the pathophysiology and management of KD-associated ACS differ in fundamental ways from those of atherosclerotic coronary artery disease, its management requires a coordinated team response, with collaboration between pediatric and adult cardiologists. Recent advances in coronary imaging, interventional techniques, and antithrombotic therapies provide an opportunity to establish a more disease-specific approach. This review synthesizes current evidence on the epidemiology and pathophysiology of coronary artery aneurysms, interventional coronary imaging, acute management, revascularization strategies, antithrombotic therapy, and post-ACS surveillance in patients with KD to guide clinical decision-making and treatment for patients with KD presenting with ACS.
中文摘要:急性冠脉综合征(ACS)在川崎病(KD)患者中仍未被充分认识。KD相关ACS的高危人群正在增加,但当前的ACS指南主要源自动脉粥样硬化性疾病,未能充分涵盖KD相关的独特机制、解剖特征和血栓风险。由于KD相关ACS的病理生理学和管理方式与动脉粥样硬化性冠状动脉疾病存在根本差异,其管理需要协调的团队响应,并需要儿科与成人心脏科医生合作。冠状动脉影像、介入技术和抗血栓治疗的最新进展为建立更具疾病特异性的方法提供了机会。本综述综合了关于KD患者冠状动脉瘤的流行病学和病理生理学、介入性冠状动脉影像、急性期管理、血运重建策略、抗血栓治疗以及ACS后监测的当前证据,以指导KD合并ACS患者的临床决策和治疗。
Circulation IF 41.3 2026-8-25 PMID: 42639679
Current dietary guidelines are largely based on evidence from the general population, and data on dietary patterns and survival after myocardial infarction (MI) remain limited. We evaluated post-MI adherence to multiple healthy dietary patterns, as well as changes in adherence from before to after MI diagnosis, in relation to mortality among MI survivors. We included 3277 women from the Nurses' Health Study and 2618 men from the Health Professionals Follow-Up Study who survived a nonfatal MI. The mean age at MI diagnosis was 68.2 (SD, 10.2) years. Diet was assessed using validated food frequency questionnaires and updated every 2 to 4 years. We calculated post-MI adherence scores for 8 healthy patterns: the Alternate Healthy Eating Index, the Healthy Eating Index-2015, the Alternate Mediterranean Diet Score, the Dietary Approaches to Stop Hypertension, the Healthful Plant-Based Diet Index, the reversed empirical dietary inflammatory pattern, the reversed empirical dietary index for hyperinsulinemia, and the reversed empirical dietary index for insulin resistance. The main outcome was total mortality, with cardiovascular disease mortality and recurrent nonfatal MI as secondary outcomes. During 15.7 years of follow-up after MI, 3858 deaths (65.4%) were documented, including 1639 cardiovascular disease deaths (42.5% of deaths). Comparing the highest with the lowest quintile, higher post-MI dietary scores were consistently associated with lower total mortality, with the hazard ratio of 0.67 (95% CI, 0.60-0.74) for Alternate Healthy Eating Index, 0.73 (95% CI, 0.65-0.81) for Healthy Eating Index-2015, 0.66 (95% CI, 0.59-0.75) for Alternate Mediterranean Diet Score, 0.77 (95% CI, 0.69-0.86) for Dietary Approaches to Stop Hypertension, 0.74 (95% CI, 0.66-0.83) for Healthful Plant-Based Diet Index, 0.77 (95% CI, 0.68-0.86) for reversed empirical dietary inflammatory pattern, 0.73 (95% CI, 0.65-0.83) for reversed empirical dietary index for insulin resistance, and 0.71 (95% CI, 0.64-0.80) for reversed empirical dietary index for hyperinsulinemia. Similar inverse associations were observed for cardiovascular disease mortality and recurrent nonfatal MI. Improved Alternate Healthy Eating Index adherence from before to after MI was associated with lower mortality (hazard ratio, 0.86 [95% CI, 0.76-0.97]), whereas decreased adherence to most patterns was associated with higher mortality. Among individuals who survived MI, adherence to post-MI dietary patterns emphasizing higher diet quality was associated with better long-term survival. These findings support dietary guidance focusing on overall diet quality for the secondary prevention of deaths among MI survivors.
中文摘要:目前的饮食指南主要基于一般人群的证据,而关于饮食模式与心肌梗死(MI)后生存的数据仍然有限。我们评估了心肌梗死后对多种健康饮食模式的依从性,以及从心肌梗死诊断前到诊断后依从性的变化,与心肌梗死幸存者死亡率的关系。我们纳入了护士健康研究中的3277名女性和卫生专业人员随访研究中的2618名男性,这些人均在非致死性心肌梗死后存活。心肌梗死诊断时平均年龄为68.2(标准差,10.2)岁。饮食通过经验证的食物频率问卷评估,并每2至4年更新一次。我们计算了心肌梗死后对8种健康模式的依从性评分:替代健康饮食指数、健康饮食指数-2015、替代地中海饮食评分、控制高血压饮食模式、健康植物性饮食指数、反向经验性膳食炎症模式、反向经验性高胰岛素血症膳食指数和反向经验性胰岛素抵抗膳食指数。主要结局为全因死亡,心血管疾病死亡和复发性非致死性心肌梗死为次要结局。在心肌梗死后15.7年的随访期间,记录了3858例死亡(65.4%),其中1639例为心血管疾病死亡(占死亡的42.5%)。与最低五分位数相比,较高的心肌梗死后饮食评分与较低的全因死亡风险持续相关,替代健康饮食指数的风险比为0.67(95%置信区间,0.60-0.74),健康饮食指数-2015为0.73(95%置信区间,0.65-0.81),替代地中海饮食评分为0.66(95%置信区间,0.59-0.75),控制高血压饮食模式为0.77(95%置信区间,0.69-0.86),健康植物性饮食指数为0.74(95%置信区间,0.66-0.83),反向经验性膳食炎症模式为0.77(95%置信区间,0.68-0.86),反向经验性胰岛素抵抗膳食指数为0.73(95%置信区间,0.65-0.83),反向经验性高胰岛素血症膳食指数为0.71(95%置信区间,0.64-0.80)。心血管疾病死亡和复发性非致死性心肌梗死也观察到类似的负相关。从心肌梗死前到心肌梗死后替代健康饮食指数依从性改善与较低死亡率相关(风险比,0.86[95%置信区间,0.76-0.97]),而对大多数模式依从性下降与较高死亡率相关。在心肌梗死后存活的个体中,遵循强调较高饮食质量的心肌梗死后饮食模式与更好的长期生存相关。这些发现支持饮食指导应关注整体饮食质量,以对心肌梗死幸存者进行死亡二级预防。
Circulation IF 41.3 2026-6-10 PMID: 42267437
Heart rate (HR) is a key prognostic factor after myocardial infarction (MI), but its relevance in the modern reperfusion era is uncertain. We aim to evaluate the association between HR and β-blocker interruption on cardiovascular outcomes. A prespecified secondary analysis of the ABYSS trial (Assessment of Beta-Blocker Interruption 1 Year After an Uncomplicated Myocardial Infarction), including 3698 stable post-MI patients (left ventricular ejection fraction ≥40%) randomized to continue or interrupt β-blockers, was conducted. Patients were grouped by prerandomization HR tertiles: <60 bpm (T1), 60 to <68 (T2), and ≥68 (T3). We examined associations between HR, treatment strategy, and the primary end point (death, MI, stroke, or cardiovascular rehospitalization), major secondary end points, and on-treatment HR. Median age in the study population was 63.5 years (55.9-71.1), and there were 621 women (17.1%). Baseline HR was not associated with the primary end point (22.4% versus 21.8% versus 21.6%; P=0.867). Higher HR was associated with increased risk of death, MI, or stroke (5.5% versus 6.4% versus 9.2%; P<0.001; T3 versus T1 adjusted hazard ratio, 1.55; 95% CI, 1.14-2.12) and death, MI, stroke, or heart failure (6.5% versus 7.1% versus 10.4%; P=0.007; T3 versus T1 adjusted hazard ratio, 1.47; 95% CI, 1.11-1.97). All-cause mortality rose across tertiles (2.9% versus 3.4% versus 5.9%; P=0.004; P trend=0.008). β-Blocker interruption produced a dose-dependent HR increase of ≈10-13 bpm during follow-up. The association between interruption and worse outcomes was consistent across HR tertiles (no significant interaction) and left ventricular ejection fraction categories (40% to 49% and >50%). In stabilized post-MI patients with preserved ejection fraction, higher HR remains associated with adverse cardiovascular events and mortality in the reperfusion era. Interrupting β-blockers substantially increases HR and is consistently linked with worse outcomes irrespective of baseline HR, supporting continuation of β-blocker therapy.
中文摘要:心率是心肌梗死后重要的预后因素,但在现代再灌注时代其相关性尚不明确。我们旨在评估心率与β受体阻滞剂中断对心血管结局的关联。本研究为ABYSS试验(无并发症心肌梗死后1年β受体阻滞剂中断评估)的预设二次分析,纳入3698例病情稳定的梗死后患者(左心室射血分数≥40%),随机分配至继续或中断β受体阻滞剂治疗。患者按随机化前心率三分位分组:<60次/分(T1)、60至<68次/分(T2)和≥68次/分(T3)。我们分析了心率、治疗策略与主要终点(死亡、心肌梗死、卒中或心血管再住院)、主要次要终点以及治疗中心率之间的关联。研究人群的中位年龄为63.5岁(55.9-71.1),女性621例(17.1%)。基线心率与主要终点无关(22.4%对21.8%对21.6%;P=0.867)。较高的心率与死亡、心肌梗死或卒中风险增加相关(5.5%对6.4%对9.2%;P<0.001;T3对T1校正风险比为1.55;95%置信区间1.14-2.12),并与死亡、心肌梗死、卒中或心力衰竭风险增加相关(6.5%对7.1%对10.4%;P=0.007;T3对T1校正风险比为1.47;95%置信区间1.11-1.97)。全因死亡率随三分位升高而增加(2.9%对3.4%对5.9%;P=0.004;趋势P=0.008)。中断β受体阻滞剂在随访期间引起约10-13次/分的剂量依赖性心率升高。中断治疗与不良结局的关联在各心率三分位(无显著交互作用)及左心室射血分数类别(40%至49%和>50%)中均一致。在射血分数保留的病情稳定梗死后患者中,再灌注时代较高的心率仍与不良心血管事件和死亡相关。中断β受体阻滞剂可显著升高心率,且无论基线心率如何均一致地与更差的结局相关,支持继续β受体阻滞剂治疗。
European journal of preventive cardiology IF 10.0 2025-10-27 PMID: 41140073
Unrecognized myocardial infarction (UMI) is associated with an adverse prognosis, but sex-specific differences in outcomes are not fully understood. We included 12 303 participants (57.6% women, mean age 64.8 years) from the Rotterdam Study. Baseline myocardial infarction (MI) status (1990-2008) was determined by electrocardiogram and medical records, categorizing participants as UMI (n = 512), recognized MI (RMI) (n = 669), or no MI (n = 11 122). Outcomes included heart failure (HF), atrial fibrillation (AF), stroke, and all-cause mortality. In women, compared with no MI, UMI was associated with larger risks of HF [hazard ratio (HR) 1.31, 95% confidence interval (CI) 1.01-1.71] and all-cause mortality (HR 1.21, 95% CI 1.05-1.40), but lost significance after adjusting for cardiovascular risk factors. Unrecognized MI was non-significantly associated with a larger risk of stroke (HR 1.27, 95% CI 0.95-1.70), but not AF (HR 0.96, 95% CI 0.70-1.33). Recognized MI in women significantly increased risks of HF (HR 2.58, 95% CI 1.94-3.43), AF (HR 1.62, 95% CI 1.13-2.32), and all-cause mortality (HR 1.81, 95% CI 1.54-2.12), but not stroke (HR 1.41, 95% CI 0.98-2.04). Among men, both UMI and RMI were associated with larger risks of HF (UMI: HR 1.90, 95% CI 1.45-2.48, RMI: HR 2.49, 95% CI 2.09-2.98), AF (UMI: HR 1.91, 95% CI 1.45-2.54, RMI: HR 1.79, 95% CI 1.46-2.19), stroke (UMI: HR 2.06, 95% CI 1.52-2.80, RMI: HR 1.36, 95% CI 1.06-1.76), and all-cause mortality (UMI: HR 1.59, 95% CI 1.36-1.85, RMI: HR 1.63, 95% CI 1.46-1.81). Unrecognized myocardial infarction has a differential impact on the long-term prognosis in women and men, highlighting the need to identify key predictors of adverse outcomes.
中文摘要:未识别心肌梗死(UMI)与不良预后相关,但结局的性别特异性差异尚未完全明了。我们纳入鹿特丹研究中12 303名参与者(57.6%为女性,平均年龄64.8岁)。基线心肌梗死(MI)状态(1990-2008年)通过心电图和医疗记录确定,将参与者分为UMI(n=512)、已识别心肌梗死(RMI)(n=669)或无MI(n=11 122)。结局包括心力衰竭(HF)、心房颤动(AF)、卒中和全因死亡。在女性中,与无MI相比,UMI与更高的HF风险[风险比(HR)1.31,95%置信区间(CI)1.01-1.71]和全因死亡风险(HR 1.21,95% CI 1.05-1.40)相关,但在校正心血管危险因素后失去显著性。未识别心肌梗死与卒中风险升高呈非显著相关(HR 1.27,95% CI 0.95-1.70),但与AF无关(HR 0.96,95% CI 0.70-1.33)。女性中已识别心肌梗死显著增加HF(HR 2.58,95% CI 1.94-3.43)、AF(HR 1.62,95% CI 1.13-2.32)和全因死亡(HR 1.81,95% CI 1.54-2.12)风险,但不增加卒中风险(HR 1.41,95% CI 0.98-2.04)。在男性中,UMI和RMI均与更高的HF(UMI:HR 1.90,95% CI 1.45-2.48;RMI:HR 2.49,95% CI 2.09-2.98)、AF(UMI:HR 1.91,95% CI 1.45-2.54;RMI:HR 1.79,95% CI 1.46-2.19)、卒中(UMI:HR 2.06,95% CI 1.52-2.80;RMI:HR 1.36,95% CI 1.06-1.76)和全因死亡(UMI:HR 1.59,95% CI 1.36-1.85;RMI:HR 1.63,95% CI 1.46-1.81)风险相关。未识别心肌梗死对女性和男性的长期预后具有不同影响,突出需要识别不良结局的关键预测因素。
European journal of preventive cardiology IF 10.0 2025-8-12 PMID: 40794603
The incidence of myocardial infarction with non-obstructive coronary artery disease (MINOCA) is higher in women than in men, but sex influence on prognosis is unclear. The aim of this study was to evaluate overall mortality and different major adverse cardiovascular events (MACE) during hospitalization and at follow-up in men and women with MINOCA. Prospective and retrospective studies reporting on the association between sex and adverse clinical outcomes in MINOCA patients were eligible. In-hospital and at follow-up outcomes in the overall pooled populations and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Fifteen studies, encompassing 42 870 patients [62.0 (3.7) years, 25 172 females (58.7%)], were included. A total of 277 patients died during hospitalization, and 2236 deaths occurred during a mean follow-up of 3.5 (0.9) years. Pooled analyses demonstrated no sex differences in in-hospital mortality (OR: 1.05; 95% CI: 0.82-1.34; I2 = 0%) or all-cause death at follow-up (OR: 0.93; 95% CI: 0.76-1.13; I2 = 54%). In the long term, men had a lower risk of non-fatal stroke (OR: 0.77; 95% CI: 0.60-0.99; I2 = 0%), but no significant sex differences were detected for other MACE. In women, MINOCA had a lower risk of in-hospital mortality than MI due to coronary artery disease (MI-CAD; OR: 0.39; 95% CI: 0.21-0.72; I2 = 70%), while no relevant differences were found in males. Sex does not seem to influence MINOCA prognosis, except for a higher incidence of stroke during follow-up found in women. In females, MINOCA has lower in-hospital mortality than MI-CAD.
中文摘要:非阻塞性冠状动脉疾病心肌梗死(MINOCA)在女性中的发生率高于男性,但性别对预后的影响尚不明确。本研究旨在评估MINOCA男性和女性患者住院期间及随访期间的总死亡率及不同主要不良心血管事件(MACE)。报告MINOCA患者性别与不良临床结局相关性的前瞻性和回顾性研究符合纳入标准。计算总体合并人群的住院和随访结局,以及比值比(OR)和95%置信区间(CI)。共纳入15项研究,涵盖42 870例患者[平均年龄62.0(3.7)岁,女性25 172例(58.7%)]。住院期间共有277例患者死亡,平均随访3.5(0.9)年期间发生2236例死亡。合并分析显示,住院死亡率(OR:1.05;95% CI:0.82-1.34;I2=0%)或随访期间全因死亡(OR:0.93;95% CI:0.76-1.13;I2=54%)均无性别差异。长期来看,男性非致死性卒中风险较低(OR:0.77;95% CI:0.60-0.99;I2=0%),但其他MACE未检测到显著性别差异。在女性中,MINOCA的住院死亡风险低于冠状动脉疾病所致心肌梗死(MI-CAD;OR:0.39;95% CI:0.21-0.72;I2=70%),而男性中未发现相关差异。性别似乎不影响MINOCA预后,但女性随访期间卒中发生率较高。在女性中,MINOCA的住院死亡率低于MI-CAD。
European heart journal IF 45.3 2026-9-21 PMID: 42766418
Intracranial haemorrhage (ICH) is a significant complication of fibrinolytic therapy for ST-elevation myocardial infarction (STEMI). The risk factors for ICH following tenecteplase (TNK) administration were evaluated, and a clinical risk prediction tool was developed. A pooled individual patient data analysis from STEMI patients who received weight-adjusted TNK with a consistent blood pressure exclusion criterion of >180/110 mmHg in six randomized controlled trials (ASSENT-2, ASSENT-3, ASSENT-3 PLUS, ASSENT-4 PCI, STREAM, STREAM-2) was undertaken. Logistic regression was used to model risk factors, and a nomogram was developed for individual risk prediction. Among 15 954 patients, 169 developed ICH. Above a systolic blood pressure (SBP) threshold of 110 mmHg, each 1 mmHg increase conferred a 2% relative increase in ICH risk [adjusted odds ratio (aOR) 1.02, 95% confidence interval (CI) 1.01-1.03; P < .0001]; risk accelerated sharply beyond 160 mmHg. With increasing dose, the likelihood of ICH increased with age, rising from 1% per year (30 mg TNK) to nearly 7% per year with 50 mg. The multivariable model incorporating age, sex, SBP, body weight, and TNK dose with the age-dose interaction demonstrated good discrimination (C index 0.718; 95% CI 0.68-0.76). Female sex conferred a 49% increased ICH risk (aOR 1.49, 95% CI 1.06-2.11; P = .023), and each 5 kg decrease in body weight was associated with 16% increased odds of ICH (aOR 1.16, 95% CI 1.03-1.30; P = .014). Dose reduction of TNK in older patients and SBP optimization before fibrinolytic administration represent modifiable strategies to potentially reduce ICH.
中文摘要:颅内出血(ICH)是ST段抬高型心肌梗死(STEMI)纤溶治疗的重要并发症。评估了替奈普酶(TNK)给药后ICH的危险因素,并开发了临床风险预测工具。对六项随机对照试验(ASSENT-2、ASSENT-3、ASSENT-3 PLUS、ASSENT-4 PCI、STREAM、STREAM-2)中接受体重调整TNK且血压排除标准一致为>180/110 mmHg的STEMI患者进行了汇总个体患者数据分析。采用logistic回归建模危险因素,并开发列线图用于个体风险预测。在15954例患者中,169例发生ICH。在收缩压(SBP)阈值110 mmHg以上,每增加1 mmHg,ICH风险相对增加2%[校正比值比(aOR)1.02,95%置信区间(CI)1.01-1.03;P<.0001];风险在超过160 mmHg后急剧加速。随着剂量增加,ICH的可能性随年龄增长而增加,从30 mg TNK的每年1%上升至50 mg的每年近7%。纳入年龄、性别、SBP、体重和TNK剂量以及年龄-剂量交互作用的多变量模型显示出良好的区分度(C指数0.718;95% CI 0.68-0.76)。女性性别使ICH风险增加49%(aOR 1.49,95% CI 1.06-2.11;P=.023),体重每减少5 kg与ICH比值增加16%相关(aOR 1.16,95% CI 1.03-1.30;P=.014)。对老年患者减少TNK剂量以及在纤溶给药前优化SBP代表了可能减少ICH的可改变策略。

基础研究 (4篇)

Cardiovascular research IF 12.5 2026-9-23 PMID: 42776037
Acute myocardial infarction (AMI) triggers an immune response characterized by a dynamic interplay between the bone marrow (BM) and the ischemic heart. However, the effect of metabolic alterations such as hypertriglyceridemia (HTG) on this inter-organ communication remains unknown. In the present study we have investigated, in a rat model of crossed-BM transplant, the impact of HTG on the BM-heart axis response to AMI under constant metabolic stress. and results: Wistar rats (n = 56) were assigned to two groups: one fed a high-sucrose diet to induce HTG and the other fed a regular chow [normolipemic (NL)-animals]. After three weeks, all combinations of crossed-BM transplants were performed (NL-BM/NL-recipient, NL-BM/HTG-recipient, HTG-BM/NL-recipient and HTG-BM/HTG-recipient) following total body irradiation (9.5 Gy). All animals, except for NL-BM/NL-recipient group, continued on a high-sucrose diet for three weeks. Then, AMI was induced by transient coronary artery ligation and five days later, animals were sacrificed. We determined infarct size, and performed echocardiography, 1H-NMR spectroscopy and multiple molecular and histological analyses. NL-BM/HTG-recipients exhibited smaller infarcts vs the other groups and showed a resolving inflammatory response, lower lipotoxicity, higher ω3 content, increased AMPK activation and S1P-related enzymes, and reparative fibrosis in the healing scar. Although no differences were detected in LVEF post-AMI among all groups, NL-BM/HTG-recipients exhibited improved systolic and diastolic parameters. Circulating triglyceride levels were significantly reduced in NL-BM/HTG-recipients three weeks post-BM transplant, whereas, conversely, they were found to be enhanced in HTG-BM/NL-recipients developing a HTG state. Furthermore, recipients of a HTG-BM showed worsened lipid profile, liver steatosis and inflammation, higher weight gain, leptin levels and lower lipoprotein lipase, AMPK and acetyl-CoA carboxylase activity in the visceral adipose tissue vs NL-BM-recipient animals. Transplantation of healthy BM into HTG animals enhances the capacity to counteract myocardial injury post-AMI and restores metabolic disturbances improving overall recovery.
中文摘要:急性心肌梗死(AMI)触发免疫反应,其特征是骨髓(BM)与缺血心脏之间的动态相互作用。然而,高甘油三酯血症(HTG)等代谢改变对这种器官间通讯的影响仍不清楚。在本研究中,我们在交叉骨髓移植大鼠模型中,研究了在持续代谢应激下HTG对AMI后BM-心脏轴反应的影响。方法及结果:Wistar大鼠(n=56)被分为两组:一组喂食高蔗糖饮食以诱导HTG,另一组喂食常规饲料[正常血脂(NL)动物]。三周后,在全身照射(9.5 Gy)后进行了所有组合的交叉BM移植(NL-BM/NL受体、NL-BM/HTG受体、HTG-BM/NL受体和HTG-BM/HTG受体)。除NL-BM/NL受体组外,所有动物继续高蔗糖饮食三周。然后,通过短暂冠状动脉结扎诱导AMI,五天后处死动物。我们测定了梗死面积,并进行了超声心动图、1H-NMR波谱以及多项分子和组织学分析。NL-BM/HTG受体相较于其他组表现出更小的梗死面积,并显示炎症反应消退、脂毒性降低、ω3含量升高、AMPK激活增加和S1P相关酶增加,以及愈合瘢痕中的修复性纤维化。尽管AMI后各组左心室射血分数(LVEF)未检测到差异,但NL-BM/HTG受体的收缩和舒张参数改善。BM移植后三周,NL-BM/HTG受体循环甘油三酯水平显著降低,相反,HTG-BM/NL受体中甘油三酯水平升高,形成HTG状态。此外,与NL-BM受体动物相比,HTG-BM受体的脂质谱恶化、肝脏脂肪变性和炎症、体重增加更多、瘦素水平更高,并且内脏脂肪组织中脂蛋白脂肪酶、AMPK和乙酰辅酶A羧化酶活性更低。将健康BM移植到HTG动物中可增强其对抗AMI后心肌损伤的能力,并恢复代谢紊乱,从而改善整体恢复。
Nature cardiovascular research IF 12.6 2026-9-23 PMID: 42773285
Myocardial infarction causes persistent mitochondrial and metabolic dysfunction that drives adverse cardiac remodeling. Here we develop NAD+-genipin nanomedicine for metabolic balance (NGB), a physiologically adaptive nanomedicine with staged intracellular release. In a mouse myocardial infarction model, NGB preferentially accumulates in ischemic myocardium, rapidly replenishes nicotinamide adenine dinucleotide (NAD+) and subsequently provides mitochondria-associated sustained NAD+-genipin exposure. This phase-linked delivery limits early mitochondrial stress, apoptosis and inflammation and later restores coordination between oxidative phosphorylation, glycolysis and fatty-acid utilization. Mechanistically, NGB supports sirtuin-1-associated oxidative metabolism and suppresses sustained upregulation of the mitochondrial uncoupling protein 2 (UCP2). In hypoxic cardiomyocytes, UCP2 knockdown plus NAD+ supplementation partially reproduces the NGB metabolic phenotype, whereas UCP2 overexpression and sirtuin 1 inhibition reverse distinct components of NGB-mediated respiratory and glycolytic recovery. NGB thereby reduces fibrosis and ventricular remodeling and preserves cardiac function, supporting temporally coordinated metabolic intervention after myocardial infarction.
中文摘要:心肌梗死会导致持续性的线粒体和代谢功能障碍,进而驱动不良心脏重构。在此,我们开发了用于代谢平衡的NAD+-京尼平纳米药物(NGB),这是一种具有阶段性细胞内释放特征的生理适应性纳米药物。在小鼠心肌梗死模型中,NGB优先蓄积于缺血心肌,快速补充烟酰胺腺嘌呤二核苷酸(NAD+),随后提供与线粒体相关的持续NAD+-京尼平暴露。这种与阶段相关的递送限制了早期线粒体应激、凋亡和炎症,并在后期恢复氧化磷酸化、糖酵解与脂肪酸利用之间的协调。机制上,NGB支持sirtuin-1相关的氧化代谢,并抑制线粒体解偶联蛋白2(UCP2)的持续性上调。在缺氧心肌细胞中,敲低UCP2联合补充NAD+可部分重现NGB的代谢表型,而UCP2过表达和sirtuin 1抑制则逆转NGB介导的呼吸和糖酵解恢复的不同组分。因此,NGB可减少纤维化和心室重构并保留心脏功能,支持心肌梗死后时间协调的代谢干预。
Circulation IF 41.3 2026-8-11 PMID: 42576811
Cardiomyocytes exhibit marked susceptibility to ferroptosis after myocardial infarction (MI), rendering ferroptosis inhibition a promising therapeutic strategy to mitigate ischemic myocardial injury. Although mitochondrial dysfunction is recognized as a core driver of ferroptosis, the potential role of mitochondrial DNA transcription in regulating cardiomyocyte ferroptosis remains unexplored. To clarify the temporal role of the various modes of cell death in MI progression, we performed time-course echocardiography in MI models treated with various cell death inhibitors. To characterize the crucial process and molecular regulator in cardiomyocyte ferroptosis, we integrated RNA sequencing and single-nucleus RNA sequencing data from murine post-MI hearts and performed functional rescue experiments using mitochondrial protective agents. To determine the role of ABHD11 (αβ-hydrolase domain-containing protein 11) in cardiomyocyte ferroptosis and cardiac repair after MI, we used loss- and gain-of-function approaches. To elucidate the underlying mechanisms, we conducted transcriptomics, nontargeted lipidomics, site-specific mutagenesis, molecular docking, coimmunoprecipitation, native gel electrophoresis, proximity ligation assay, methylation-specific polymerase chain reaction, and chromatin immunoprecipitation assay. We found that cardiac ferroptosis peaked at day 7 after MI and was enriched in peri-infarct cardiomyocytes. Mitochondrial dysfunction was a key driver of cardiomyocyte ferroptosis after MI, and the lipid enzyme ABHD11 was identified as a potential regulator of both processes. ABHD11 expression was consistently reduced in mouse and human MI hearts, and its transcription was repressed by DNMT1 (DNA methyltransferase 1)-mediated promoter hypermethylation. Functionally, cardiac-specific overexpression of ABHD11 markedly alleviated cardiomyocyte ferroptosis and improved cardiac function after MI. Conversely, loss of ABHD11 in adult mice exacerbated pathological cardiac remodeling and heart failure. Mechanistically, independent of its canonical enzymatic activities, ABHD11 acted as a mitochondrial DNA transcription coactivator by enhancing the TEFM (mitochondrial transcription elongation factor)-POLRMT (mitochondrial RNA polymerase) interaction. This promoted mitochondrial DNA transcription, restored mitochondrial function, and reduced reactive oxygen species/PUFA-PLs (polyunsaturated fatty acid-containing glycerophospholipids)-driven lipid peroxidation and 4-hydroxynonenal generation. The reduction in 4-hydroxynonenal stabilized YY1 (Yin Yang 1), which subsequently regulated key ferroptosis-driving genes governing iron deposition, reactive oxygen species production, and polyunsaturated fatty acid lipids accumulation, further inhibiting lipid peroxidation and ferroptosis, and ultimately promoting cardiac recovery after MI. This study revealed that ABHD11-mediated mitochondrial DNA transcription attenuated cardiomyocyte ferroptosis after MI by orchestrating a mitochondrial-nuclear crosstalk, offering a novel therapeutic strategy for ischemic myocardial injury.
中文摘要:心肌梗死后心肌细胞对铁死亡表现出显著易感性,因此抑制铁死亡是减轻缺血性心肌损伤的一种有前景的治疗策略。尽管线粒体功能障碍被认为是铁死亡的核心驱动因素,但线粒体DNA转录在调控心肌细胞铁死亡中的潜在作用尚未被探索。为阐明不同类型细胞死亡在心肌梗死进展中的时间性作用,我们在接受多种细胞死亡抑制剂治疗的心肌梗死模型中进行了时序超声心动图检查。为刻画心肌细胞铁死亡中的关键过程与分子调控因子,我们整合了小鼠梗死后心脏的RNA测序与单核RNA测序数据,并使用线粒体保护剂进行了功能挽救实验。为确定ABHD11在心肌梗死后心肌细胞铁死亡与心脏修复中的作用,我们采用了功能缺失与功能获得方法。为阐明潜在机制,我们进行了转录组学、非靶向脂质组学、位点特异性突变、分子对接、共免疫沉淀、天然凝胶电泳、邻近连接试验、甲基化特异性聚合酶链反应和染色质免疫沉淀试验。我们发现,心脏铁死亡在心肌梗死后第7天达到峰值,并富集于梗死周边区心肌细胞。线粒体功能障碍是心肌梗死后心肌细胞铁死亡的关键驱动因素,而脂质酶ABHD11被鉴定为这两个过程的潜在调控因子。ABHD11表达在小鼠和人心肌梗死心脏中持续降低,其转录受到DNMT1介导的启动子高甲基化抑制。在功能上,心脏特异性过表达ABHD11可显著减轻心肌细胞铁死亡并改善心肌梗死后心功能。相反,成年小鼠中ABHD11缺失会加重病理性心脏重构和心力衰竭。在机制上,ABHD11不依赖其经典酶活性,而是通过增强TEFM与POLRMT相互作用而作为线粒体DNA转录共激活因子。这促进了线粒体DNA转录,恢复了线粒体功能,并减少了活性氧/含多不饱和脂肪酸甘油磷脂驱动的脂质过氧化和4-羟基壬烯醛生成。4-羟基壬烯醛减少可稳定YY1,随后调控控制铁沉积、活性氧产生和多不饱和脂肪酸脂质积累的关键铁死亡驱动基因,进一步抑制脂质过氧化和铁死亡,最终促进心肌梗死后心脏恢复。该研究揭示,ABHD11介导的线粒体DNA转录通过协调线粒体-细胞核串扰减轻心肌梗死后心肌细胞铁死亡,为缺血性心肌损伤提供了新的治疗策略。
Cardiovascular research IF 12.5 2026-9-18 PMID: 42755716
Adult cardiomyocytes (CMs) have minimal proliferative capacity, limiting the heart's ability to regenerate after injury. While neonatal CMs can proliferate, the signaling pathways governing this process are poorly understood. This study aims to identify and reintroduce the neonatal-specific CM proliferation sensitizing signal to restore cell-cycle in adult CMs. We identified CD36 as a marker for the neonatal spontaneously proliferating CMs. Bulk and Single cell RNAseq, and spatial transcriptomics analyses of the P1 WT, CD36KO and CD36CKO hearts revealed that a CD36/FABP5/PPARδ signaling axis was uniquely expressed in spontaneously proliferating CMs. Using unbiased metabolomics and spatial metabolomics, we discovered that CD36KO and CD36cKO hearts had a 50% reduction in retinoic acid (RA) levels, implicating CD36 in regulating RA intracellular levels. Moreover, the pro-proliferative effect of RA treatment was lost in CD36KO or FABP5 knockdown CMs. To confirm the causality of this proposed mechanism, in vivo, crossing CD36KO with CM-specific PPARδ overexpression (PPARδCTG) only in CMs rescued the proliferation deficiency phenotype in CD36KO in the P1 hearts. Finally, reintroduction of FABP5, the rate limiting step of this signaling pathway, in adult hearts, using an inducible CM-specific FABP5 knock-in mouse (FABP5KI) was sufficient to drive CM cell cycle entry and led to significantly improved cardiac function following myocardial infarction in adult mice. RA/CD36/FABP5/PPARδ signaling pathway is essential for spontaneous neonatal CM proliferation. Re-activating this pathway in adult hearts through FABP5 overexpression is sufficient to induce functional recovery after ischemic injury, identifying FABP5 as a potential therapeutic target for cardiac regeneration.
中文摘要:成年心肌细胞(CMs)的增殖能力极低,限制了心脏在损伤后的再生能力。尽管新生期CMs能够增殖,但调控这一过程的信号通路尚不清楚。本研究旨在鉴定并重新引入新生期特异性的CM增殖致敏信号,以恢复成年CMs的细胞周期。我们将CD36鉴定为新生期自发增殖CMs的标志物。对P1野生型、CD36KO和CD36CKO心脏的bulk和单细胞RNA测序以及空间转录组学分析显示,CD36/FABP5/PPARδ信号轴在自发增殖的CMs中独特表达。利用无偏代谢组学和空间代谢组学,我们发现CD36KO和CD36CKO心脏中视黄酸(RA)水平降低了50%,提示CD36参与调控RA的细胞内水平。此外,RA治疗的促增殖效应在CD36KO或FABP5敲低的CMs中消失。为在体内证实该机制的因果关系,将CD36KO与仅在CMs中过表达PPARδ(PPARδCTG)的小鼠杂交,可挽救P1心脏中CD36KO的增殖缺陷表型。最后,利用诱导型CM特异性FABP5敲入小鼠(FABP5KI),在成年心脏中重新引入FABP5——该信号通路的限速步骤——足以驱动CM细胞周期进入,并在成年小鼠心肌梗死后显著改善心脏功能。RA/CD36/FABP5/PPARδ信号通路对新生期CM自发增殖至关重要。通过FABP5过表达在成年心脏中重新激活该通路,足以诱导缺血性损伤后的功能恢复,从而将FABP5确定为心脏再生的潜在治疗靶点。

2脑卒中/脑血管病 (7篇)

临床研究 (3篇)

JAMA neurology IF 23.6 2026-9-21 PMID: 42766300
The Head Impulse, Nystagmus, Test of Skew (HINTS) examination is a widely recognized bedside tool for distinguishing peripheral vestibular disorders from central causes, such as stroke, in patients presenting with acute vestibular syndrome. However, despite its introduction in 2009, confusion persists regarding its proper application. Misuse of the HINTS examination, particularly when applied to inappropriate patient populations, may lead to misdiagnosis, unnecessary imaging, or missed strokes. This review aims to clarify the appropriate use of the HINTS examination and to address misconceptions that contribute to diagnostic errors in emergency and clinical practice. HINTS is most effective when performed for patients with continuous dizziness and spontaneous nystagmus at rest. However, various guidelines and educational resources have failed to clearly define these criteria, leading to widespread misapplication of the test. Common errors include using HINTS for patients without nystagmus, failing to screen for central features before performing the examination, and misinterpreting test components. Studies show that the HINTS examination, when applied correctly, has high sensitivity for detecting stroke, but its diagnostic accuracy declines significantly when used for inappropriate patients. Furthermore, recent guidelines, such as the third Guidelines for Reasonable and Appropriate Care in the Emergency Department (GRACE-3), may have introduced ambiguities that may contribute to ongoing confusion in clinical practice. To optimize the diagnostic utility of the HINTS examination and reduce stroke misdiagnosis, clinicians should first screen for central features before applying HINTS and ensure it is only performed for patients with nystagmus at rest. Future guidelines should provide clearer recommendations to prevent inappropriate HINTS use and thus avoid inaccurate results. Emphasizing the correct application of HINTS in the right patient population will enhance its reliability as a critical tool for emergency physicians in distinguishing central from peripheral causes of dizziness, ultimately improving patient outcomes and reducing unnecessary investigations.
中文摘要:头脉冲-眼震-偏斜试验(HINTS)是广泛认可的床旁工具,用于在表现为急性前庭综合征的患者中区分周围性前庭疾病与中枢性病因,如卒中。然而,尽管该检查于2009年提出,关于其正确应用仍存在困惑。HINTS检查的误用,尤其是用于不合适的患者人群时,可能导致误诊、不必要的影像检查或漏诊卒中。本综述旨在阐明HINTS检查的恰当使用,并澄清导致急诊和临床实践中诊断错误的误解。HINTS在用于存在持续性头晕且静息时有自发性眼震的患者时最为有效。然而,各种指南和教育资源未能清晰界定这些标准,导致该检查被广泛误用。常见错误包括对无眼震患者使用HINTS、在实施检查前未筛查中枢性特征,以及误读检查组成部分。研究表明,正确应用时,HINTS检查对检测卒中具有高敏感性,但用于不合适患者时其诊断准确性显著下降。此外,近期指南,如《急诊科合理和适当照护指南第三版》(GRACE-3),可能引入了模糊之处,从而导致临床实践中持续存在困惑。为优化HINTS检查的诊断效用并减少卒中误诊,临床医生应先筛查中枢性特征,再应用HINTS,并确保仅对静息时有眼震的患者实施该检查。未来指南应提供更明确的推荐意见,以防止不恰当地使用HINTS,从而避免不准确的结果。强调在正确患者人群中正确应用HINTS,将增强其作为急诊医生区分头晕中枢性与周围性病因的关键工具的可靠性,最终改善患者结局并减少不必要的检查。
Stroke IF 11.1 2026-9-17 PMID: 42751787
Artificial intelligence is increasingly integrated into acute stroke management, demonstrating strong performance in tasks such as large vessel occlusion detection, Alberta Stroke Program Early Computed Tomography Score scoring, and functional outcome prediction. However, concerns persist regarding both the black-box nature of these models and algorithmic bias that may exacerbate disparities in stroke incidence, treatment, and outcomes across racial and socioeconomic subgroups. This review synthesizes the current literature on explainable artificial intelligence and fairness in artificial intelligence applications for acute stroke management, identifies persistent challenges, and outlines recommendations for the development of equitable and trustworthy systems in stroke care. Recent studies have increasingly adopted post hoc explainability methods, though these are limited by approximation and misleading interpretations, especially since explanations are rarely formally tested. Explainability and fairness remain largely disconnected, with fairness evaluation remaining uncommon due to limited demographic metadata, regulatory constraints, and the absence of stroke-specific fairness criteria. Generalizability also remains a concern due to suboptimal data set partitioning strategies and inadequate reporting practices. Responsible artificial intelligence for acute stroke management requires unified evaluation frameworks that jointly assess explainability, fairness, and generalizability.
中文摘要:人工智能正日益整合到急性卒中管理中,在大血管闭塞检测、阿尔伯塔卒中项目早期CT评分以及功能结局预测等任务中表现出色。然而,人们对这些模型的黑箱性质以及算法偏倚的担忧持续存在,后者可能加剧不同种族和社会经济亚组在卒中发病率、治疗和结局方面的差异。本综述综合了当前关于可解释人工智能和人工智能应用公平性在急性卒中管理中的文献,识别了持续存在的挑战,并概述了在卒中照护中开发公平且可信系统的建议。近期研究越来越多地采用事后可解释性方法,但这些方法受限于近似性和误导性解释,尤其是因为解释很少经过正式检验。可解释性与公平性在很大程度上仍然相互脱节,公平性评估仍不常见,原因包括人口统计学元数据有限、监管限制以及缺乏卒中特异性公平标准。由于数据集划分策略欠佳和报告实践不充分,泛化性也仍是一个问题。急性卒中管理中负责任的人工智能需要统一评估框架,以共同评估可解释性、公平性和泛化性。
Stroke IF 11.1 2026-9-17 PMID: 42751781
Pediatric stroke is a significant cause of long-term disability worldwide, with outcomes influenced by age, stroke subtype, and access to care. Our objective was to define the global burden of pediatric stroke by its impact on mortality and disability. The Global Burden of Disease study uses advanced statistical modeling to analyze health across locations, synthesizing data on mortality, morbidity, and risk factors. We examined 2023 data from the study to assess deaths, years of life lost, and years lived with disability during 3 eras (1990-2001, 2002-2013, and 2014-2023) across high-income and low- and middle-income countries. We stratified the analysis by sex, age group, and stroke subtype. We calculated the proportion of burden attributable to disability (years lived with disability/[years lived with disability+years of life lost]) to assess shifts from fatal to nonfatal disease over time. Between 1990 and 2023, global age-standardized pediatric stroke incidence declined only modestly, whereas age-standardized years of life lost rates declined significantly, indicating that the lower mortality burden reflected better survival rather than a large reduction in disease occurrence. Because years lived with disability rates remained comparatively stable as mortality declined, the proportion of disease burden attributable to disability rose from 14.6% (1990-2001) to 21.7% (2014-2023). This transition was uneven across settings: high-income countries achieved faster mortality declines and reached a higher disability share, whereas low- and middle-income countries retained a higher mortality burden, reflecting a dual burden of ongoing premature death and rising disability. These patterns were consistent across age and sex strata. These data indicate that pediatric stroke is undergoing an epidemiological transition from a mortality-dominant burden to one increasingly driven by disability, reflecting improved survival but with uneven distribution worldwide. Reducing the disability burden, through better stroke recognition education and expanded access to prevention, acute stroke care systems, reperfusion, and rehabilitation, particularly in low- and middle-income countries, should be prioritized alongside efforts to close persistent global inequities in outcomes.
中文摘要:儿童卒中是全球长期残疾的重要原因,其结局受年龄、卒中亚型和医疗可及性影响。我们的目标是通过其对死亡和残疾的影响来界定儿童卒中的全球负担。全球疾病负担研究采用先进统计模型分析不同地区的健康状况,综合死亡、患病和危险因素数据。我们检查了该研究的2023年数据,以评估3个时期(1990-2001年、2002-2013年和2014-2023年)在高收入国家以及低收入和中等收入国家中的死亡、寿命损失年和残疾生存年。我们按性别、年龄组和卒中亚型对分析进行了分层。我们计算了归因于残疾的负担比例(残疾生存年/[残疾生存年+寿命损失年]),以评估疾病随时间从致死性向非致死性的转变。1990年至2023年间,全球年龄标化儿童卒中发病率仅略有下降,而年龄标化寿命损失年率显著下降,表明死亡负担降低反映的是生存改善,而非疾病发生的大幅减少。由于在死亡率下降的同时,残疾生存年率保持相对稳定,归因于残疾的疾病负担比例从14.6%(1990-2001年)上升至21.7%(2014-2023年)。这种转变在不同地区并不均衡:高收入国家实现了更快的死亡率下降,并达到更高的残疾占比,而低收入和中等收入国家仍保留较高的死亡负担,反映出持续过早死亡与残疾上升的双重负担。这些模式在年龄和性别分层中一致。这些数据表明,儿童卒中正在经历流行病学转变,从以死亡为主的负担转向日益由残疾驱动的负担,反映出生存改善,但全球分布不均。应优先通过更好的卒中识别教育,以及扩大预防、急性卒中救治体系、再灌注和康复的可及性来降低残疾负担,尤其是在低收入和中等收入国家,同时努力缩小全球结局方面持续存在的不平等。

基础研究 (4篇)

Circulation research IF 18.0 2026-9-23 PMID: 42775432
Negative clinical trials foster therapeutic nihilism and public skepticism, especially if they follow optimistic preclinical results. One way to increase the likelihood of successful clinical trials is to enhance the preclinical testing of new treatments. Recently, multicenter preclinical testing networks have gained attention as one tool to enhance rigor and reduce the likelihood of erroneously recommending a new candidate treatment for advancement to clinical trial testing. The SPAN (Stroke Preclinical Assessment Network) consists of 6 research laboratories performing the experiments and 1 coordinating center at which treatments are prepared in a blinded manner, subjects are randomized, and statistical analysis is performed. We conducted a rigorous trial that included both sexes, multiple comorbidities, randomization, concealment of treatment status, blinded outcome assessments, prespecified sample sizes, and comprehensive data tracking. Five promising treatments were evaluated: BPN-27332, a lipoxygenase inhibitor; uric acid, a potent natural scavenger of free radicals; tatCN19o, a peptide inhibitor of activated CaMKII (Ca2+/CaM-dependent protein kinase II); GSK2256294, an inhibitor of sEH (soluble epoxide hydrolase); and NVX-058, an oxygen-carrying compound. A behavioral battery was selected as the end point for the primary analysis. The primary analysis used the modified intention-to-treat population. In total, 1768 rodents (882 females and 886 males) were enrolled: 441 young healthy mice, 444 aging mice, 450 mice with obesity-induced hyperglycemia and metabolic syndrome, and 433 spontaneously hypertensive rats. Data missing due to death before 30 days of follow-up were imputed from the same treatment group, animal model, sex, and stage. Although none of the candidates met the prespecified efficacy boundary, GSK2256294 showed an odds ratio for benefit of 1.28 (95% CI, 0.99-1.65), which was significant at P<0.05. The second SPAN study reaffirms the importance and feasibility of rigorous, multilaboratory preclinical testing networks to potentially reduce false positives in the development pipeline.
中文摘要:阴性临床试验会助长治疗虚无主义和公众怀疑,尤其是在其 preceded 乐观的临床前结果之后。提高临床试验成功可能性的一种方法是加强新疗法的临床前测试。近来,多中心临床前测试网络作为增强严谨性并降低错误推荐新候选疗法进入临床试验测试可能性的一种工具而受到关注。SPAN(卒中临床前评估网络)由6个开展实验的研究实验室和1个协调中心组成,在协调中心以盲法方式制备治疗、随机分配受试者并进行统计分析。我们开展了一项严谨的试验,纳入雌雄两性、多种合并症、随机化、治疗状态隐藏、盲法结局评估、预先设定的样本量以及全面的数据追踪。评估了五种有前景的治疗:BPN-27332,一种脂氧合酶抑制剂;尿酸,一种强效的天然自由基清除剂;tatCN19o,一种活化CaMKII(Ca2+/CaM依赖性蛋白激酶II)的肽抑制剂;GSK2256294,一种sEH(可溶性环氧化物水解酶)抑制剂;以及NVX-058,一种携氧化合物。选择一组行为学测试作为主要分析的终点。主要分析采用改良意向治疗人群。总共纳入1768只啮齿动物(882只雌性和886只雄性):441只年轻健康小鼠、444只衰老小鼠、450只肥胖诱导的高血糖和代谢综合征小鼠,以及433只自发性高血压大鼠。因随访30天前死亡导致的数据缺失,按同一治疗组、动物模型、性别和阶段进行插补。尽管没有候选治疗达到预先设定的疗效界值,GSK2256294显示出获益的比值比为1.28(95% CI,0.99-1.65),且在P<0.05水平显著。第二项SPAN研究再次证实了严谨的多实验室临床前测试网络的重要性与可行性,其可能减少研发流程中的假阳性。
Ageing research reviews IF 15.5 2026-9-22 PMID: 42772579
Intracerebral hemorrhage (ICH), caused by the rupture of blood vessels within the brain parenchyma, represents the most severe form of stroke, characterized by the highest mortality rate and predominantly affecting the elderly population. Glial cells, including microglia, astrocytes, and oligodendrocytes, serve as the resident immune cells of the central nervous system and undergo significant metabolic reprogramming following ICH. Microglia exhibit dual roles in post-ICH tissue damage by altering their polarization states: they contribute to secondary brain injury through pro-inflammatory responses while also promoting hematoma clearance via anti-inflammatory mechanisms. Astrocytes primarily provide neuroprotective effects by extending branched processes to maintain neuronal architecture and preserve the integrity of the blood-brain barrier. Oligodendrocytes are susceptible to metabolic dysregulation following ICH, leading to myelin sheath damage and subsequent axonal dysfunction. Metabolically, the acute phase of ICH is marked by suppressed glucose metabolism, which gradually normalizes in later stages. Concurrently, oxidative stress and lipid peroxidation disrupt glial cell homeostasis. The extravasation of blood components leads to iron overload, exacerbating metabolic disturbances through impaired iron regulation. These metabolic disruptions propagate through intracellular signaling pathways, thereby influencing glial pathophysiology. Unlike previous reviews that primarily describe these changes, this review offers a conceptual framework that explicitly integrates aging, metabolic reprogramming, and intercellular communication across different phases of injury. We critically assess the robustness of current evidence, differentiate between correlative observations and causal mechanisms, and identify significant knowledge gaps. We conclude that the age-related metabolic vulnerability of glial cells constitutes a promising therapeutic target, and we propose testable hypotheses to guide future mechanistic and translational research. By synthesizing recent literature within this integrative framework, this review seeks to enhance understanding of metabolic regulation in glial cells following ICH, thereby laying the groundwork for the development of targeted metabolic interventions.
中文摘要:脑出血(ICH)由脑实质内血管破裂引起,是卒中中最严重的形式,死亡率最高,且主要影响老年人群。胶质细胞,包括小胶质细胞、星形胶质细胞和少突胶质细胞,作为中枢神经系统的常驻免疫细胞,在ICH后发生显著的代谢重编程。小胶质细胞通过改变其极化状态在ICH后组织损伤中发挥双重作用:它们通过促炎反应促进继发性脑损伤,同时也通过抗炎机制促进血肿清除。星形胶质细胞主要通过伸出分支突起维持神经元结构并保持血脑屏障完整性来提供神经保护作用。少突胶质细胞在ICH后易发生代谢失调,导致髓鞘损伤和随后的轴突功能障碍。在代谢方面,ICH急性期的特征是葡萄糖代谢受抑制,并在后期逐渐恢复正常。同时,氧化应激和脂质过氧化破坏胶质细胞稳态。血液成分外渗导致铁过载,通过铁调节受损加剧代谢紊乱。这些代谢紊乱通过细胞内信号通路传播,从而影响胶质细胞的病理生理。与以往主要描述这些变化的综述不同,本综述提供了一个概念框架,明确整合了衰老、代谢重编程和不同损伤阶段的细胞间通讯。我们批判性评估当前证据的稳健性,区分相关性观察与因果机制,并识别重要的知识空白。我们得出结论:胶质细胞与年龄相关的代谢脆弱性是一个有前景的治疗靶点,并提出可检验的假设以指导未来的机制和转化研究。通过在这一整合框架内综合近期文献,本综述旨在加深对ICH后胶质细胞代谢调控的理解,从而为开发靶向代谢干预措施奠定基础。
Acta pharmacologica Sinica IF 10.4 2026-9-18 PMID: 42754703
Hypoxia has therapeutic potential, but global hypoxia is toxic. Inducing safe, cell-specific hypoxia remains a clinically unmet need. We hypothesized that small-molecule-augmented oxygen consumption in adjacent cells induces neuron-specific hypoxia, representing a safe ischemic stroke strategy that mimics neural-directed developmental neovascularization. Using single-cell sequencing, a hypoxic probe, and knockout mice, we showed that ADT-OH (an active metabolite of a hepatoprotective drug) targeted sulfide-quinone oxidoreductase (SQR) to increase aerobic respiration in microglia/macrophages, thereby generating neuron-specific hypoxia after cerebral ischemia. Neuronal hypoxia promoted functional angiogenesis by specifically stabilizing hypoxia-inducible factor to upregulate the expression of neuron-derived vascular endothelial growth factor, supporting a neural-directed angiogenic mechanism. ADT-OH also restored the blood-brain barrier (BBB) via microglial/macrophage SQR. Notably, microglia/macrophage UCP2, the downstream mediator of SQR, was required for ADT-OH-induced BBB repair but not angiogenesis. Mechanistically, ADT-OH targeted UCP2 to increase Wnt/β-catenin signaling, which has been shown to mediate developmental BBB formation. In summary, one small molecule targeting SQR achieves therapeutic cell-specific hypoxia.
中文摘要:缺氧具有治疗潜力,但全身性缺氧具有毒性。诱导安全、细胞特异性的缺氧仍是临床尚未满足的需求。我们假设,小分子增强邻近细胞的氧消耗可诱导神经元特异性缺氧,从而构成一种安全的缺血性脑卒中治疗策略,模拟神经导向的发育性新生血管形成。利用单细胞测序、缺氧探针和基因敲除小鼠,我们证明ADT-OH(一种保肝药物的活性代谢产物)靶向硫醌氧化还原酶(SQR),增加小胶质细胞/巨噬细胞的有氧呼吸,从而在脑缺血后产生神经元特异性缺氧。神经元缺氧通过特异性稳定缺氧诱导因子,上调神经元来源的血管内皮生长因子的表达,促进功能性血管新生,支持神经导向的血管生成机制。ADT-OH还通过小胶质细胞/巨噬细胞的SQR恢复血脑屏障(BBB)。值得注意的是,作为SQR下游介质的小胶质细胞/巨噬细胞UCP2,是ADT-OH诱导BBB修复所必需的,但对血管新生并非必需。在机制上,ADT-OH靶向UCP2以增强Wnt/β-catenin信号通路,而该通路已被证明介导发育期BBB的形成。总之,一种靶向SQR的小分子即可实现治疗性的细胞特异性缺氧。
Cell IF 45.1 2026-8-1 PMID: 42537647
The brain vasculature comprises diverse specialized cells that are essential for brain function, yet their spatial organization remains poorly understood. Here, we construct a comprehensive cerebrovascular cell atlas encompassing 314,535 transcriptomes that captures the arteriovenous axis and defines consensus cell states. We then perform spatial transcriptomics to map 1,529,740 cells across the human temporal cortex and hippocampus, uncovering stereotyped micro-communities termed vascular cell ensembles. These ensembles comprise specialized subsets of endothelial cells, mural cells, fibroblasts, and perivascular macrophages that align with the arteriovenous architecture to coordinate segment-specific functions, such as neurovascular coupling, blood-brain barrier transport, and immune surveillance. By overlaying genetic risk and pharmacologic reactivity, we identify ensemble-specific susceptibilities and candidate therapeutic targets across neurological diseases, including small vessel disease and stroke. This study provides a resource to dissect the spatial and functional logic underlying human cerebrovascular biology and establishes a blueprint for decoding neurological disease susceptibility and therapeutic response.
中文摘要:脑脉管系统由多种特化细胞组成,这些细胞对脑功能至关重要,但它们的空间组织仍知之甚少。在此,我们构建了一个全面的脑血管细胞图谱,涵盖314,535个转录组,捕获了动静脉轴并定义了共识细胞状态。随后,我们进行空间转录组学,在人类颞叶皮层和海马中映射了1,529,740个细胞,揭示了被称为血管细胞集合体的模式化微群落。这些集合体由内皮细胞、血管壁细胞、成纤维细胞和血管周围巨噬细胞的特殊亚群组成,它们与动静脉结构对齐以协调节段特异性功能,如神经血管耦合、血脑屏障转运和免疫监视。通过叠加遗传风险和药物反应性,我们识别了神经系统疾病(包括小血管病和卒中)中集合体特异性的易感性和候选治疗靶点。本研究提供了一个资源,用于剖析人类脑血管生物学背后的空间和功能逻辑,并建立了解码神经系统疾病易感性和治疗反应的蓝图。

3高血压 (6篇)

临床研究 (4篇)

EBioMedicine IF 11.2 2026-9-22 PMID: 42771993
Cataract is a highly prevalent cause of visual impairment and blindness worldwide. Although genome-wide association studies (GWAS) have mapped multiple cataract risk loci, further work is required towards translating these signals and integrating multi-omics evidence for preventing or delaying age-related cataract progression. A senile cataract GWAS was first conducted in All of Us, followed by ancestry-specific GWAS meta-analyses in European-ancestry (161,812 cases and 1,099,738 controls) and East Asian ancestry (66,679 cases and 521,995 controls). To prioritise candidate targets, we performed Mendelian randomisation (MR) and colocalisation using cis-expression quantitative trait loci (cis-eQTL) instruments from eQTLGen. We then conducted a plasma proteome-wide cis-pQTL MR scan with colocalisation using UKB-PPP and deCODE for European analyses, and cis-pQTL data from the China Kadoorie Biobank for East Asian analyses. We identified 78 and 4 independent loci for cataract in Europeans and East Asians, respectively, including 8 and 3 putatively unreported loci. By integrating the meta-GWAS with cis-eQTL MR, we prioritised 16 genes, including MTMR3, NT5DC2, and EFNA1, with eQTL-GWAS colocalisation further supporting MTMR3 and NT5DC2. Proteome-wide cis-pQTL MR prioritised 32 proteins for senile cataract in Europeans, and colocalisation refined these to EFNA1 and RALY. In East Asians, MR highlighted APOE and ALDH2 as candidate targets. We also identified colocalised pleiotropic signals shared between cataract and related traits, including myopia, hypertension, and type 2 diabetes, highlighting candidate genes such as TCF7L2, BMP4, CDKAL1, PAX4, and ALDH2. These findings advance cross-ancestry understanding of cataract genetic architecture and prioritise genetically supported candidates. This work was supported by the Joint Funds for the Innovation of Science and Technology, Fujian Joint Innovation Fund in Science and Technology Project (Grant No. 2025Y9437).
中文摘要:白内障是全球范围内视力损害和失明的高度常见原因。尽管全基因组关联研究(GWAS)已定位多个白内障风险位点,但仍需进一步工作,将这些信号转化并整合多组学证据,以预防或延缓年龄相关性白内障进展。我们首先在All of Us中进行了老年性白内障GWAS,随后在欧洲血统(161,812例病例和1,099,738例对照)和东亚血统(66,679例病例和521,995例对照)中进行了血统特异性GWAS荟萃分析。为优先筛选候选靶点,我们使用来自eQTLGen的顺式表达数量性状位点(cis-eQTL)工具进行了孟德尔随机化(MR)和共定位分析。随后,我们使用UKB-PPP和deCODE对欧洲分析进行血浆蛋白质组范围cis-pQTL MR扫描及共定位,并使用中国慢性病前瞻性研究(China Kadoorie Biobank)的cis-pQTL数据进行东亚分析。我们在欧洲人和东亚人中分别鉴定出78个和4个独立的白内障位点,其中包括8个和3个推测未报道的位点。通过整合荟萃GWAS与cis-eQTL MR,我们优先选出16个基因,包括MTMR3、NT5DC2和EFNA1,eQTL-GWAS共定位进一步支持MTMR3和NT5DC2。蛋白质组范围cis-pQTL MR在欧洲人中优先选出32个与老年性白内障相关的蛋白质,共定位将其精炼为EFNA1和RALY。在东亚人中,MR突出显示APOE和ALDH2为候选靶点。我们还鉴定出白内障与相关性状(包括近视、高血压和2型糖尿病)之间共享的共定位多效性信号,突出显示TCF7L2、BMP4、CDKAL1、PAX4和ALDH2等候选基因。这些发现推进了对白内障遗传结构的跨血统理解,并优先选出有遗传学支持的候选靶点。本研究由福建省科技创新联合资金项目、福建科技计划联合创新基金资助(资助号:2025Y9437)。
European journal of preventive cardiology IF 10.0 2025-7-29 PMID: 40727976
This study aimed to assess the association between menopausal status and menopausal hormone therapy (MHT) with cardiovascular risk factor (CVRF) prevalence. We analysed data from women aged 40-70, without previous cardiovascular disease, enrolled in the prospective CARdioVAscular Risk factors (CARVAR) 92 cohort study conducted in the Hauts-de-Seine department, France, between 2010 and 2023. Cardiovascular risk factors were assessed through blood analysis and medical check-up results. Menopausal status and hormone therapy use were self-reported. Of the 16 879 subjects included in CARVAR 92, 7395 women were analysed, including 2607 non-menopausal and 4788 menopausal women. After adjusting for age, menopausal women were at higher risk of obesity {odds ratio (OR), 1.44 [95% confidence interval (CI), 1.21, 1.70]; P < 0.001}, waist obesity [OR, 1.33 (95% CI, 1.17, 1.53); P < 0.001], hypertension [OR, 1.17 (95% CI, 1.01, 1.36); P = 0.049], diabetes mellitus [OR, 1.84 (95% CI, 1.31, 2.61); P < 0.001], and dyslipidaemia [OR, 1.74 (95% CI, 1.49, 2.03); P < 0.001] compared with non-menopausal women. However, menopausal women using MHT did not show significant differences in the prevalence of CVRF compared with non-menopausal women. These findings remained robust across various models. Menopausal women exhibited an increase in all modifiable CVRF compared with non-menopausal women. Menopausal hormone therapy use may have a beneficial effect on the prevalence of these risk factors. These findings highlight the importance of considering menopausal status and MHT use when assessing and managing cardiovascular risk in women. IRB00012437.
中文摘要:本研究旨在评估绝经状态和绝经激素治疗(MHT)与心血管危险因素(CVRF)患病率之间的关联。我们分析了2010年至2023年在法国上塞纳省开展的前瞻性心血管危险因素(CARVAR)92队列研究中40-70岁、既往无心血管疾病的女性数据。心血管危险因素通过血液分析和医学检查结果评估。绝经状态和激素治疗使用情况为自我报告。在CARVAR 92纳入的16879名受试者中,分析了7395名女性,包括2607名未绝经女性和4788名绝经女性。校正年龄后,与未绝经女性相比,绝经女性肥胖风险更高{比值比(OR),1.44 [95%置信区间(CI),1.21,1.70];P < 0.001}、腹型肥胖[OR,1.33(95% CI,1.17,1.53);P < 0.001]、高血压[OR,1.17(95% CI,1.01,1.36);P = 0.049]、糖尿病[OR,1.84(95% CI,1.31,2.61);P < 0.001]和血脂异常[OR,1.74(95% CI,1.49,2.03);P < 0.001]。然而,使用MHT的绝经女性与未绝经女性相比,CVRF患病率未显示显著差异。这些发现在各种模型中均稳健。与未绝经女性相比,绝经女性所有可改变CVRF均增加。绝经激素治疗的使用可能对这些危险因素的患病率有有益影响。这些发现强调在评估和管理女性心血管风险时考虑绝经状态和MHT使用的重要性。IRB00012437。
British journal of sports medicine IF 15.5 2026-7-16 PMID: 42457535
To evaluate the effects of supervised exercise on gestational diabetes mellitus (GDM) and other pregnancy outcomes and examine dose-response relationships. Systematic review with random-effects meta-analysis and meta-regression. Four databases were searched up to November 2025. Randomised controlled trials in pregnant women comparing supervised exercise with usual care were included if they reported GDM. GDM was prespecified as the primary outcome, while other outcomes were extracted where available, including gestational hypertension (GH), pre-eclampsia, excessive gestational weight gain (EGWG), macrosomia, caesarean delivery, preterm birth and low birth weight. Nineteen studies (n=6213; 48.6% in intervention groups) were included, with moderate certainty of evidence. Supervised exercise reduced the risk of GDM (risk ratio (RR) 0.74, 95% CI 0.57 to 0.96; I2=47%), GH (RR 0.55, 95% CI 0.40 to 0.77; I2=1%), EGWG (RR 0.75, 95% CI 0.61 to 0.92; I2=70%) and macrosomia (RR 0.61, 95% CI 0.46 to 0.81; I2=27%). Subgroup analyses for these outcomes suggested greater effects with earlier intervention (initiated in early pregnancy or duration >20 weeks), higher adherence (≥80%), combined aerobic and resistance training, and weekly exercise duration ≥150 min/week. Significant subgroup differences in GDM risk were observed for intervention initiation timing (p=0.009) and intervention duration (p=0.010). Dose-response analysis showed a peak effect at approximately 500-550 metabolic equivalent task-minutes per week for EGWG, with a plateau at higher doses. Supervised exercise during pregnancy reduces adverse pregnancy outcomes when initiated early, with high adherence, at moderate doses, and with combined aerobic and resistance training.
中文摘要:评估监督下运动对妊娠期糖尿病(GDM)及其他妊娠结局的影响,并考察剂量-反应关系。采用系统综述、随机效应荟萃分析和荟萃回归。检索4个数据库至2025年11月。纳入在孕妇中比较监督下运动与常规护理、且报告GDM的随机对照试验。GDM被预先设定为主要结局,其他可获取的结局也被提取,包括妊娠期高血压(GH)、子痫前期、妊娠期体重过度增加(EGWG)、巨大儿、剖宫产、早产和低出生体重。共纳入19项研究(n=6213;干预组占48.6%),证据确定性为中等。监督下运动降低了GDM风险(风险比(RR)0.74,95% CI 0.57至0.96;I2=47%)、GH风险(RR 0.55,95% CI 0.40至0.77;I2=1%)、EGWG风险(RR 0.75,95% CI 0.61至0.92;I2=70%)和巨大儿风险(RR 0.61,95% CI 0.46至0.81;I2=27%)。这些结局的亚组分析提示,更早干预(在妊娠早期开始或持续时间>20周)、更高依从性(≥80%)、有氧与抗阻联合训练,以及每周运动时长≥150分钟/周时效果更大。GDM风险的亚组差异在干预开始时机(p=0.009)和干预持续时间(p=0.010)方面具有统计学意义。剂量-反应分析显示,对于EGWG,效果在约500-550代谢当量任务分钟/周时达到峰值,更高剂量时趋于平台。妊娠期监督下运动在早期开始、高依从性、中等剂量以及有氧与抗阻联合训练时,可减少不良妊娠结局。
Diabetes care IF 22.6 2026-9-17 PMID: 42752803
Fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) may not fully capture the heterogeneity underlying dysglycemia or its associations with cardiometabolic risk factors (CMRFs). We cross-sectionally investigated whether continuous glucose monitoring (CGM) measures and glycemic profiles could reveal 10-year cardiovascular disease (CVD) risk and individual CMRFs among individuals without diabetes. We included 1,356 participants without prevalent diabetes or CVD from the Framingham Heart Study, who wore a blinded Dexcom G6 Pro CGM for up to 10 days. CGM glycemic profiles were characterized using 1) binary classification of glycemic burden and variability and 2) unsupervised clustering of CGM measures. We performed multivariable-adjusted linear and logistic regression models to examine associations of CGM measures and profiles with 10-year CVD risk estimates (PREVENT equations) and individual CMRFs. Participants' mean was age 59.3 years; 55.8% were women, and 92.6% were non-Hispanic White. CGM measures were positively associated with 10-year CVD risk estimates and CMRFs. For example, 1 SD higher percentage of time spent at glucose levels >140 mg/dL (15.4%) was associated with 2% higher 10-year CVD risk estimates and 21-26% higher odds of hypertension and dyslipidemia, even after adjusting for FPG. Glycemic profiles representing higher CGM dysglycemia revealed discordance with traditionally defined glycemic status (FPG and HbA1c). Although 48.1-84.2% of individuals with traditionally defined prediabetes were included in CGM profiles representing higher dysglycemia, such profiles were associated with 6-7% higher 10-year CVD risk estimates, in addition to worse CMRFs. Glycemic measures reflective of continuous glucose dynamics may provide additional insights into cardiometabolic risk beyond traditional measures.
中文摘要:空腹血糖(FPG)和糖化血红蛋白(HbA1c)可能无法充分反映血糖异常背后的异质性或其与心血管代谢危险因素(CMRFs)的关联。我们开展横断面研究,探讨在无糖尿病个体中,连续血糖监测(CGM)指标和血糖谱能否揭示10年心血管疾病(CVD)风险和个体CMRFs。我们纳入Framingham心脏研究中1,356名无现患糖尿病或CVD的参与者,他们佩戴盲法Dexcom G6 Pro CGM最长10天。采用1)对血糖负荷和变异性的二分类以及2)对CGM指标的无监督聚类来刻画CGM血糖谱。我们使用多变量校正的线性回归和logistic回归模型,检验CGM指标和血糖谱与10年CVD风险估计(PREVENT方程)及个体CMRFs的关联。参与者平均年龄59.3岁;55.8%为女性,92.6%为非西班牙裔白人。CGM指标与10年CVD风险估计和CMRFs呈正相关。例如,血糖水平>140 mg/dL的时间百分比(15.4%)每升高1个标准差,与10年CVD风险估计升高2%以及高血压和血脂异常风险增加21-26%相关,即使在校正FPG后也是如此。代表更高CGM血糖异常的血糖谱与传统定义的血糖状态(FPG和HbA1c)不一致。尽管传统定义糖尿病前期的个体中有48.1-84.2%被纳入代表更高血糖异常的CGM血糖谱,但这些血糖谱与10年CVD风险估计升高6-7%以及更差的CMRFs相关。反映连续血糖动态的血糖指标可能为传统指标之外的心血管代谢风险提供额外见解。

基础研究 (2篇)

Acta pharmacologica Sinica IF 10.4 2026-9-23 PMID: 42773185
Blood pressure (BP) is positively correlated with the activity of volume-regulated chloride channels (VRCCs) in vascular smooth muscle cells (VSMCs) during hypertension, and LRRC8A has recently been identified as the key molecular component of VRCCs. However, the role of LRRC8A in BP regulation remains unclear. Here, we generated SMC-specific LRRC8A knockout (CKO) mice and performed bulk RNA-sequencing, ChIP-sequencing, and coimmunoprecipitation coupled with mass spectrometry to elucidate the underlying mechanisms. We found that systolic BP was largely reduced in CKO mice under basal conditions as well as in those with angiotensin II- or DOCA-salt-induced hypertension. Aortas from CKO mice exhibited decreased vasoconstriction, whereas vasodilation and cardiac function remained unaffected. Mechanistically, LRRC8A deletion reduced STAT1 degradation and enhanced Calcrl transcription, thereby strengthening the inhibitory effect of Calcrl on myosin light chain phosphorylation and identifying LRRC8A deficiency as a negative regulator of VSMC contractility. Moreover, LRRC8A deficiency promoted the interaction between CSRP2 and PIAS1 and subsequently suppressed STAT1 degradation. Pharmacological inhibition of STAT1 with fludarabine abolished the protective effects of LRRC8A deficiency against hypertension and vasoconstriction. In summary, our findings reveal an essential role for LRRC8A in BP regulation and highlight a potential therapeutic strategy for hypertension.
中文摘要:高血压时,血压(BP)与血管平滑肌细胞(VSMCs)中容量调节性氯通道(VRCCs)的活性呈正相关,而LRRC8A最近被鉴定为VRCCs的关键分子组分。然而,LRRC8A在血压调节中的作用仍不清楚。在此,我们构建了平滑肌细胞特异性LRRC8A敲除(CKO)小鼠,并进行bulk RNA测序、ChIP测序以及免疫共沉淀联合质谱,以阐明潜在机制。我们发现,在基础状态下以及血管紧张素II或DOCA-盐诱导的高血压模型中,CKO小鼠的收缩压均显著降低。CKO小鼠的主动脉表现出血管收缩减弱,而血管舒张和心脏功能未受影响。机制上,LRRC8A缺失减少了STAT1降解并增强了Calcrl转录,从而增强了Calcrl对肌球蛋白轻链磷酸化的抑制作用,并确定LRRC8A缺陷是VSMC收缩性的负调控因素。此外,LRRC8A缺陷促进了CSRP2与PIAS1之间的相互作用,随后抑制了STAT1降解。使用氟达拉滨对STAT1进行药理学抑制可消除LRRC8A缺陷对高血压和血管收缩的保护作用。总之,我们的研究结果揭示了LRRC8A在血压调节中的重要作用,并提示了一种潜在的高血压治疗策略。
Food chemistry IF 10.4 2026-9-22 PMID: 42771966
Although fermented soybean foods are recognized as sources of antihypertensive peptides, the microorganisms responsible for their production and the underlying mechanisms remain poorly understood. Here, defined starter cultures were used to directly link microbial fermentation with the generation of antihypertensive peptides in doenjang-meju. Among the tested starters, Bacillus velezensis produced the strongest angiotensin-converting enzyme (ACE)-inhibitory activity. Bioactivity-guided fractionation combined with LC-Q-TOF-MS identified two ACE-inhibitory peptides, SAGPV and GDSM. Both peptides significantly reduced blood pressure in high-fat diet-induced hypertensive mice, with efficacy comparable to captopril. Mechanistically, they decreased circulating ACE and angiotensin II levels, suppressed cardiac ACE expression, and restored the protective ACE2-MAS1 axis of the renin-angiotensin system. In addition, B. velezensis-fermented soybean attenuated hypertension more effectively than non-fermented soybean. These findings identify SAGPV and GDSM as antihypertensive peptides generated during B. velezensis fermentation and provide mechanistic evidence that targeted microbial fermentation can enhance the cardiovascular benefits of soybean foods.
中文摘要:尽管发酵大豆食品被认为是抗高血压肽的来源,但负责其产生的微生物及其潜在机制仍知之甚少。本研究使用确定的发酵剂培养物,将微生物发酵与韩国发酵大豆 doenjang-meju 中抗高血压肽的生成直接关联起来。在测试的发酵剂中,贝莱斯芽孢杆菌(Bacillus velezensis)产生了最强的血管紧张素转换酶(ACE)抑制活性。生物活性导向的分级分离结合 LC-Q-TOF-MS 鉴定出两种 ACE 抑制肽,SAGPV 和 GDSM。这两种肽均显著降低了高脂饮食诱导的高血压小鼠的血压,其疗效与卡托普利相当。在机制上,它们降低了循环 ACE 和血管紧张素 II 水平,抑制了心脏 ACE 表达,并恢复了肾素-血管紧张素系统中保护性的 ACE2-MAS1 轴。此外,贝莱斯芽孢杆菌发酵大豆比未发酵大豆更有效地减轻高血压。这些发现将 SAGPV 和 GDSM 鉴定为贝莱斯芽孢杆菌发酵过程中产生的抗高血压肽,并提供了机制证据,表明靶向微生物发酵可以增强大豆食品的心血管益处。

4心房颤动 (6篇)

临床研究 (5篇)

European heart journal IF 45.3 2026-4-30 PMID: 42059513
Large-scale randomized data comparing clinical outcomes of atrial fibrillation patients of Asian vs non-Asian races are limited. Data from A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation, which pooled patient-level data from the four pivotal randomized trials of direct oral anticoagulants (DOACs) vs warfarin in patients with atrial fibrillation, were analysed. Baseline characteristics and clinical outcomes in patients of Asian race (Asians) vs non-Asian race were compared. The relative efficacy and safety of DOACs compared with warfarin in Asians vs non-Asians, assessing for interactions between race and treatment effect, were investigated. Outcomes across the range of body weight and creatinine clearance in Asians were also explored. A total of 10 212 Asian patients and 61 471 non-Asians were identified. Compared with non-Asians, Asians were on average 3.2 years younger and 20 kg lighter, had worse renal function (mean creatinine clearance 64.9 vs 77.3 mL/min), and had higher rates of prior stroke/transient ischaemic attack (37.2% vs 26.6%) (P < .001 for each). In the warfarin arm (median time in therapeutic range 57.7% for Asians vs 66.2% for non-Asians, P < .001), Asians had a higher adjusted risk of stroke/systemic embolic events (SEEs), major bleeding, intracranial haemorrhage, gastrointestinal bleeding, and primary net clinical outcome (stroke/SEE, major bleeding, or death). Compared with warfarin, standard-dose (SD) DOACs significantly reduced the risks in Asians to a greater degree than non-Asians for stroke/SEE (hazard ratio [HR] .65, 95% confidence interval .53-.80 vs HR .86, 95% confidence interval .78-.95), major bleeding (HR .62 [.52-.75] vs HR .91 [.84-.98]), and primary net clinical outcome (HR .76 [.68-.85] vs HR .94 [.90-.98]; Pint < .02 for each). Standard-dose DOACs increased gastrointestinal bleeding only in non-Asians (Asians HR .92 [.69-1.23] vs non-Asians HR 1.41 [1.25-1.58], Pint = .009). In Asians, SD DOACs reduced the risks of clinical events across the wide range of body weight and creatinine clearance. Compared with SD DOACs, lower-dose DOACs significantly increased the risk of stroke/SEE (HR 1.57 [1.15-2.13]) and secondary net clinical outcome (stroke/SEE, intracranial haemorrhage, or death; HR 1.23 [1.03-1.48]) in Asians. Clinical outcomes with SD DOACs vs warfarin in patients with atrial fibrillation were generally even more favourable in patients of Asian than non-Asian race. Compared with warfarin, SD DOACs did not increase the risk of gastrointestinal bleeding in Asians. Standard-dose DOACs are preferred over warfarin or lower-dose DOACs in patients of Asian race.
中文摘要:大规模比较亚洲与非亚洲种族心房颤动患者临床结局的随机数据有限。本研究分析了A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation的数据,该研究汇总了四项直接口服抗凝药(DOACs)对比华法林治疗心房颤动患者的关键随机试验的患者水平数据。比较了亚洲种族患者(亚洲人)与非亚洲种族患者的基线特征和临床结局。探讨了DOACs相比华法林在亚洲人与非亚洲人中的相对疗效和安全性,并评估种族与治疗效应之间的交互作用。还探索了亚洲人中不同体重范围和肌酐清除率下的结局。共识别出10 212例亚洲患者和61 471例非亚洲患者。与非亚洲人相比,亚洲人平均年轻3.2岁、轻20 kg,肾功能更差(平均肌酐清除率64.9 vs 77.3 mL/min),既往卒中/短暂性脑缺血发作比例更高(37.2% vs 26.6%)(每项P < .001)。在华法林组(亚洲人的治疗窗内时间中位数57.7% vs 非亚洲人66.2%,P < .001),亚洲人校正后卒中/系统性栓塞事件(SEEs)、大出血、颅内出血、胃肠道出血和主要净临床结局(卒中/SEE、大出血或死亡)风险更高。与华法林相比,标准剂量(SD)DOACs在亚洲人中降低卒中/SEE(风险比[HR] .65,95%置信区间 .53-.80 vs HR .86,95%置信区间 .78-.95)、大出血(HR .62 [.52-.75] vs HR .91 [.84-.98])和主要净临床结局(HR .76 [.68-.85] vs HR .94 [.90-.98];每项Pint < .02)风险的程度显著大于非亚洲人。标准剂量DOACs仅增加非亚洲人的胃肠道出血风险(亚洲人HR .92 [.69-1.23] vs 非亚洲人HR 1.41 [1.25-1.58],Pint = .009)。在亚洲人中,SD DOACs在广泛体重和肌酐清除率范围内降低临床事件风险。与SD DOACs相比,较低剂量DOACs显著增加亚洲人卒中/SEE风险(HR 1.57 [1.15-2.13])和次要净临床结局(卒中/SEE、颅内出血或死亡;HR 1.23 [1.03-1.48])风险。在心房颤动患者中,SD DOACs相比华法林的临床结局在亚洲人中总体甚至比非亚洲人更有利。与华法林相比,SD DOACs未增加亚洲人的胃肠道出血风险。在亚洲种族患者中,标准剂量DOACs优于华法林或较低剂量DOACs。
European heart journal IF 45.3 2026-4-16 PMID: 41985940
Patients with heart failure with reduced ejection fraction (HFrEF) derive less benefit from cardiac resynchronization therapy (CRT) if they have coexisting atrial fibrillation (AF). Observational data suggest that atrioventricular node ablation (AVNA) may enhance CRT efficacy in this population. This trial aimed to evaluate the effect of AVNA compared with medical rate control therapy (MRCT) on CRT outcomes in patients with HFrEF and permanent AF. The CAAN-AF trial was an international, prospective, multicentre, randomized controlled trial evaluating the impact of AVNA in patients with HFrEF, permanent AF, and CRT-defibrillators (CRT-D). Participants were randomly assigned (1:1) to AVNA or MRCT targeting a resting heart rate <90 bpm. All participants received device optimization. The primary endpoint was a composite of all-cause mortality and nonfatal heart failure events. Secondary endpoints included cardiovascular mortality, unplanned hospitalizations, ventricular arrhythmias requiring device therapy, 6-min walk distance (6MWD), and quality of life. With early termination of the trial due to futility, a total of 143 patients were randomized (67 to AVNA, 76 to MRCT). Baseline characteristics were similar across groups. No significant difference was found in the primary endpoint [47 vs. 46 events; incident rate ratio (IRR), 1.16; 95% confidence interval (CI), 0.60-2.24]. Secondary outcomes, including cardiovascular mortality (odds ratio, 1.93; 95% CI 0.60-6.20), unplanned hospitalizations (IRR, 1.01; 95% CI 0.71-1.74), ventricular arrhythmias requiring device therapy (IRR, 0.68; 95% CI 0.17-2.63), 6MWD, and SF-36 scores, also showed no significant differences. This randomized trial of patients with permanent AF and CRT-D found no evidence of a reduction in all-cause mortality and nonfatal heart failure events with AVNA compared with MRCT. NCT01522898.
中文摘要:射血分数降低的心力衰竭(HFrEF)患者若合并心房颤动(AF),从心脏再同步化治疗(CRT)中获益较少。观察性数据提示,房室结消融(AVNA)可能增强此类人群的CRT疗效。本试验旨在评估AVNA与药物心率控制治疗(MRCT)相比对HFrEF合并永久性AF患者CRT结局的影响。CAAN-AF试验是一项国际性、前瞻性、多中心、随机对照试验,评估AVNA在HFrEF、永久性AF并植入心脏再同步化治疗除颤器(CRT-D)患者中的影响。参与者按1:1随机分配至AVNA组或MRCT组,MRCT目标为静息心率<90次/分。所有参与者均接受器械优化。主要终点为全因死亡和非致死性心力衰竭事件的复合终点。次要终点包括心血管死亡、非计划住院、需要器械治疗的室性心律失常、6分钟步行距离(6MWD)和生活质量。因无效而提前终止试验后,共143例患者被随机分配(67例至AVNA组,76例至MRCT组)。各组基线特征相似。主要终点未见显著差异[47 vs. 46起事件;发生率比(IRR),1.16;95%置信区间(CI),0.60-2.24]。次要结局,包括心血管死亡(比值比,1.93;95% CI 0.60-6.20)、非计划住院(IRR,1.01;95% CI 0.71-1.74)、需要器械治疗的室性心律失常(IRR,0.68;95% CI 0.17-2.63)、6MWD和SF-36评分,也均未见显著差异。这项针对永久性AF并植入CRT-D患者的随机试验发现,与MRCT相比,AVNA没有降低全因死亡和非致死性心力衰竭事件的证据。NCT01522898。
European heart journal IF 45.3 2026-4-14 PMID: 41979041
Vascular access site complications are the most common procedure-related adverse event of atrial fibrillation catheter ablation. Whether ultrasound-guided femoral venous puncture reduces these vascular access complications remains uncertain. In this investigator-initiated, multicentre, open-label, superiority trial, patients undergoing atrial fibrillation or left atrial tachycardia catheter ablation were randomized to an ultrasound-guided venous puncture strategy (intervention group) or to a conventional venous puncture group guided by palpation (control group). The composite primary outcome was the occurrence of venous access site complications until 30 days after the procedure, defined as arteriovenous fistula, false aneurysm, or access site bleeding requiring intervention or leading to prolonged hospitalization. Secondary endpoints included procedure duration, puncture duration, procedure-related stroke/transient ischaemic attack within 30 days, number of unintended arterial punctures, and number of failed venous access attempts, as well as hospital stay duration. In six centres, 986 patients were randomized. A total of 496 patients were assigned to the ultrasound-guided puncture group, and 490 patients to the conventional puncture group. The trial was stopped for efficacy, following the first interim analysis after enrolment of half of the planned patients. The composite primary outcome occurred in 3 patients (0.6%) in the intervention group and 16 patients (3.3%) in the control group (risk ratio 0.19; 95% confidence interval 0.05-0.63; P = .002). Additionally, ultrasound-guided venous puncture significantly reduced the rate of an unintended arterial puncture (2% vs 16%, P < .0001) and the rate of unsuccessful venous access attempts requiring crossover to the other group (0.2% vs 8.2%, P < .0001). Ultrasound-guided venous access for atrial fibrillation ablation procedures significantly reduced vascular access site complications. NCT06403527.
中文摘要:血管入路部位并发症是心房颤动导管消融最常见的操作相关不良事件。超声引导股静脉穿刺是否减少这些血管入路并发症仍不确定。在这项由研究者发起、多中心、开放标签、优效性试验中,接受心房颤动或左房性心动过速导管消融的患者被随机分配至超声引导静脉穿刺策略(干预组)或触诊引导的传统静脉穿刺组(对照组)。复合主要结局为术后30天内静脉入路部位并发症的发生,定义为动静脉瘘、假性动脉瘤,或需要干预或导致住院时间延长的入路部位出血。次要终点包括手术持续时间、穿刺持续时间、30天内手术相关卒中/短暂性脑缺血发作、非预期动脉穿刺次数、静脉入路尝试失败次数以及住院时间。在六个中心,986例患者被随机分组。共496例患者分配至超声引导穿刺组,490例患者分配至传统穿刺组。在入组一半计划患者后的首次期中分析后,试验因疗效而停止。复合主要结局在干预组3例(0.6%)和对照组16例(3.3%)中发生(风险比0.19;95%置信区间0.05-0.63;P=0.002)。此外,超声引导静脉穿刺显著降低了非预期动脉穿刺率(2% vs 16%,P<0.0001)以及需要交叉至另一组的静脉入路尝试失败率(0.2% vs 8.2%,P<0.0001)。超声引导静脉入路用于心房颤动消融手术显著减少了血管入路部位并发症。NCT06403527。
European heart journal IF 45.3 2026-3-31 PMID: 41914181
Stroke and systemic embolism are recognized but poorly characterized complications of atrial fibrillation (AF) and left atrial flutter (AFL) catheter ablation. Their incidence, outcomes, and procedural associations remain insufficiently defined. Retrospective global registry was initiated by the European Heart Rhythm Association Scientific Committee. A secure database captured data from ablation centres worldwide on general AF and left AFL ablation activity, as well as detailed information on patients with symptomatic embolic events between 2017 and 2024. Overall, 204 centres reported 335 743 ablation procedures and 550 embolic events (incidence 0.16%). Centre-level rate ranged from 0% to 3.1%. Most events were cerebral (94%), followed by peripheral (5%), and combined (1%). Coronary air embolism accounted for 62% of all peripheral events. Intraprocedural events occurred in 93 patients (17%), within 72 h in 357 (78%) and beyond 72 h in 100 (22%); 128 cases (23%) were diagnosed after hospital discharge. Nonparoxysmal AF (0.23% vs 0.15%; P < .001), centre experience, and ablation energy source (radiofrequency, 0.16%; cryoballoon, 0.16%; pulsed field ablation, 0.25%; laserballoon, 0.88%; P < .001) were associated with embolic risk. Median NIHSS score after stroke was 4 (interquartile range, 2-9). Three-month follow-up was available for 518 patients with embolism (95%): 181 (35%) had sequelae and 16 (3%) died. Symptomatic embolic events are infrequent but associated with significant morbidity and mortality. Most events occur early, though a substantial proportion arise later. Higher event rates were observed with laser and possibly with pulsed field ablation. A greater centre experience was associated with a lower embolism incidence.
中文摘要:卒中与系统性栓塞是心房颤动(AF)和左心房扑动(AFL)导管消融中已被认识但特征描述不足的并发症。其发生率、结局及与手术操作的相关性仍未充分明确。这项回顾性全球注册研究由欧洲心律学会科学委员会发起。一个安全数据库收集了全球各消融中心关于一般AF和左AFL消融活动的数据,以及2017年至2024年间出现症状性栓塞事件患者的详细信息。总体而言,204个中心报告了335743例消融手术和550例栓塞事件(发生率0.16%)。中心层面发生率范围为0%至3.1%。大多数事件为脑栓塞(94%),其次为外周栓塞(5%)和合并栓塞(1%)。冠状动脉空气栓塞占所有外周事件的62%。术中事件发生于93例患者(17%),72小时内发生357例(78%),72小时后发生100例(22%);128例(23%)在出院后诊断。非阵发性AF(0.23% vs 0.15%;P < .001)、中心经验和消融能量来源(射频,0.16%;冷冻球囊,0.16%;脉冲场消融,0.25%;激光球囊,0.88%;P < .001)与栓塞风险相关。卒中后NIHSS评分中位数为4(四分位距2-9)。518例栓塞患者(95%)可获得3个月随访:181例(35%)有后遗症,16例(3%)死亡。症状性栓塞事件不常见,但与显著发病率和死亡率相关。大多数事件发生较早,但相当一部分发生较晚。激光消融以及可能脉冲场消融观察到更高的事件发生率。中心经验越多与栓塞发生率越低相关。
European heart journal IF 45.3 2026-3-28 PMID: 41895321
Atrial fibrillation (AF) is frequently classified by episode duration and cumulative burden, yet these methods fail to characterize temporal episode distribution (AF density), which may be more clinically relevant and prognostically important. This study evaluated AF density's association with ischaemic stroke and whether it improves risk stratification compared with AF burden. Data from two US cohorts with cardiac implantable electronic devices remotely monitored by the Veterans Health Administration and University of North Carolina (January 2010-May 2025) were analysed. AF burden (percentage of time in AF) and density [range: 0 (dispersed episodes) to 1 (consolidated episodes)] were assessed in 30-day intervals and categorized as low (>0-0.3), medium (>0.3-0.6), medium-high (>0.6-0.9), and high (>0.9-1.0). Patients with permanent AF or no episodes ≥6 min were excluded. G-formula modelling estimated 1-year stroke risk ratios (RRs), adjusting for baseline and time-varying covariates. Results were pooled using random-effects meta-analysis. Of 41 780 patients, 12 868 met inclusion criteria (mean age 72.0 years; median CHA2DS2-VASc 4.0); 336 experienced ischaemic stroke over a median 4.0-year follow-up (6.3 per 1000 person-years). Atrial fibrillation density demonstrated a dose-response relationship with 1-year stroke risk (RR 1.75; 95% confidence interval 1.25-2.44) and findings were consistent across device types, comorbidities, age, and anticoagulation status. At each level of AF burden, patients with high density exhibited greater stroke risk. Atrial fibrillation density demonstrated robust dose-response relationships with ischaemic stroke independent of AF burden and enhanced risk stratification, suggesting that density may enable more precise stroke risk assessment and personalized prevention strategies.
中文摘要:心房颤动(AF)常按发作持续时间与累积负荷进行分类,但这些方法无法刻画发作的时间分布(AF密度),而后者可能更具临床相关性并在预后上更重要。本研究评估了AF密度与缺血性卒中的关联,以及其相较AF负荷是否能改善风险分层。研究分析了来自美国两个队列的数据,这些患者植入了心脏植入式电子设备并由退伍军人健康管理局和北卡罗来纳大学进行远程监测(2010年1月至2025年5月)。AF负荷(处于AF的时间百分比)和密度[范围:0(分散发作)至1(集中发作)]按30天间隔进行评估,并分为低(>0-0.3)、中(>0.3-0.6)、中高(>0.6-0.9)和高(>0.9-1.0)。永久性AF或无≥6分钟发作的患者被排除。采用G公式模型估计1年卒中风险比(RR),并校正基线和时变协变量。结果采用随机效应荟萃分析进行合并。在41 780例患者中,12 868例符合纳入标准(平均年龄72.0岁;中位CHA2DS2-VASc 4.0);在中位4.0年随访期间,336例发生缺血性卒中(6.3/1000人年)。AF密度与1年卒中风险呈剂量-反应关系(RR 1.75;95%置信区间1.25-2.44),且在不同设备类型、合并症、年龄和抗凝状态中结果一致。在每一AF负荷水平下,高密度患者的卒中风险更高。AF密度与缺血性卒中表现出稳健的剂量-反应关系,且独立于AF负荷并增强了风险分层,提示密度可能有助于更精确的卒中风险评估和个体化预防策略。

基础研究 (1篇)

European journal of preventive cardiology IF 10.0 2026-9-18 PMID: 42759499
We aimed to investigate in a rodent model whether the detrimental cardiovascular effects of chronic strenuous exercise observed in males (atrial fibrillation, right ventricle and vascular maldaption) also occur in females. Male and female Wistar rats underwent a 16-week high-intensity treadmill regimen or remained sedentary. Structural and functional cardiac parameters were assessed through echocardiography, electrocardiography, invasive hemodynamics, histology, molecular biology, and transcriptomic profiling. Exercise induced comparable physiological left ventricular remodeling in both sexes, alongside systolic and diastolic right ventricular dysfunction. Notably, females developed atrial fibrosis and exhibited a similar propensity for atrial fibrillation as their male counterparts. However, transcriptional remodeling in the atria was sex- and chamber-specific, with exercise-induced gene expression changes being more pronounced in the left atrium of females. In the vasculature, sedentary females displayed superior endothelial function, but unlike males, failed to improve after training. Furthermore, exercised females developed tunica media fibrosis without accompanying oxidative stress, suggesting divergent mechanisms of vascular injury. Plasma proteomic profiling at rest identified Ccl20 as a candidate biomarker of exercise-induced cardiovascular damage; acute post-exercise responses revealed numerous sex-specific alterations in circulating biomarkers, including those associated with inflammation and fibrosis. Females engaged in regular strenuous endurance exercise are at an increased risk of atrial fibrillation and vascular harm, similar to males. However, underlying mechanisms and phenotypic expressions are strongly sex-dependent. These findings highlight the importance of incorporating sex-specific approaches into the diagnostic and prognostic evaluation of cardiovascular adaptations and risks associated with endurance training.
中文摘要:我们旨在通过啮齿动物模型研究,在雄性中观察到的慢性剧烈运动的心血管有害效应(心房颤动、右心室和血管适应不良)是否也发生在雌性中。雄性和雌性Wistar大鼠接受16周高强度跑台方案或保持久坐。通过超声心动图、心电图、侵入性血流动力学、组织学、分子生物学和转录组分析评估结构和功能心脏参数。运动在两种性别中诱导了相似的生理性左心室重塑,并伴有收缩期和舒张期右心室功能障碍。值得注意的是,雌性出现心房纤维化,并表现出与雄性相似的心房颤动易感性。然而,心房转录重塑具有性别和腔室特异性,运动诱导的基因表达变化在雌性左心房中更为明显。在血管方面,久坐雌性表现出更优的内皮功能,但与雄性不同,训练后未能改善。此外,运动雌性出现中膜纤维化,而不伴随氧化应激,提示血管损伤机制不同。静息时血浆蛋白质组分析确定Ccl20为运动诱导心血管损伤的候选生物标志物;运动后急性反应揭示循环生物标志物中大量性别特异性改变,包括与炎症和纤维化相关的标志物。定期进行剧烈耐力运动的雌性与雄性相似,心房颤动和血管损害风险增加。然而,潜在机制和表型表达强烈依赖性别。这些发现强调,在耐力训练相关心血管适应和风险的诊断与预后评估中纳入性别特异性方法的重要性。

5冠心病/心绞痛 (5篇)

临床研究 (4篇)

Circulation IF 41.3 2026-9-22 PMID: 42770221
The diagnostic value of coronary computed tomography angiography-derived fractional flow reserve (FFR-CT) in stable coronary artery disease is well established. The prognostic value of predicting future cardiovascular events is less clear, as studies are limited by small populations, variable measurement points, composite outcomes, and short follow-up. A nationwide cohort of coronary computed tomography angiography with 3-year follow-up was used to examine the association between FFR-CT measurements and future cardiovascular events. Patients receiving coronary computed tomography angiography and clinically indicated FFR-CT analysis (HeartFlow) for stable coronary artery disease between 2017 and 2020 at 27 sites across England were included. Lowest per-patient stenosis-specific and distal vessel FFR-CT measurements were related to individual outcomes of myocardial infarction (MI), cardiovascular mortality, all-cause mortality, and revascularization. FFR-CT measurements were divided into subgroups to investigate for a gradient of risk: normal FFR-CT (>0.8), borderline (0.71-0.8), reduced (0.51-0.7), and severely reduced (≤0.5). In total, 7836 patients aged 63 (56.0-71.0), 37.4% women, underwent FFR-CT analysis. Stenosis-specific FFR-CT was associated with future MI (hazard ratio [HR], 2.08-5.73; P<0.001), cardiovascular death (HR, 1.51-3.40; P<0.001), all-cause death (HR, 1.01-1.58; P=0.01), and revascularization (HR, 4.79-24.48; P<0.001), with lower FFR-CT values associated with incrementally greater risk. After adjusting for cardiovascular risk factors and coronary stenosis severity (Coronary Artery Disease Reporting and Data System), stenosis-specific FFR-CT≤0.7 was associated with MI (adjusted HR, 2.94-3.39; P<0.001), ≤0.5 with cardiovascular death (adjusted HR, 2.92; P=0.02), all-cause death (adjusted HR, 1.49; P=0.045), and ≤0.8 with revascularization (adjusted HR, 3.02-9.42; P<0.001). The addition of FFR-CT improved discrimination for MI or cardiovascular death compared with a risk factor and stenosis severity model (C index, 0.783; ∆C index, 0.012; P<0.001). An FFR-CT value of 0.67 defined the optimal cutoff for risk of future cardiovascular events. Distal-vessel FFR-CT was associated with outcomes similar to stenosis-specific FFR-CT. Stenosis-specific and distal-vessel FFR-CT discordance was common (36.4%), but when stenosis-specific FFR-CT was normal, event rates were low (1.5% at 3 years for MI or cardiovascular death). FFR-CT is associated with the individual outcomes of MI, cardiovascular death, and all-cause death independent of risk factors and stenosis severity, with lower FFR-CT values associated with worse outcomes. Reduced and severely reduced FFR-CT have the strongest association with future cardiovascular events, with a value of 0.67 defining the optimal risk threshold.
中文摘要:冠状动脉计算机断层扫描血管成像衍生血流储备分数(FFR-CT)在稳定性冠心病中的诊断价值已明确。其预测未来心血管事件的预后价值尚不明确,因为相关研究受限于人群较小、测量点不一、复合终点和随访时间短。一项全国性冠状动脉计算机断层扫描血管成像队列随访3年,用于检验FFR-CT测量值与未来心血管事件之间的关联。纳入2017年至2020年间在英格兰27个中心因稳定性冠心病接受冠状动脉计算机断层扫描血管成像及有临床指征的FFR-CT分析(HeartFlow)的患者。每位患者最低的狭窄特异性及远端血管FFR-CT测量值与心肌梗死(MI)、心血管死亡、全因死亡和血运重建等个体结局相关。将FFR-CT测量值分为亚组以探讨风险梯度:正常FFR-CT(>0.8)、临界(0.71-0.8)、降低(0.51-0.7)和严重降低(≤0.5)。总共7836例患者,年龄63(56.0-71.0)岁,女性占37.4%,接受了FFR-CT分析。狭窄特异性FFR-CT与未来MI(风险比[HR],2.08-5.73;P<0.001)、心血管死亡(HR,1.51-3.40;P<0.001)、全因死亡(HR,1.01-1.58;P=0.01)和血运重建(HR,4.79-24.48;P<0.001)相关,FFR-CT值越低,风险递增。在调整心血管危险因素和冠状动脉狭窄严重程度(冠状动脉疾病报告和数据系统)后,狭窄特异性FFR-CT≤0.7与MI相关(校正HR,2.94-3.39;P<0.001),≤0.5与心血管死亡相关(校正HR,2.92;P=0.02)、全因死亡相关(校正HR,1.49;P=0.045),≤0.8与血运重建相关(校正HR,3.02-9.42;P<0.001)。与仅包含危险因素和狭窄严重程度的模型相比,加入FFR-CT改善了对MI或心血管死亡的区分能力(C指数,0.783;ΔC指数,0.012;P<0.001)。FFR-CT值0.67界定了未来心血管事件风险的最佳截断值。远端血管FFR-CT与结局的关联与狭窄特异性FFR-CT相似。狭窄特异性与远端血管FFR-CT不一致较常见(36.4%),但当狭窄特异性FFR-CT正常时,事件率较低(3年时MI或心血管死亡为1.5%)。FFR-CT与MI、心血管死亡和全因死亡等个体结局相关,且独立于危险因素和狭窄严重程度;FFR-CT值越低,结局越差。降低和严重降低的FFR-CT与未来心血管事件的关联最强,0.67为最佳风险阈值。
Circulation IF 41.3 2026-8-25 PMID: 42639673
Apo (apolipoprotein) AI glycation has been implicated in HDL (high-density lipoprotein) dysfunction, but its site-resolved landscape, clinical relevance, relationship with diabetic atherosclerosis, and underlying mechanisms remain incompletely defined. We performed unbiased site-resolved glycation proteomics in 860 patients with type 2 diabetes and coronary atherosclerosis (CAS) and 294 controls with type 2 diabetes without CAS to define the plasma apo AI glycation landscape. Apo AI glycation signatures associated with diabetic CAS were identified using integrated unsupervised and supervised analyses. An Apo AI Glycation Index was developed using least absolute shrinkage and selection operator regression and evaluated in training, testing, and independent validation cohorts. To assess functional relevance, a glycation-resistant apo AI mutant, cross-linked apo AI (apo AICL), was engineered and tested under glycation conditions using surface plasmon resonance, in vitro and in vivo reverse cholesterol transport assays, HDL remodeling analyses, and atherosclerosis models. RNA sequencing, macrophage-specific knockout models, receptor-binding assays, signaling inhibition, and cholesterol efflux rescue experiments were used to investigate the underlying macrophage pathway. Apo AI glycation patterns differed between patients with type 2 diabetes with and without CAS, with K96 and K106/107 emerging as prominent disease-associated glycation sites. The Apo AI Glycation Index was independently associated with CAS and coronary artery disease in patients with type 2 diabetes and was inversely associated with HDL-mediated reverse cholesterol transport and lecithin-cholesterol acyltransferase activity. Compared with native apo AI, apo AICL showed reduced key-site glycation, preserved structural stability, enhanced binding affinity to lecithin-cholesterol acyltransferase, and improved HDL-mediated reverse cholesterol transport under glycation conditions. In diabetic mouse models, apo AICL attenuated HDL dysfunction and atherosclerotic lesion formation compared with glycated apo AI. These data support a candidate mechanism in which glycated apo AI enhances RAGE (receptor for advanced glycation end products) interaction and activates ERK1/2 (extracellular signal-regulated kinase 1/2)-NF-κB (nuclear factor κB)/p65 signaling, leading to upregulation of NR2C2 (nuclear receptor subfamily 2 group C member 2). LXRα (liver X receptor α) activation and macrophage NR2C2 deficiency restored cholesterol efflux in glycated apo AI-treated macrophages. This study provides a comprehensive site-resolved map of apo AI glycation in patients with diabetes and identifies the Apo AI Glycation Index as a glycation signature associated with diabetic CAS and impaired HDL function. Experimental data support a mechanism in which site-specific apo AI glycation contributes to HDL dysfunction and macrophage cholesterol efflux impairment through RAGE-associated NR2C2-LXRα signaling. Glycation-resistant apo AICL preserves HDL function and attenuates atherosclerosis in preclinical models, supporting site-specific apo AI glycation as a mechanistically relevant feature of diabetic atherosclerosis. URL: https://www.clinicaltrials.gov; Unique identifier: NCT05659043.
中文摘要:载脂蛋白(Apo)AI糖基化已被认为与HDL(高密度脂蛋白)功能障碍有关,但其位点分辨图谱、临床相关性、与糖尿病动脉粥样硬化的关系及潜在机制仍未完全明确。我们对860例2型糖尿病合并冠状动脉粥样硬化(CAS)患者和294例2型糖尿病不合并CAS的对照者进行了无偏位点分辨糖基化蛋白质组学分析,以描绘血浆Apo AI糖基化图谱。通过整合无监督和有监督分析,识别出与糖尿病CAS相关的Apo AI糖基化特征。采用最小绝对收缩和选择算子回归构建Apo AI糖基化指数,并在训练、测试和独立验证队列中评估。为评估功能相关性,我们构建了一种抗糖基化Apo AI突变体——交联Apo AI(apo AICL),并在糖基化条件下通过表面等离子体共振、体外和体内逆向胆固醇转运实验、HDL重塑分析及动脉粥样硬化模型进行测试。使用RNA测序、巨噬细胞特异性敲除模型、受体结合实验、信号抑制和胆固醇外流挽救实验来探究潜在的巨噬细胞通路。合并CAS与不合并CAS的2型糖尿病患者的Apo AI糖基化模式不同,其中K96和K106/107成为突出的疾病相关糖基化位点。Apo AI糖基化指数与2型糖尿病患者的CAS和冠状动脉疾病独立相关,并与HDL介导的逆向胆固醇转运及卵磷脂-胆固醇酰基转移酶活性呈负相关。与天然Apo AI相比,apo AICL在糖基化条件下显示出关键位点糖基化减少、结构稳定性保持、与卵磷脂-胆固醇酰基转移酶的结合亲和力增强以及HDL介导的逆向胆固醇转运改善。在糖尿病小鼠模型中,与糖基化Apo AI相比,apo AICL减轻了HDL功能障碍和动脉粥样硬化病变形成。这些数据支持一种候选机制,即糖基化Apo AI增强RAGE(晚期糖基化终产物受体)相互作用并激活ERK1/2(细胞外信号调节激酶1/2)-NF-κB(核因子κB)/p65信号,导致NR2C2(核受体亚家族2C组成员2)上调。LXRα(肝X受体α)激活和巨噬细胞NR2C2缺陷可恢复糖基化Apo AI处理巨噬细胞中的胆固醇外流。本研究提供了糖尿病患者Apo AI糖基化的全面位点分辨图谱,并确定Apo AI糖基化指数为与糖尿病CAS和HDL功能受损相关的糖基化特征。实验数据支持一种机制,即位点特异性Apo AI糖基化通过RAGE相关的NR2C2-LXRα信号促进HDL功能障碍和巨噬细胞胆固醇外流受损。抗糖基化apo AICL在临床前模型中保留HDL功能并减轻动脉粥样硬化,支持位点特异性Apo AI糖基化是糖尿病动脉粥样硬化中具有机制相关性的特征。网址:https://www.clinicaltrials.gov;唯一标识符:NCT05659043。
European journal of preventive cardiology IF 10.0 2026-4-12 PMID: 41964642
The aim of this study was to present sex-specific reference data for peak oxygen uptake (V̇O2peak) in Norwegian patients with coronary artery disease (CAD) undergoing cardiac rehabilitation and examine its association with major adverse cardiovascular events (MACEs). We retrospectively analysed treadmill cardiopulmonary exercise test (CPET) data from 1651 CAD patients (21% women; mean (SD) age 61 (9) years) attending inpatient cardiac rehabilitation (2004-2022). Patients were categorized by index event: myocardial infarction (MI), coronary artery bypass grafting (CABG), or percutaneous coronary intervention/pharmacologically treated CAD (PCI/CAD). Age-, sex-, and diagnosis-specific V̇O2peak reference data were generated. Associations between V̇O2peak and a combined MACE endpoint (all-cause mortality, acute coronary syndrome, stroke, or heart failure) were assessed using Cox proportional hazards models, including natural cubic splines for assessing non-linear patterns. Men had higher V̇O2peak than women (26.9 (6.7) vs. 23.2 (5.3) mL·kg-1·min-1; P < 0.001). V̇O2peak was on average 2.5 and 1.7 mL·kg-1·min-1 lower per decade of age in men and women, respectively. Patients with a previous MI had the highest V̇O2peak, followed by CABG and PCI/CAD (P < 0.001). During 7880 person-years, 510 patients (36%) experienced MACE. Each 1 mL·kg-1·min-1 higher V̇O2peak was associated with a 7% lower MACE risk (HR [95% CI]; 0.93 [0.92-0.95]) in men and 5% (HR [95% CI]; 0.95 [0.91-0.99]) in women. Patients in the highest cardiorespiratory fitness quartile had a 55% lower risk compared to the lowest quartile. Associations were consistent across CAD subcategories. Sex-specific natural cubic spline models revealed inverse, non-linear associations. This study provides novel sex- and diagnosis-specific V̇O2peak reference values for Norwegian CAD patients and confirms V̇O2peak as a strong prognostic marker, supporting its integration into routine secondary prevention and individualized care.
中文摘要:本研究的目的是呈现挪威接受心脏康复的冠状动脉疾病(CAD)患者按性别区分的峰值摄氧量(V̇O2peak)参考数据,并探讨其与主要不良心血管事件(MACE)的关联。我们回顾性分析了1651例参加住院心脏康复(2004-2022年)的CAD患者的跑台心肺运动试验(CPET)数据(21%为女性;平均(SD)年龄61(9)岁)。患者按索引事件分类:心肌梗死(MI)、冠状动脉旁路移植术(CABG)或经皮冠状动脉介入治疗/药物治疗的CAD(PCI/CAD)。生成了按年龄、性别和诊断分层的V̇O2peak参考数据。采用Cox比例风险模型评估V̇O2peak与复合MACE终点(全因死亡、急性冠脉综合征、卒中或心力衰竭)之间的关联,并纳入自然三次样条以评估非线性模式。男性V̇O2peak高于女性(26.9(6.7) vs. 23.2(5.3) mL·kg-1·min-1;P < 0.001)。在男性和女性中,年龄每增加10岁,V̇O2peak平均分别降低2.5和1.7 mL·kg-1·min-1。既往MI患者的V̇O2peak最高,其次为CABG和PCI/CAD(P < 0.001)。在7880人年的随访期间,510例患者(36%)发生MACE。V̇O2peak每升高1 mL·kg-1·min-1,男性MACE风险降低7%(HR [95% CI];0.93 [0.92-0.95]),女性降低5%(HR [95% CI];0.95 [0.91-0.99])。心肺适能最高四分位组患者相较于最低四分位组风险降低55%。这种关联在CAD各亚组中一致。按性别分层的自然三次样条模型显示反向非线性关联。本研究提供了挪威CAD患者按性别和诊断区分的新的V̇O2peak参考值,并证实V̇O2peak是强有力的预后标志物,支持将其纳入常规二级预防和个体化照护。
Cardiovascular research IF 12.5 2026-9-19 PMID: 42762227
Inadequate pharmacologic stress may limit the diagnostic and prognostic accuracy of myocardial perfusion imaging (MPI). The splenic ratio (SR), a measure of stress adequacy, has emerged as a potential imaging biomarker. We developed an artificial intelligence (AI) method to derive SR and evaluated the prognostic value in a large multicentre 82Rb-PET cohort undergoing regadenoson stress testing. We retrospectively analysed 16 650 patients from six sites in the REFINE PET registry with clinically indicated MPI and linked clinical outcomes. SR was calculated using fully automated algorithms as the ratio of splenic uptake at stress vs. rest. Patients were stratified by SR into decile groups. The primary outcome was major adverse cardiovascular events (MACE). Survival analysis was conducted using Kaplan-Meier and Cox proportional hazards models adjusted for clinical and imaging covariates, including myocardial flow reserve (MFR ≥2 vs. <2) and presence of ischaemia. The cohort had a median age of 69 years, with 59% male patients. Common risk factors included hypertension (81%), dyslipidaemia (77%), diabetes (35%), and prior coronary artery disease (31%). Median follow-up was 3.4 years. Patients with high SR in the testing cohort (n = 950) had an increased risk of MACE [hazard ratio (HR) 1.19, 95% confidence interval (CI) 1.06-1.34, P = 0.005]. Among testing patients with preserved MFR (≥2; n = 8067), high SR remained independently associated with MACE (HR 1.43, 95% CI 1.20-1.70, P < 0.001). Even among patients with preserved MFR and no ischaemia in the testing cohort(MFR≥2, SDS<2; n = 6508), high SR remained independently associated with MACE (HR 1.54 95% CI 1.26-1.88, P < 0.001). Elevated AI-derived SR was independently associated with adverse cardiovascular outcomes, including among patients with preserved MFR. These findings support SR as a novel, automated imaging biomarker for risk stratification in 82Rb PET MPI.
中文摘要:药物负荷不充分可能限制心肌灌注显像(MPI)的诊断与预后准确性。脾脏比值(SR)作为反映负荷充分性的一项指标,已成为一种潜在的影像生物标志物。我们开发了一种人工智能(AI)方法来计算SR,并在一个接受瑞加德松负荷试验的大型多中心82Rb-PET队列中评估其预后价值。我们回顾性分析了REFINE PET注册研究中来自6个中心的16 650例具有临床指征的MPI患者,并关联其临床结局。SR通过全自动算法计算,即负荷状态与静息状态脾脏摄取的比值。按SR将患者分层为十分位组。主要结局为主要不良心血管事件(MACE)。采用Kaplan-Meier法进行生存分析,并应用Cox比例风险模型,校正临床与影像协变量,包括心肌血流储备(MFR≥2 vs. <2)及是否存在缺血。队列中位年龄为69岁,男性占59%。常见危险因素包括高血压(81%)、血脂异常(77%)、糖尿病(35%)和既往冠心病(31%)。中位随访时间为3.4年。在测试队列(n=950)中,SR较高的患者MACE风险增加[风险比(HR)1.19,95%置信区间(CI)1.06-1.34,P=0.005]。在MFR保留(≥2;n=8067)的测试队列患者中,高SR仍与MACE独立相关(HR 1.43,95% CI 1.20-1.70,P<0.001)。即使在测试队列中MFR保留且无缺血的患者(MFR≥2,SDS<2;n=6508)中,高SR仍与MACE独立相关(HR 1.54,95% CI 1.26-1.88,P<0.001)。AI推导的SR升高与不良心血管结局独立相关,包括在MFR保留的患者中。这些发现支持将SR作为一种新型的自动化影像生物标志物,用于82Rb PET MPI的风险分层。

基础研究 (1篇)

Archives of toxicology IF 10.9 2026-9-19 PMID: 42762264
Clozapine is indispensable for treatment-resistant schizophrenia, but its effects on endothelial repair and their potential relevance to coronary artery disease remain insufficiently characterized. We combined a propensity score-matched nationwide cohort of 28,802 patients with experiments in primary human endothelial progenitor cells and Tg(fli1:EGFP) zebrafish embryos. Clozapine use was associated with a higher incidence of coronary artery disease during up to 12 years of follow-up (adjusted hazard ratio 1.24, 95% confidence interval 1.13-1.36). In primary human endothelial progenitor cells, clozapine was tested at 1-30 μM for 24-48 h. It concentration-dependently reduced cell growth, migration, tube formation, oxygen consumption, and extracellular acidification. In silico docking predicted a potential interaction with the aryl hydrocarbon receptor (AHR) ligand-binding pocket. Clozapine increased CYP1A1 mRNA expression and reduced AHR protein level. The AHR antagonist CH-223191 (10 μM) partially restored cell growth and shifted extracellular acidification toward control levels, supporting involvement of AHR signaling. Clozapine also increased autophagosome accumulation and LC3-II abundance, while 3-methyladenine intensified growth inhibition, consistent with a potentially compensatory autophagy-associated response. Tg(fli1:EGFP) zebrafish embryos exposed to clozapine (15 or 30 μM) during 12-30 or 30-72 h post-fertilization developed concentration-dependent vascular abnormalities and increased mortality. These findings identify AHR-associated metabolic and angiogenic dysfunction as a plausible vascular effect of clozapine, while further studies are required to determine its contribution to the clinical association and its relevance to chronic therapeutic exposure.
中文摘要:氯氮平对于难治性精神分裂症不可或缺,但其对内皮修复的影响及其与冠状动脉疾病的潜在相关性仍未得到充分阐明。我们将一个包含28,802例患者的倾向评分匹配的全国性队列与在原代人内皮祖细胞和Tg(fli1:EGFP)斑马鱼胚胎中进行的实验相结合。氯氮平使用与随访长达12年期间冠状动脉疾病发生率升高相关(校正风险比1.24,95%置信区间1.13-1.36)。在原代人内皮祖细胞中,氯氮平以1-30 μM处理24-48 h进行测试。它以浓度依赖性方式降低细胞生长、迁移、成管、耗氧量和细胞外酸化。计算机对接预测其可能与芳香烃受体(AHR)配体结合口袋发生相互作用。氯氮平增加CYP1A1 mRNA表达并降低AHR蛋白水平。AHR拮抗剂CH-223191(10 μM)部分恢复细胞生长,并使细胞外酸化向对照水平偏移,支持AHR信号参与其中。氯氮平还增加自噬体积累和LC3-II丰度,而3-甲基腺嘌呤加重生长抑制,这与一种可能具有代偿性的自噬相关反应一致。在受精后12-30或30-72 h暴露于氯氮平(15或30 μM)的Tg(fli1:EGFP)斑马鱼胚胎出现浓度依赖性血管异常和死亡率增加。这些发现提示,AHR相关的代谢和血管生成功能障碍可能是氯氮平的一种血管效应,但仍需进一步研究以确定其对临床相关性的贡献及其与长期治疗暴露的相关性。

6心力衰竭 (5篇)

临床研究 (1篇)

Pharmacological research IF 12.2 2026-9-21 PMID: 42767539
Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous multisystem syndrome characterized by diastolic dysfunction, metabolic inflexibility, and impaired mitochondrial reserve. Human myocardial metabolomic and proteomic studies support broad oxidative and mitochondrial remodeling, but they do not establish a uniform primary defect in ketone oxidation across HFpEF. Evidence for reduced MCT1, BDH1, or SCOT/OXCT1 and for a ketolytic bottleneck is strongest in selected experimental cardiometabolic or multifactorial models; direct human myocardial ketone flux data remain sparse. Circulating β-hydroxybutyrate (β-OHB), transcardiac extraction, myocardial uptake, and complete mitochondrial oxidation are distinct measurements and may change in different directions. We therefore propose a phenotype-dependent framework that interprets systemic ketone supply together with myocardial transport and ketolysis, mitochondrial oxidative reserve, and extra-cardiac comorbidity, rather than treating ketone metabolism as a single uniformly activated or impaired pathway. β-OHB may also influence redox, inflammatory, histone deacetylase (HDAC), and lysine β-hydroxybutyrylation (Kbhb) pathways, although these effects are metabolically coupled and direct causal evidence in human HFpEF is lacking. Acute and short-term ketone interventions have produced selected hemodynamic changes without consistent improvement in exercise capacity, and clinical trials have not established ketone metabolism as a mediator of sodium-glucose cotransporter 2 inhibitor benefit. Ketone-targeted strategies should therefore be tested in phenotype-stratified studies using direct flux and mechanism-specific functional endpoints.
中文摘要:保留射血分数的心力衰竭(HFpEF)是一种异质性多系统综合征,以舒张功能障碍、代谢不灵活和线粒体储备受损为特征。人类心肌代谢组学和蛋白质组学研究支持广泛的氧化和线粒体重塑,但并未确立HFpEF中酮氧化存在统一的原发性缺陷。关于MCT1、BDH1或SCOT/OXCT1降低以及酮解瓶颈的证据,在选定的实验性心脏代谢或多因素模型中最强;直接的人体心肌酮通量数据仍然稀少。循环β-羟基丁酸(β-OHB)、跨心脏摄取、心肌摄取和完整的线粒体氧化是不同的测量指标,可能朝不同方向变化。因此我们提出一个表型依赖的框架,将全身酮供应与心肌转运和酮解、线粒体氧化储备及心外合并症一并解释,而不是把酮代谢视为单一统一激活或受损的通路。β-OHB还可能影响氧化还原、炎症、组蛋白去乙酰化酶(HDAC)和赖氨酸β-羟基丁酰化(Kbhb)通路,尽管这些效应在代谢上相互耦联,且在人类HFpEF中缺乏直接因果证据。急性和短期酮干预已产生选择性的血流动力学变化,但未一致改善运动能力,临床试验尚未确立酮代谢作为钠-葡萄糖协同转运蛋白2抑制剂获益的介质。因此,靶向酮的策略应在表型分层研究中测试,使用直接通量和机制特异性功能终点。

基础研究 (4篇)

Circulation IF 41.3 2026-9-22 PMID: 42770210
Heart failure remains a leading cause of mortality globally, driven by persistent mitochondrial dysfunction and maladaptive cardiac hypertrophy. Although impaired autophagic flux contributes to cardiac deterioration, the precise molecular mechanisms are still unclear. The ubiquitin-proteasome system serves as a critical regulator linking protein ubiquitination to autophagic flux and mitochondrial homeostasis. Asb2 (ankyrin repeat-containing protein with suppressor of cytokine signaling box 2), a muscle-specific E3 ubiquitin ligase essential for embryonic cardiogenesis, is uncharacterized in adult cardiac homeostasis and disease pathogenesis. Male mice with inducible cardiomyocyte-specific Asb2 knockout were generated to investigate Asb2's role in cardiac remodeling. Adeno-associated virus 9-mediated cardiomyocyte-specific Asb2 overexpression and KIF11 (kinesin family member 11) downregulation were used in transverse aortic constriction-induced hypertrophy and aging models. RNA sequencing, metabolite profiling, and mass spectrometry were used to assess the molecular mechanism by which Asb2 regulates cardiac metabolism and hypertrophy. Asb2β expression was significantly reduced in multiple forms of human cardiomyopathy and in hypertrophic murine hearts. Inducible Asb2 deletion in adult male mice led to the spontaneous development of cardiac hypertrophy and heart failure, accompanied by progressive accumulation of dysfunctional mitochondria and metabolic dysregulation. Mechanistically, Asb2 deficiency impaired ubiquitin-mediated degradation of KIF11, causing aberrant peripheral lysosomal redistribution and disrupting autophagosome-lysosome fusion, which resulted in impaired late-stage autophagic flux and metabolic disturbances. Notably, therapeutic restoration of Asb2 expression via adeno-associated virus 9-mediated delivery attenuated pressure overload-induced and age-related cardiac hypertrophy and heart failure. Moreover, both genetic and pharmacological inhibition of KIF11 effectively restored autophagic flux and mitochondrial homeostasis, thereby reversing pathological cardiac remodeling in Asb2-deficient hearts and transverse aortic constriction-induced cardiac dysfunction. Asb2 is a novel regulator of mitochondrial quality control in cardiomyocytes via KIF11-mediated lysosomal redistribution. Targeting the Asb2-KIF11 axis may be a promising strategy for improving mitochondrial homeostasis and cardiomyocyte function in chronic heart failure.
中文摘要:心力衰竭仍是全球主要死亡原因,其驱动因素包括持续存在的线粒体功能障碍和适应不良的心肌肥厚。尽管自噬流受损会促进心脏恶化,但确切的分子机制仍不清楚。泛素-蛋白酶体系统是将蛋白质泛素化与自噬流和线粒体稳态联系起来的关键调节因子。Asb2(含锚蛋白重复序列和细胞因子信号转导抑制盒2的蛋白)是一种肌肉特异性E3泛素连接酶,为胚胎期心脏发生所必需,但其在成体心脏稳态和疾病发病机制中的作用尚未明确。研究构建了成年雄性小鼠诱导性心肌细胞特异性Asb2敲除模型,以探讨Asb2在心脏重构中的作用。在横主动脉缩窄诱导的肥厚模型和衰老模型中,采用腺相关病毒9介导的心肌细胞特异性Asb2过表达和KIF11(驱动蛋白家族成员11)下调。利用RNA测序、代谢物谱分析和质谱分析评估Asb2调控心脏代谢和肥厚的分子机制。在多种类型的人类心肌病和肥厚小鼠心脏中,Asb2β表达显著降低。成年雄性小鼠中诱导性Asb2缺失导致自发性心肌肥厚和心力衰竭,并伴随功能失调的线粒体进行性积聚和代谢紊乱。机制上,Asb2缺乏损害泛素介导的KIF11降解,引起异常的周围溶酶体再分布并破坏自噬体-溶酶体融合,从而导致晚期自噬流受损和代谢紊乱。值得注意的是,通过腺相关病毒9介导的递送恢复Asb2表达的治疗策略减轻了压力超负荷诱导的和年龄相关的心肌肥厚与心力衰竭。此外,遗传学和药理学抑制KIF11均有效恢复了自噬流和线粒体稳态,从而逆转了Asb2缺陷心脏中的病理性心脏重构以及横主动脉缩窄诱导的心脏功能障碍。Asb2是通过KIF11介导的溶酶体再分布来调控心肌细胞线粒体质量控制的新型调节因子。靶向Asb2-KIF11轴可能是改善慢性心力衰竭中线粒体稳态和心肌细胞功能的一种有前景的策略。
Acta pharmacologica Sinica IF 10.4 2026-9-19 PMID: 42760346
Heart failure with preserved ejection fraction (HFpEF) accounts for approximately 50% of all heart failure cases worldwide, yet effective targeted therapies remain limited. Tectorigenin (Tec), a bioactive isoflavone derived from traditional Chinese medicine, exhibits diverse cardioprotective effects; however, its therapeutic potential and underlying mechanisms in HFpEF remain incompletely understood. This study aimed to investigate the effects of Tec on HFpEF and elucidate the underlying molecular mechanisms. A mouse model of HFpEF was established using the "two-hit" approach (high-fat diet + L-NAME). In vivo experiments included echocardiography, histological staining, treadmill testing, metabolic assessments, and molecular analyses. In vitro, neonatal rat ventricular myocytes (NRVMs) exposed to palmitic acid (PA) were used to model cardiomyocyte lipotoxicity. RNA sequencing, network pharmacology, molecular docking, surface plasmon resonance, pull-down assays, chromatin immunoprecipitation, and gene silencing were employed to elucidate the regulatory mechanisms. Tec attenuated HFpEF progression and retained therapeutic efficacy when administered after HFpEF establishment. In vitro, Tec alleviated PA-induced cardiomyocyte lipotoxicity. Mechanistically, Tec directly bound EGFR at the E762/M793 sites and inhibited its aberrant activation. Inhibition of EGFR signaling suppressed the downstream EGFR-EGR2 axis, thereby upregulating Acot1 and improving myocardial lipid metabolic homeostasis. Cardiac-specific Acot1 knockdown or pharmacological activation of EGFR markedly attenuated Tec-mediated improvements in cardiac function, remodeling, and myocardial lipid metabolism. Tec ameliorates HFpEF through the EGFR-EGR2-Acot1 axis, highlighting a potential therapeutic strategy for HFpEF.
中文摘要:射血分数保留的心力衰竭(HFpEF)约占全球所有心力衰竭病例的50%,但有效的靶向治疗仍然有限。鸢尾苷元(Tectorigenin,Tec)是一种源自中药的生物活性异黄酮,具有多种心脏保护作用;然而,其在HFpEF中的治疗潜力和潜在机制仍不完全清楚。本研究旨在探讨Tec对HFpEF的作用并阐明其潜在分子机制。采用「双打击」方法(高脂饮食+L-NAME)建立小鼠HFpEF模型。体内实验包括超声心动图、组织学染色、跑台测试、代谢评估和分子分析。体外,使用暴露于棕榈酸(PA)的新生大鼠心室肌细胞(NRVMs)来模拟心肌细胞脂毒性。采用RNA测序、网络药理学、分子对接、表面等离子体共振、pull-down实验、染色质免疫沉淀和基因沉默来阐明调控机制。Tec减轻了HFpEF进展,并且在HFpEF建立后给药仍保持治疗效果。体外,Tec减轻了PA诱导的心肌细胞脂毒性。机制上,Tec直接结合EGFR的E762/M793位点并抑制其异常激活。抑制EGFR信号传导可抑制下游EGFR-EGR2轴,从而上调Acot1并改善心肌脂质代谢稳态。心脏特异性Acot1敲低或EGFR的药理学激活显著减弱了Tec介导的心脏功能、重构和心肌脂质代谢改善。Tec通过EGFR-EGR2-Acot1轴改善HFpEF,突出了HFpEF的潜在治疗策略。
Molecular biomedicine IF 13.0 2026-9-18 PMID: 42754758
Pathological cardiac remodeling is a significant contributor to heart failure and mortality. Studies have demonstrated that extracellular signal regulated kinase 3 (ERK3) in cardiac fibroblasts aggravates pressure overload-evoked pathological cardiac remodeling via mitogen activated protein kinase-activated protein kinase-5 (MK5). However, myocardial ERK3 does not activate MK5, thus the role of myocardial ERK3 remains unclear. Through in vivo and in vitro experiments, we revealed that myocardial ERK3 expression increases under pressure overload and the protein accumulates significantly in the nucleus. Using cardiomyocyte-specific Erk3-deficient mice, neonatal rat cardiomyocytes and adult mouse cardiomyocytes, we found that cardiomyocyte-specific Erk3 deficiency ameliorated pressure overload-induced pathological cardiac remodeling in vivo. Co-immunoprecipitation, mass spectrometry, and single nucleus RNA sequencing were used to analyse for the nuclear translocation and downstream signaling mechanisms of ERK3. Specifically, pressure overload enhances the binding of Aly/REF export factor (ALY) to ERK3, resulting in the truncation of the ERK3 C-terminal and its subsequent nuclear translocation to activate the thioredoxin-interacting protein (TXNIP)/NOD-like receptor thermal protein domain associated protein 3 (NLRP3) pathway through the expression of the splicing factor proline and glutamine rich (SFPQ). To screen for targeted drugs, we conducted a virtual screening and identified estrone sulfate as an inhibitor of ALY to counteract hypertrophic effects. Collectively, our findings indicate that estrone sulfate functions as a novel inhibitor of the ALY-ERK3 signaling pathway, potentially serving as a promising therapeutic candidate for the management of pathological cardiac remodeling.
中文摘要:病理性心脏重塑是心力衰竭和死亡的重要促成因素。研究表明,心脏成纤维细胞中的细胞外信号调节激酶3(ERK3)通过丝裂原活化蛋白激酶激活蛋白激酶-5(MK5)加重压力超负荷诱发的病理性心脏重塑。然而,心肌ERK3并不激活MK5,因此心肌ERK3的作用仍不清楚。通过体内和体外实验,我们发现心肌ERK3表达在压力超负荷下增加,并且该蛋白在细胞核中显著积累。使用心肌细胞特异性Erk3缺陷小鼠、新生大鼠心肌细胞和成年小鼠心肌细胞,我们发现在体内心肌细胞特异性Erk3缺陷可改善压力超负荷诱导的病理性心脏重塑。采用共免疫沉淀、质谱分析和单核RNA测序分析ERK3的核转位及下游信号机制。具体而言,压力超负荷增强Aly/REF输出因子(ALY)与ERK3的结合,导致ERK3 C端截短及其随后的核转位,通过表达富含脯氨酸和谷氨酰胺的剪接因子(SFPQ)激活硫氧还蛋白相互作用蛋白(TXNIP)/NOD样受体热蛋白结构域相关蛋白3(NLRP3)通路。为筛选靶向药物,我们进行了虚拟筛选并鉴定出硫酸雌酮作为ALY抑制剂以抵消肥大效应。总之,我们的研究结果表明,硫酸雌酮作为ALY-ERK3信号通路的新型抑制剂,可能成为治疗病理性心脏重塑的有前景的候选药物。
Redox biology IF 16.2 2026-9-19 PMID: 42762777
Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous and increasingly prevalent syndrome for which effective disease-modifying therapies remain limited, in part because its multicellular pathophysiology remains incompletely understood. Mitochondrial dysfunction has emerged as an important contributor to HFpEF, yet most studies have examined mitochondrial abnormalities within individual cell types rather than as part of an integrated cardiac microenvironment. This review discusses evidence that cell-type-specific mitochondrial alterations in cardiomyocytes, fibroblasts, and endothelial cells may interact through redox, metabolic, and paracrine signaling to promote diastolic dysfunction, myocardial stiffening, and impaired energetic reserve. In cardiomyocytes, disrupted mitochondrial calcium (mCa2+) handling and redox imbalance uncouple ATP production from energetic demand, contributing to Ca2+ overload, mitochondrial reactive oxygen species (mtROS) generation, and impaired relaxation. In fibroblasts, mitochondrial and metabolic reprogramming support profibrotic activation and extracellular matrix (ECM) deposition. In endothelial cells, mitochondrial dysfunction reduces nitric oxide bioavailability, enhances oxidative stress, and contributes to microvascular dysfunction. Together, these cell-type-specific mitochondrial abnormalities may converge on a redox-calcium-energetics axis that helps explain the dissociation between preserved systolic function and impaired diastolic performance in HFpEF. We further highlight mitochondrial heterogeneity and intercellular crosstalk as potential determinants of disease progression and discuss emerging therapeutic strategies targeting mitochondrial pathways as a rationale for precision approaches in HFpEF.
中文摘要:射血分数保留的心力衰竭(HFpEF)是一种异质性高且患病率不断上升的综合征,目前仍缺乏有效的疾病修饰治疗,部分原因在于其多细胞病理生理机制尚未被完全理解。线粒体功能障碍已成为HFpEF的重要促成因素,但多数研究是在单一细胞类型中考察线粒体异常,而非将其作为整合的心脏微环境的一部分。本综述讨论以下证据:心肌细胞、成纤维细胞和内皮细胞中细胞类型特异性的线粒体改变可能通过氧化还原、代谢和旁分泌信号相互作用,促进舒张功能障碍、心肌僵硬和能量储备受损。在心肌细胞中,线粒体钙(mCa2+)处理紊乱和氧化还原失衡使ATP产生与能量需求解偶联,导致Ca2+超载、线粒体活性氧(mtROS)生成和松弛受损。在成纤维细胞中,线粒体和代谢重编程支持促纤维化激活和细胞外基质(ECM)沉积。在内皮细胞中,线粒体功能障碍降低一氧化氮生物利用度、增强氧化应激并促进微血管功能障碍。总之,这些细胞类型特异性的线粒体异常可能汇聚于氧化还原-钙-能量轴,有助于解释HFpEF中收缩功能保留与舒张功能受损之间的分离。我们进一步强调线粒体异质性和细胞间通讯可能是疾病进展的潜在决定因素,并讨论靶向线粒体通路的新兴治疗策略,作为HFpEF精准治疗路径的依据。

7心律失常(非房颤) (3篇)

临床研究 (1篇)

European heart journal IF 45.3 2026-9-22 PMID: 42771720
A major component of long QT syndrome (LQTS) is LQT2 due to pathogenic variants in KCNH2, which frequently cause trafficking defects. Despite progress in therapeutic management, there is an unmet clinical need for mechanism-targeted therapies. It has been previously shown, using patient-specific human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), that lumacaftor (LUM), currently used for cystic fibrosis, can partially correct hERG trafficking. A single-arm phase 2 study was conducted to determine whether LUM could shorten QTc in LQT2 patients with trafficking defects. Sixteen adult patients with genetically confirmed trafficking-defective KCNH2 variants were enrolled. Participants were admitted to hospital and received LUM for 7 days under continuous telemetry. QTc was quantified on serial electrocardiograms and 12-lead Holter recordings. For mechanistic correlation, hiPSC-CMs were generated from the first five participants with distinct genetic variants and assessed for hERG maturation and trafficking. Overall, lumacaftor produced a significant QTc shortening (P < .001). The per-patient change averaged 31 ± 21 ms. Patients with baseline QTc ≥500 ms exhibited the most substantial effect, with 75% achieving reductions ≥40 ms. No ventricular arrhythmias occurred, and adverse effects were primarily gastrointestinal and self-limited. In hiPSC-CMs, LUM restored hERG trafficking in three out of five variants, mirroring the clinical observations. Short-term LUM therapy is safe and yields a significant QTc shortening in LQT2 patients with a trafficking defect. Concordance between cellular and clinical findings reinforces the value of a mechanism-based, variant-informed approach and supports the feasibility of trafficking-correction strategies within a precision-medicine framework for inherited arrhythmia syndromes.
中文摘要:长QT综合征(LQTS)的一个重要组成部分是LQT2,其由KCNH2致病性变异引起,常导致转运缺陷。尽管治疗管理取得进展,但仍存在对机制靶向治疗的未满足临床需求。此前利用患者特异性人诱导多能干细胞来源心肌细胞(hiPSC-CMs)已表明,目前用于囊性纤维化的lumacaftor(LUM)可部分纠正hERG转运。开展了一项单臂2期研究,以确定LUM能否缩短伴转运缺陷的LQT2患者的QTc。纳入16例经基因确诊携带转运缺陷型KCNH2变异的成年患者。参与者住院并在持续遥测下接受LUM治疗7天。通过系列心电图和12导联Holter记录定量QTc。为进行机制关联,从具有不同基因变异的前5例参与者中生成hiPSC-CMs,并评估hERG成熟和转运。总体而言,lumacaftor产生显著的QTc缩短(P < .001)。每例患者的变化平均为31 ± 21毫秒。基线QTc ≥500毫秒的患者表现出最显著的效果,其中75%达到≥40毫秒的降低。未发生室性心律失常,不良反应主要为胃肠道反应且具有自限性。在hiPSC-CMs中,LUM在5种变异中的3种恢复了hERG转运,与临床观察一致。短期LUM治疗安全,并在伴转运缺陷的LQT2患者中产生显著的QTc缩短。细胞与临床发现之间的一致性强化了基于机制、结合变异信息的策略的价值,并支持在遗传性心律失常综合征的精准医学框架内实施转运纠正策略的可行性。

基础研究 (2篇)

Cardiovascular research IF 12.5 2026-9-21 PMID: 42764720
Enhanced spatial variation in ventricular action potential duration (APD) is known to contribute to arrhythmia development under long QT conditions, although the causes of APD variation are unclear. Specifically, between-individual variation in the locations of pro-arrhythmic long APD islands and associated repolarisation gradients is difficult to explain in the context of established regional variation in electrophysiology. This study aimed to explore the mechanisms underlying the spatial heterogeneity of ventricular APD under baseline and long QT conditions. New Zealand White rabbit hearts (n = 26) were Langendorff-perfused with oxygenated Tyrode's solution and loaded with blebbistatin and FluoVolt. Optical mapping of transmembrane voltage from the anterior epicardial surface of the right (RV) and left ventricles (LV) during sinus rhythm revealed a strong inverse relationship between activation time and APD90 in all hearts (linear regression slope: -0.85 ± 0.17, r2: 0.60 ± 0.12, p < 0.0001), despite considerable between-heart variation in the activation sequence. Lengthening of the pacing cycle length (350 to 1000 ms) and dofetilide-induced IKr blockade each induced greater AP prolongation in ventricular sites with earlier sinus activation, contributing to increased spatial heterogeneity of APD90. Optical measurement of APD90 from cardiomyocytes isolated after optical mapping of the intact heart indicated that myocytes from ventricular sites with earlier sinus activation had longer intrinsic APD90. Isolated RV myocytes also exhibited shorter average APD90 than LV myocytes. Measurement of the mRNA levels of 22 genes encoding cardiac ion channel, transporter and regulatory proteins demonstrated that ventricular sites with distinct sinus activation times exhibit different gene expression profiles. With increasing sinus activation time, the mRNA levels of Scn5a and most repolarisation genes decreased while that of Kcnip2 increased. Ventricular sites with distinct sinus activation times exhibit different electrophysiological properties which contribute to enhanced spatial heterogeneity of APD under long QT conditions.
中文摘要:已知在长QT条件下,心室动作电位时程(APD)的空间变异增强会促进心律失常发生,但APD变异的成因尚不清楚。具体而言,促心律失常的长APD岛及其相关复极梯度的位置在个体间存在差异,而在已确立的电生理区域变异背景下,这种差异难以解释。本研究旨在探讨基线和长QT条件下心室APD空间异质性的机制。对26只新西兰白兔心脏进行Langendorff灌流,灌流液为氧合Tyrode液,并负载blebbistatin和FluoVolt。在窦性心律下,对右心室(RV)和左心室(LV)前壁心外膜表面跨膜电压进行光学标测,显示在所有心脏中激动时间与APD90呈强负相关(线性回归斜率:-0.85 ± 0.17,r2:0.60 ± 0.12,p < 0.0001),尽管心脏间激动顺序存在相当大的变异。延长起搏周期长度(350至1000 ms)以及多非利特诱导的IKr阻滞,均使窦性激动较早的心室部位AP延长更明显,从而导致APD90空间异质性增加。在完整心脏光学标测后分离心肌细胞并进行APD90光学测量,表明来自窦性激动较早心室部位的心肌细胞具有更长的内在APD90。分离的RV心肌细胞平均APD90也短于LV心肌细胞。对22个编码心脏离子通道、转运体和调节蛋白的基因mRNA水平进行测量,证明具有不同窦性激动时间的心室部位表现出不同的基因表达谱。随着窦性激动时间增加,Scn5a及大多数复极相关基因的mRNA水平下降,而Kcnip2的mRNA水平升高。具有不同窦性激动时间的心室部位表现出不同的电生理特性,这些特性促进长QT条件下APD空间异质性增强。
Cardiovascular research IF 12.5 2026-9-19 PMID: 42760609
In the heart, endogenous nicotinic acid adenine dinucleotide phosphate (NAADP) triggers lysosomal calcium (Ca2+) release to augment sarcoplasmic reticulum (SR) Ca2+ sequestration, producing larger Ca2+ transients. However, the role of lysosomal Ca2+ signals in pacemaker activity, a distinct Ca2+-operated function of the sinoatrial node (SAN), or in the atrial myocardium has not been investigated. Pharmacological or genetic ablation of the NAADP pathway inhibits the spontaneous beating rate response to β-adrenergic stimulation in intact SAN. We found intracellular signaling microdomains between lysosomes and neighboring SR or mitochondria in mouse, and goat tissue. The spatial relationship between lysosomes and other Ca2+-handling organelles are altered in goat atrial fibrillation. Furthermore, we demonstrate atrial myocytes produce 3'-5'-cyclic adenosine monophosphate (cAMP) in response to lysosomal signaling, adding a novel trigger for cyclic nucleotide signaling. Our findings support the hypothesis that lysosomal Ca2+ signaling contributes to regulation of cardiomyocyte cAMP levels and pacemaker activity.
中文摘要:在心脏中,内源性烟酸腺嘌呤二核苷酸磷酸(NAADP)触发溶酶体钙(Ca2+)释放,以增强肌浆网(SR)的Ca2+隔离,产生更大的Ca2+瞬变。然而,溶酶体Ca2+信号在起搏活动——窦房结(SAN)一种独特的Ca2+操作功能——或心房肌中的作用尚未被研究。药理学或遗传学上消除NAADP通路可抑制完整SAN对β-肾上腺素能刺激的自发搏动频率反应。我们在小鼠和山羊组织中发现溶酶体与相邻SR或线粒体之间的细胞内信号微区。在山羊心房颤动中,溶酶体与其他Ca2+处理细胞器之间的空间关系发生改变。此外,我们证明心房肌细胞响应溶酶体信号产生3'-5'-环磷酸腺苷(cAMP),为环核苷酸信号增添了一个新的触发因素。我们的发现支持以下假说:溶酶体Ca2+信号有助于调节心肌细胞cAMP水平和起搏活动。

8肺动脉高压 (2篇)

临床研究 (1篇)

Circulation IF 41.3 2026-9-22 PMID: 42770225
The right ventricular (RV) response to pressure overload is a crucial determinant of outcomes in pulmonary arterial (PA) hypertension. Sotatercept improves clinical outcomes, but its effects on the right ventricle have been inconsistent. We evaluated the effects of sotatercept on load-independent measures of RV contractility, RV-PA coupling, and right heart deformation at rest and exertion in patients with PA hypertension. In this prospective trial among participants with PA hypertension recruited between July 2024 and May 2025, we performed simultaneous echocardiography and invasive pressure measurements during rest and exercise to evaluate changes in RV contractility (end-systolic elastance [Ees]), afterload (PA elastance [Ea]), RV-PA coupling (ratio of arterial Ea to Ees), and right heart deformation, including RV and right atrial strain, before and after 24 weeks of sotatercept using mixed models. Among 30 participants (n=21; 70% female; mean age, 49.3 years [SD 13.5]), sotatercept decreased PA Ea. These changes were associated with reduced RV contractility, PA pulsatility index, and the maximal rate of RV pressure increase over time (dP/dtmax; P<0.001 for all). The decrease in Ees was associated with a decrease in PA Ea (r=+0.70 [95% CI, +0.44 to +0.85]; P<0.0001) with preserved RV-PA coupling (mean difference, +0.08 [95% CI, -0.11 to +0.26]; P=0.42). Although systolic indices measured at the base of the right ventricle (tricuspid annular plane systolic excursion and systolic velocity of the lateral tricuspid annulus) decreased after sotatercept use, there was an increase in RV free wall-dependent systolic indices, including resting and exercise RV free wall strain (mean difference, +6.2% [95% CI, +4.5 to +7.8]; P<0.0001) and fractional area change (P=0.0001). Beyond the right ventricle, there was also improved right atrial filling and contractile performance across rest and exercise (P<0.0001 for all). Sotatercept decreases RV contractility in proportion to reduced afterload, while preserving the RV-PA coupling relationship. Despite decreased RV contractility, global measures of right heart performance, such as RV free wall strain and RA strain, improve, alongside redistribution of RV deformation from annular motion to free wall shortening. These data suggest that sotatercept causes an energetically favorable reduction in resting RV contractility to match the lower afterload, which does not appear physiologically detrimental when considering the concurrent improvement in RV free wall contractile mechanics and exertional right heart reserve. URL: https://www.clinicaltrials.gov; Unique identifier: NCT06409026.
中文摘要:右心室(RV)对压力超负荷的反应是肺动脉(PA)高压结局的关键决定因素。Sotatercept 可改善临床结局,但其对右心室的影响并不一致。我们评估了 Sotatercept 对肺动脉高压患者静息和运动时右心室收缩力非负荷依赖性指标、右心室-肺动脉耦联以及右心形变的影响。在这项于2024年7月至2025年5月期间招募肺动脉高压参与者的前瞻性试验中,我们在静息和运动期间同步进行超声心动图和有创压力测量,以使用混合模型评估 Sotatercept 治疗24周前后右心室收缩力(收缩末期弹性[Ees])、后负荷(肺动脉弹性[Ea])、右心室-肺动脉耦联(动脉 Ea 与 Ees 比值)以及右心形变(包括右心室和右心房应变)的变化。在30名参与者中(n=21;70%为女性;平均年龄49.3岁[标准差13.5]),Sotatercept 降低了肺动脉 Ea。这些变化与右心室收缩力、肺动脉搏动指数以及右心室压力随时间最大上升速率(dP/dtmax)降低相关(所有 P<0.001)。Ees 降低与肺动脉 Ea 降低相关(r=+0.70[95% CI,+0.44至+0.85];P<0.0001),且右心室-肺动脉耦联得以保持(平均差,+0.08[95% CI,-0.11至+0.26];P=0.42)。尽管使用 Sotatercept 后,在右心室基底测得的收缩期指标(三尖瓣环收缩期位移和三尖瓣环侧壁收缩期速度)降低,但右心室游离壁依赖性收缩期指标增加,包括静息和运动时右心室游离壁应变(平均差,+6.2%[95% CI,+4.5至+7.8];P<0.0001)和面积变化分数(P=0.0001)。除右心室之外,静息和运动时右心房充盈和收缩性能也得到改善(所有 P<0.0001)。Sotatercept 降低右心室收缩力,其程度与后负荷降低成比例,同时保持右心室-肺动脉耦联关系。尽管右心室收缩力降低,右心整体性能指标(如右心室游离壁应变和右心房应变)改善,同时右心室形变从瓣环运动向游离壁缩短重新分布。这些数据提示,Sotatercept 引起静息右心室收缩力在能量学上有利的降低,以匹配较低的后负荷;当考虑右心室游离壁收缩力学和运动时右心储备同时改善时,这似乎没有生理学上的不利影响。URL:https://www.clinicaltrials.gov;唯一标识符:NCT06409026。

基础研究 (1篇)

Redox biology IF 16.2 2026-9-19 PMID: 42762775
Metabolic reprogramming, impaired mitochondrial quality control, and mitochondrial redox imbalance are increasingly recognized as central drivers of pulmonary arterial hypertension (PAH). Spermidine (SPD) has been reported to exert cardiovascular protective effects; however, its effects on endothelial metabolism and redox homeostasis in PAH remain incompletely characterized. HADHA, the α-subunit of mitochondrial trifunctional protein, participates in long-chain fatty acid β-oxidation (FAO) and provides a potential link between fatty acid utilization, mitochondrial respiration, mitophagy-related quality control, and redox homeostasis. Here, using integrated metabolomics, lipidomics, and molecular biology approaches in monocrotaline (MCT)-induced PAH rats and palmitic acid-stimulated pulmonary microvascular endothelial cells (PMVECs), we examined the contribution of HADHA to the effects of SPD on endothelial FAO and mitochondrial redox homeostasis. SPD treatment markedly attenuated pulmonary hypertension and vascular remodeling, accompanied by reduced inflammatory activation and endothelial injury. Metabolomic and lipidomic profiling indicated that SPD partially corrected pathological lipid-metabolic remodeling, including phosphatidylethanolamine-associated lipid alterations, and improved FAO-related mitochondrial function under lipotoxic stress. SPD reduced lipid accumulation and lipotoxic mitochondrial injury, inhibited PLIN2-vimentin-associated endothelial-to-mesenchymal transition (EndMT) marker changes, and increased PINK1/Parkin-related mitophagy markers together with TOM20/LC3B/LAMP2 colocalization, consistent with improved mitophagy-related mitochondrial quality control. Molecular dynamics simulation, cellular thermal shift assay, and microscale thermophoresis supported SPD-HADHA binding and SPD-associated HADHA stabilization. Importantly, HADHA knockdown markedly attenuated several effects of SPD on FAO-related function, mitochondrial redox balance, and lipotoxic phenotypes in PMVECs. These findings suggest that HADHA may contribute to the effects of SPD on fatty acid oxidation, redox homeostasis, and endothelial protection in PAH.
中文摘要:代谢重编程、线粒体质量控制受损以及线粒体氧化还原失衡日益被认为是肺动脉高压(PAH)的核心驱动因素。亚精胺(SPD)已被报道具有心血管保护作用;然而,其在PAH中对内皮代谢和氧化还原稳态的影响仍未完全阐明。HADHA是线粒体三功能蛋白的α亚基,参与长链脂肪酸β氧化(FAO),并在脂肪酸利用、线粒体呼吸、线粒体自噬相关质量控制与氧化还原稳态之间提供潜在联系。本研究在野百合碱(MCT)诱导的PAH大鼠和棕榈酸刺激的肺微血管内皮细胞(PMVECs)中,采用整合的代谢组学、脂质组学和分子生物学方法,考察HADHA在SPD影响内皮FAO和线粒体氧化还原稳态中的作用。SPD治疗显著减轻肺动脉高压和血管重塑,并伴随炎症激活和内皮损伤减少。代谢组学和脂质组学分析表明,SPD部分纠正了病理性脂质代谢重塑,包括磷脂酰乙醇胺相关脂质改变,并改善了脂毒性应激下FAO相关线粒体功能。SPD减少脂质蓄积和脂毒性线粒体损伤,抑制PLIN2-波形蛋白相关的内皮-间充质转化(EndMT)标志物变化,并增加PINK1/Parkin相关线粒体自噬标志物以及TOM20/LC3B/LAMP2共定位,与线粒体自噬相关线粒体质量控制改善一致。分子动力学模拟、细胞热位移实验和微量热泳动支持SPD-HADHA结合以及SPD相关的HADHA稳定化。重要的是,HADHA敲低显著减弱了SPD对PMVECs中FAO相关功能、线粒体氧化还原平衡和脂毒性表型的若干影响。这些发现提示,HADHA可能参与SPD在PAH中对脂肪酸氧化、氧化还原稳态和内皮保护的作用。

9心肌病/心肌炎 (2篇)

临床研究 (2篇)

European heart journal IF 45.3 2026-6-5 PMID: 42244336
Arrhythmogenic cardiomyopathy (ACM) is a form of inheritable cardiomyopathy characterized by ventricular scarring and/or fibro-fatty replacement. ACM is associated with a significant risk of sudden cardiac death due to ventricular arrhythmias, especially in young patients and endurance athletes. Aim of this review is to summarize the changing in understanding and framing of this multifaceted disease, in particular highlighting the current transition from a phenotype-first to a genotype-first framework for diagnosis and management.
中文摘要:致心律失常性心肌病(ACM)是一种遗传性心肌病,以心室瘢痕形成和/或纤维脂肪替代为特征。ACM因室性心律失常而具有显著的心脏性猝死风险,尤其是在年轻患者和耐力运动员中。本综述旨在总结对这一多面性疾病在认识和框架方面的变化,特别强调目前诊断和管理正从表型优先向基因型优先框架转变。
British journal of sports medicine IF 15.5 2026-9-17 PMID: 42754379
The "athlete anterior repolarisation pattern", characterised by J-point elevation with ascending convex ST-segments and anterior T-wave inversion (ATWI) confined to leads V1-V4, has been considered a normal finding in athletes of Black ethnicity (African-Caribbean descent). This repolarisation pattern was considered to potentially represent an underlying cardiomyopathy in non-Black athletes although recent studies have challenged this. We assessed the prevalence and significance of ATWI among professional Black and non-Black football players in the UK. Athletes underwent pre-participation screening (2017-2024), including a health questionnaire, a 12-lead ECG and an echocardiogram. ATWI was defined as TWI confined to leads V1 to V3 or V4. Ethnicity was categorised as Black or non-Black. 10 955 athletes were studied, comprising 9009 (82.2%) males and 1946 (17.8%) females. 2372 (21.7%) athletes were of Black ethnicity and 8583 (78.3%) were non-Black. Black athletes were marginally younger (18.3±3.8 vs 19.2±4.7 years; p<0.001). ATWI was observed in 255 (10.8%) Black athletes versus 115 (1.3%) non-Black athletes (p<0.001). ATWI was more common in Black males compared with females (251 (11.0%) vs 4 (4.3%); p=0.04). Among non-Black athletes, ATWI was less common in males (81 (1.2%) males vs 34 (1.8%) females; p=0.04). The "athlete anterior repolarisation pattern" was present in 245 (10.3%) Black athletes and 42 (0.5%) non-Black athletes (p<0.001). None of the Black athletes with ATWI exhibited major cardiac pathology, whereas one (0.9%) non-Black athlete with ATWI and isoelectric ST-segments was diagnosed with arrhythmogenic cardiomyopathy. The "athlete anterior repolarisation pattern" was 20 times more common in Black athletes than in non-Black athletes. However, this repolarisation pattern was not associated with major pathology in either Black or non-Black athletes in this UK screening cohort. By contrast, the only cardiomyopathy identified in an athlete with any ATWI occurred in a non-Black athlete with isoelectric ST-segments extending to V4.
中文摘要:以J点抬高、ST段呈上升型凸面以及局限于V1-V4导联的前壁T波倒置(ATWI)为特征的「运动员前壁复极模式」,一直被认为在黑人族裔(非洲-加勒比血统)运动员中属于正常发现。尽管近期研究对此提出挑战,但该复极模式曾被认作在非黑人运动员中可能提示潜在心肌病。我们评估了英国职业黑人和非黑人足球运动员中ATWI的患病率及其意义。运动员接受了赛前筛查(2017—2024年),包括健康问卷、12导联心电图和超声心动图。ATWI定义为T波倒置局限于V1至V3或V4导联。族裔被分为黑人或非黑人。共研究了10 955名运动员,其中男性9009名(82.2%),女性1946名(17.8%)。2372名(21.7%)运动员为黑人族裔,8583名(78.3%)为非黑人。黑人运动员略年轻(18.3±3.8岁 vs 19.2±4.7岁;p<0.001)。黑人运动员中观察到ATWI者255名(10.8%),非黑人运动员中115名(1.3%)(p<0.001)。ATWI在黑人男性中比黑人女性更常见(251名(11.0%) vs 4名(4.3%);p=0.04)。在非黑人运动员中,ATWI在男性中较少见(男性81名(1.2%) vs 女性34名(1.8%);p=0.04)。「运动员前壁复极模式」见于245名(10.3%)黑人运动员和42名(0.5%)非黑人运动员(p<0.001)。伴有ATWI的黑人运动员均未表现出重大心脏病理,而一名(0.9%)伴有ATWI且ST段等电位的非黑人运动员被诊断为致心律失常性心肌病。「运动员前壁复极模式」在黑人运动员中的发生率是非黑人运动员的20倍。然而,在该英国筛查队列中,这种复极模式与黑人运动员或非黑人运动员的重大病理均无关联。相比之下,在任何ATWI运动员中唯一发现的心肌病发生在一名ST段等电位延伸至V4的非黑人运动员中。

10心血管疾病 (2篇)

临床研究 (2篇)

European journal of preventive cardiology IF 10.0 2025-12-11 PMID: 41379001
This study aims to investigate the role of biological aging pace and quantify its contributions in explaining sex disparities in cardiovascular disease (CVD) risk. A population-based study was conducted, including 371 032 participants in the UK Biobank. Two measures of biological aging pace were assessed, including phenotypic age acceleration (PhenoAgeAccel) and telomere length. The chronological age was similar between females [56.1 (8.0) years] and males [56.1 (8.2) years]. Male participants consistently had higher CVD risks than female participants, including any CVD [hazard ratio (HR), 1.66; 95% confidence interval (CI), 1.54-1.80], atrial fibrillation (HR, 1.78; 95% CI, 1.73-1.83), coronary heart disease (HR, 2.11; 95% CI, 2.05-2.18), heart failure (HR, 1.72; 95% CI, 1.65-1.80), and stroke (HR, 1.44; 95% CI, 1.38-1.51). Females had 0.71-2.90 years longer time to CVD than males. Males had a faster biological aging pace of 1.02 (95% CI, 0.99-1.06) years in PhenoAgeAccel than females, with 17.1% explained by unhealthy lifestyles, followed by prevalent chronic diseases (8.6%) and metabolic factors (6.5%). The sex disparities in PhenoAgeAccel significantly explained 65.0% of male-associated any CVD, 64.7% of atrial fibrillation, 68.2% of coronary heart disease, 64.4% of heart failure, and 60.4% of stroke, respectively. Similar findings were observed when using the telomere length for evaluating biological aging pace or controlling for sex hormones. Our findings reveal that the biological aging pace might partially explain sex disparities in CVD risk, highlighting the importance of monitoring the biological aging pace to address the huge sex gap and promote sex-specific CVD primary prevention.
中文摘要:本研究旨在探讨生物学衰老速度的作用,并量化其在解释心血管疾病(CVD)风险性别差异中的贡献。研究基于人群,纳入英国生物银行371 032名参与者。评估了两种生物学衰老速度指标,包括表型年龄加速(PhenoAgeAccel)和端粒长度。女性和男性的实际年龄相似,分别为56.1(8.0)岁和56.1(8.2)岁。男性参与者的CVD风险始终高于女性参与者,包括任何CVD(风险比HR为1.66;95%置信区间CI为1.54-1.80)、心房颤动(HR为1.78;95%CI为1.73-1.83)、冠心病(HR为2.11;95%CI为2.05-2.18)、心力衰竭(HR为1.72;95%CI为1.65-1.80)和脑卒中(HR为1.44;95%CI为1.38-1.51)。女性发生CVD的时间比男性长0.71-2.90年。男性在PhenoAgeAccel上的生物学衰老速度比女性快1.02年(95%CI为0.99-1.06),其中17.1%可由不健康生活方式解释,其次为常见慢性病(8.6%)和代谢因素(6.5%)。PhenoAgeAccel的性别差异分别显著解释了与男性相关的任何CVD的65.0%、心房颤动的64.7%、冠心病的68.2%、心力衰竭的64.4%和脑卒中的60.4%。使用端粒长度评估生物学衰老速度或控制性激素后,也观察到类似结果。我们的研究结果揭示,生物学衰老速度可能部分解释CVD风险的性别差异,强调监测生物学衰老速度对于应对巨大的性别差距和促进性别特异性CVD一级预防的重要性。
European journal of preventive cardiology IF 10.0 2026-9-18 PMID: 42755098
Chronic inflammation is a major driver of cardiovascular diseases, but mechanisms linking systemic inflammation to cardiac remodelling remain incompletely understood. We aimed to evaluate the role of cytokine-mediated signalling and the influence of environmental and genetic factors on inflammation and cardiac phenotypes in a large population-based cohort. We analysed subsets of 488 079 UK Biobank participants with metabolomic and proteomic profiling, cardiac magnetic resonance (CMR) imaging, and longitudinal outcomes. Chronic inflammation was quantified using glycoprotein acetyls (GlycA) by nuclear magnetic resonance spectroscopy. Machine learning-based analysis extracted CMR phenotypes. Multivariable linear regression assessed GlycA-cardiac associations. Mediation analysis tested 80 inflammatory proteins as potential mediators. Cox models evaluated GlycA levels and major adverse cardiovascular events (MACEs). An exposome-wide association study identified environmental determinants of inflammation, and gene-environment interactions were assessed using multi-ancestry polygenic risk scores. Higher GlycA levels were associated with reduced left ventricular indexed end-diastolic volume (β=-2.09) and stroke volume (β=-1.12), with compensatory increased heart rate (β=1.38; all P<10-228). Interleukin (IL)-1 receptor antagonist statistically mediated 27% of the GlycA effect on end-diastolic volume (average causal mediated effect -0.53 [95% CI, -0.64 to -0.41]; P<10-16). The highest GlycA quintile had 43% higher MACE risk versus the lowest (adjusted HR, 1.43 [95% CI, 1.38-1.49]). Trunk fat mass (β=0.35), current smoking (β=0.39), psychological distress, and low socioeconomic status were the strongest GlycA determinants (all P<10-50). Cardiovascular polygenic risk scores modified associations between environmental exposures, inflammation, and MACE. Chronic systemic inflammation is associated with reduced left ventricular volumes and increased cardiovascular risk in the community, with circulating cytokines and growth factors including IL-1 and TNF identified as potential mediators of these associations. Exposure-gene interactions are associated with inflammatory responses such that risk may reflect the convergence of inherited and acquired factors.
中文摘要:慢性炎症是心血管疾病的主要驱动因素,但连接全身性炎症与心脏重构的机制仍不完全清楚。我们旨在在一个大型基于人群的队列中评估细胞因子介导的信号传导的作用,以及环境和遗传因素对炎症和心脏表型的影响。我们分析了488 079名英国生物银行(UK Biobank)参与者中具有代谢组学和蛋白质组学分析、心脏磁共振(CMR)成像和纵向结局的子集。使用核磁共振波谱法测定的糖蛋白乙酰基(GlycA)量化慢性炎症。基于机器学习的分析提取CMR表型。多变量线性回归评估GlycA与心脏的关联。中介分析检验80种炎症蛋白作为潜在中介因子。Cox模型评估GlycA水平和主要不良心血管事件(MACE)。一项暴露组全关联研究识别炎症的环境决定因素,并使用多祖源多基因风险评分评估基因-环境交互作用。较高的GlycA水平与左心室指数化舒张末期容积降低(β=-2.09)和每搏输出量降低(β=-1.12)相关,并伴有代偿性心率增加(β=1.38;所有P<10-228)。白细胞介素(IL)-1受体拮抗剂在统计学上中介了GlycA对舒张末期容积效应的27%(平均因果中介效应 -0.53 [95% CI, -0.64 to -0.41];P<10-16)。最高GlycA五分位组相比最低五分位组MACE风险高43%(校正HR,1.43 [95% CI, 1.38-1.49])。躯干脂肪量(β=0.35)、当前吸烟(β=0.39)、心理困扰和低社会经济地位是最强的GlycA决定因素(所有P<10-50)。心血管多基因风险评分改变了环境暴露、炎症与MACE之间的关联。慢性全身性炎症与社区人群中左心室容积降低和心血管风险增加相关,循环细胞因子和生长因子包括IL-1和TNF被确定为这些关联的潜在中介因子。暴露-基因交互作用与炎症反应相关,因此风险可能反映了遗传和获得性因素的汇聚。

11卒中/脑血管 (2篇)

临床研究 (1篇)

British journal of sports medicine IF 15.5 2026-9-17 PMID: 42754383
Current guidelines suggest limiting physical activity in pregnant individuals carrying twins but this recommendation is not based on empirical evidence. We assessed maternal and fetal cardiovascular response to submaximal exercise testing in singleton versus twin pregnancies. Females with a singleton (n=12, 26±5 weeks of gestation, 33±3 years of age) and twin (n=12, 26±5 weeks of gestation, 33±2 years of age) pregnancies were recruited. Maternal cardiac function (heart rate (HR); cardiac output (CO), stroke volume (SV) and ejection fraction (EF) via echocardiography) and mean arterial pressure (MAP; photoplethysmography) were measured at rest and during incremental cycling exercise to 70% HR reserve. Fetal HR and umbilical blood flow were measured pre-exercise and post-exercise. Compared to those with singleton pregnancies, women pregnant with twins had a higher resting HR (95±12 vs 83±6 bpm; p=0.003) and MAP (91±8 vs 82±9 mm Hg; p=0.013), but similar to SV, EF and CO. In response to a submaximal cycling exercise test, individuals with twins and singletons had similar changes in HR (Δ46±22 vs Δ56±11 bpm; p=0.16), CO (Δ6.2±3.9 vs Δ7.2±2.8 L/min; p=0.50), and ΔMAP (Δ14±7 vs Δ15±6 mm Hg; p=0.75). Fetal HR was unchanged in response to exercise at 70% HR reserve in both groups (singleton: Δ-1±4 vs twin: Δ0±4; p=0.53), with no incidence of fetal bradycardia or tachycardia. Umbilical blood flow was unchanged. While resting haemodynamics were generally higher in individuals with twin compared with singleton pregnancies, the cardiovascular response to exercise was not different between groups and exercise did not impact fetal well-being.
中文摘要:当前指南建议限制怀有双胎的孕妇进行体力活动,但该建议并非基于实证证据。我们评估了单胎与双胎妊娠对次极量运动试验的母体与胎儿心血管反应。招募了单胎(n=12,妊娠26±5周,年龄33±3岁)和双胎(n=12,妊娠26±5周,年龄33±2岁)妊娠女性。在静息时以及进行递增式自行车运动至70%心率储备期间,测量母体心脏功能(心率(HR);通过超声心动图测定的心输出量(CO)、每搏输出量(SV)和射血分数(EF))和平均动脉压(MAP;光电容积描记法)。在运动前和运动后测量胎儿心率和脐带血流。与单胎妊娠者相比,双胎妊娠女性静息HR更高(95±12 vs 83±6 bpm;p=0.003)且MAP更高(91±8 vs 82±9 mm Hg;p=0.013),但SV、EF和CO相似。对于次极量自行车运动试验的反应,双胎与单胎个体的HR变化(Δ46±22 vs Δ56±11 bpm;p=0.16)、CO变化(Δ6.2±3.9 vs Δ7.2±2.8 L/min;p=0.50)和ΔMAP(Δ14±7 vs Δ15±6 mm Hg;p=0.75)相似。在70%心率储备运动后,两组胎儿HR均无变化(单胎:Δ-1±4 vs 双胎:Δ0±4;p=0.53),未发生胎儿心动过缓或心动过速。脐带血流无变化。虽然双胎妊娠者静息血流动力学普遍高于单胎妊娠者,但两组对运动的心血管反应无差异,且运动未影响胎儿健康。

基础研究 (1篇)

Cardiovascular research IF 12.5 2026-9-21 PMID: 42764701
Engineered cardiac tissue models for in vitro physiological studies often fail to replicate the pump function of the heart. Despite promising advancements, the use of engineered cardiac chambers is often hindered by complex fabrication processes and invasive characterization techniques. Here, we engineered a chamber-like human cardiac model with pumping function, referred to as a 'mini-heart', by employing a novel sacrificial molding approach within a customized bioreactor. Human pluripotent stem cell-derived cardiomyocytes and human cardiac fibroblasts were embedded in a fibrin mix and casted around two gelatin bodies within a customized bioreactor. After fibrin polymerization, thermal degradation of gelatin was induced to obtain a single-inlet cardiac chamber coupled to a glass capillary inlet.The mini-heart's pumping capability was confirmed through optical recording of fluid displacement at the engineered tissue inlet, enabling the non-invasive acquisition of hemodynamic parameters such as stroke volume, stroke work, ejection fraction, and developed pressure. Morphological analysis of the engineered tissues revealed organized sarcomeres and extracellular matrix self-determination, highlighting the advantage of our degradable mold technology. Additionally, we have measured calcium transients during both spontaneous and electrically-paced beating, and observed a positive inotropic response to the β-adrenergic agonist drug isoproterenol. We present a biomimetic, chamber-like human cardiac model with intrinsic pumping function that enables non-invasive functional assessment of cardiac hemodynamics in vitro.
中文摘要:用于体外生理研究的工程化心脏组织模型往往无法复制心脏的泵功能。尽管取得了有前景的进展,工程化心腔的使用仍常受制于复杂的制造工艺和有创表征技术。在此,我们在定制生物反应器内采用一种新型牺牲成型方法,构建了具有泵送功能的腔室样人类心脏模型,称为「微型心脏」。将人类多能干细胞来源的心肌细胞和人类心脏成纤维细胞嵌入纤维蛋白混合物中,并在定制生物反应器内浇铸于两个明胶体周围。纤维蛋白聚合后,诱导明胶热降解,从而获得与玻璃毛细管入口相连的单入口心腔。通过光学记录工程化组织入口处的液体位移,证实了微型心脏的泵送能力,从而能够无创获取每搏输出量、每搏功、射血分数和产生压力等血流动力学参数。对工程化组织的形态学分析显示,肌节排列有序且细胞外基质可自主决定,突显了我们可降解模具技术的优势。此外,我们测量了自发搏动和电起搏搏动期间的钙瞬变,并观察到对β-肾上腺素能激动剂药物异丙肾上腺素的正性肌力反应。我们提出了一种具有内在泵送功能的仿生腔室样人类心脏模型,使得能够在体外对心脏血流动力学进行无创功能评估。

12儿童心血管病 (1篇)

临床研究 (1篇)

European journal of preventive cardiology IF 10.0 2026-9-22 PMID: 42772756
Regular physical activity offers numerous benefits to children's health and well-being and is essential for reducing cardiovascular risk in children with cardiovascular disease. Despite increasing evidence supporting its benefits, many young patients remain insufficiently active because of concerns regarding exercise related risks, limited expertise. This clinical consensus statement provides practical guidance for the prescription of exercise and physical activity in children and adolescents aged 6 to 17 years with cardiovascular disease. The document aims to bridge the gap between evidence supporting the benefits of physical activity and its implementation in daily clinical practice, promoting safe participation in sport and exercise across a broad spectrum of cardiovascular conditions. This consensus statement outlines an individualised, patient-centred approach to exercise prescription based on clinical assessment, cardiovascular risk stratification, and the FITT principle: frequency, intensity, time, and type. Specific recommendations are provided for congenital and acquired heart disease, cardiomyopathies, arrhythmias, pulmonary hypertension, cardio-oncology patients, and children with physical disabilities or syndromes. The document emphasises the importance of multidisciplinary care, periodic follow up, exercise testing when indicated, and tailored programs adapted to the child's clinical condition, developmental stage, and personal preferences. The overarching goal is to encourage safe and enjoyable participation in physical activity, improve quality of life and functional capacity, and foster lifelong healthy behaviours in children with cardiovascular disease.
中文摘要:规律的身体活动对儿童的健康与福祉有诸多益处,并且对于降低心血管病患儿的心血管风险至关重要。尽管支持其益处的证据不断增加,许多年轻患者仍活动不足,原因是担心运动相关风险以及专业知识有限。本临床共识声明为6至17岁心血管病儿童和青少年的运动与身体活动处方提供了实用指导。该文件旨在弥合支持身体活动益处的证据与其在日常临床实践中实施之间的差距,促进广泛心血管疾病状况下安全参与体育运动和锻炼。本共识声明概述了一种个体化、以患者为中心的运动处方方法,基于临床评估、心血管风险分层以及FITT原则:频率、强度、时间和类型。针对先天性和获得性心脏病、心肌病、心律失常、肺动脉高压、肿瘤心脏病学患者以及有身体残疾或综合征的儿童,提供了具体建议。该文件强调多学科护理、定期随访、有指征时进行运动测试,以及根据儿童临床状况、发育阶段和个人偏好调整的定制化方案的重要性。总体目标是鼓励心血管病儿童安全、愉快地参与身体活动,改善生活质量和功能能力,并培养终身健康行为。

13血栓形成 (1篇)

基础研究 (1篇)

Blood IF 23.9 2026-9-22 PMID: 42771581
B-type natriuretic peptide (BNP) is a cardiac-derived vasodilator and a well-established biomarker for heart failure. Elevated BNP and its cleavage product N-terminal proBNP (NT-proBNP) also predict adverse outcomes in acute coronary syndromes and other cardiovascular diseases. However, it remains unclear whether BNP directly contributes to cardiovascular disease pathogenesis, such as by promoting thrombosis, or merely serves as a biomarker. We investigated the effect of BNP on platelets in vitro and thrombosis in vivo. Incubation of platelets with BNP significantly increased intracellular cGMP levels and enhanced platelet aggregation, granule secretion, spreading, and clot retraction in vitro. We further identified that platelets express the receptor for BNP, natriuretic peptide receptor-A (NPRA). The effects of BNP on cGMP production and platelet activation were abolished in NPRA-deficient platelets. Using FeCl₃ carotid injury-induced arterial thrombosis model and a thromboplastin-induced pulmonary embolism model, we found that BNP administration accelerated thrombus formation in wild-type mice. Moreover, NPRA-deficient mice exhibited prolonged tail bleeding times and delayed arterial occlusion following vascular injury. BNP injection failed to promote thrombosis in NPRA-deficient mice. Our study demonstrates that BNP promotes platelet activation and enhances arterial thrombosis and thromboembolism via NPRA signaling. These findings suggest that BNP may not only serve as a biomarker of cardiovascular disease, but may also contribute directly to thrombotic risk, providing a potential mechanistic link between elevated cGMP levels and thrombosis.
中文摘要:B型利钠肽(BNP)是一种心脏来源的血管扩张剂,也是心力衰竭公认的生物标志物。升高的BNP及其裂解产物N末端proBNP(NT-proBNP)还可预测急性冠脉综合征及其他心血管疾病的不良结局。然而,BNP是否直接参与心血管疾病发病机制(例如通过促进血栓形成),还是仅作为生物标志物,目前仍不清楚。我们在体外研究BNP对血小板的作用,并在体内研究其对血栓形成的影响。将血小板与BNP孵育可显著增加细胞内cGMP水平,并在体外增强血小板聚集、颗粒分泌、铺展和血凝块回缩。我们进一步发现血小板表达BNP的受体——利钠肽受体A(NPRA)。在NPRA缺陷的血小板中,BNP对cGMP生成和血小板活化的效应被消除。利用FeCl₃诱导的颈动脉损伤动脉血栓形成模型和凝血活酶诱导的肺栓塞模型,我们发现给予BNP可加速野生型小鼠中的血栓形成。此外,NPRA缺陷小鼠表现出尾出血时间延长以及血管损伤后动脉闭塞延迟。在NPRA缺陷小鼠中,注射BNP未能促进血栓形成。我们的研究表明,BNP通过NPRA信号促进血小板活化,并增强动脉血栓形成和血栓栓塞。这些发现提示,BNP可能不仅是心血管疾病的生物标志物,还可能直接促进血栓风险,从而为cGMP水平升高与血栓形成之间提供潜在机制联系。

14心脑血管病 (1篇)

临床研究 (1篇)

European journal of preventive cardiology IF 10.0 2025-8-30 PMID: 40882992
Polycystic ovary syndrome (PCOS) affects 5-20% of reproductive-aged women and is linked to cardiovascular risk factors and atherosclerosis. Yet, its long-term association with atherosclerotic cardiovascular disease remains uncertain and will be the focus of this study. Women diagnosed with PCOS (1995-2024) were identified through Danish nationwide registries and matched 1:4 with female controls from the background population by age and year of index. The primary outcome was a composite of acute myocardial infarction and ischaemic stroke, with the individual components serving as secondary outcomes. The study included 25 513 women with PCOS and 102 052 matched controls (median age 29.9 years). Women with PCOS had a higher prevalence of cardiovascular risk factors compared with controls. The 25-year cumulative incidence of the composite outcome was higher in women with PCOS [3.4% (95% confidence interval (CI) 2.8-4.2%)] compared with controls [2.0% (95% CI 1.8-2.3%)]. In Cox regression analyses, PCOS was associated with an increased risk of the composite outcome [unadjusted hazard ratio (HR) 1.82 (95% CI 1.56-2.11), adjusted HR 1.53 (95% CI 1.30-1.81)], acute myocardial infarction [unadjusted HR 1.86 (95% CI 1.45-2.39), adjusted HR 1.58 (95% CI 1.21-2.07)], and ischaemic stroke [unadjusted HR 1.83 (95% CI 1.52-2.22), adjusted HR 1.56 (95% CI 1.27-1.91)]. The associations did not vary by use of oral contraception, metformin, anti-androgens, spironolactone, or glucagon-like peptide (GLP)-1 analogues. Women with PCOS were at increased associated risk of acute myocardial infarction and ischaemic stroke compared with controls. While absolute risks were low, these findings highlight the potential benefits of early cardiovascular risk assessment and preventive strategies in this population.
中文摘要:多囊卵巢综合征(PCOS)影响5-20%的育龄女性,并与心血管危险因素和动脉粥样硬化相关。然而,其与动脉粥样硬化性心血管疾病的长期关联仍不确定,本研究将对此进行探讨。研究通过丹麦全国登记数据库识别1995-2024年间诊断为PCOS的女性,并按年龄和索引年份以1:4与背景人群中的女性对照匹配。主要结局为急性心肌梗死与缺血性卒中的复合终点,各单独成分作为次要结局。研究纳入25 513例PCOS女性和102 052例匹配对照(中位年龄29.9岁)。与对照相比,PCOS女性心血管危险因素患病率更高。PCOS女性复合结局的25年累积发生率高于对照,分别为3.4%(95%置信区间(CI)2.8-4.2%)和2.0%(95%置信区间(CI)1.8-2.3%)。在Cox回归分析中,PCOS与复合结局风险增加相关(未校正风险比(HR)1.82(95%置信区间(CI)1.56-2.11),校正后HR 1.53(95%置信区间(CI)1.30-1.81)),与急性心肌梗死风险增加相关(未校正HR 1.86(95%置信区间(CI)1.45-2.39),校正后HR 1.58(95%置信区间(CI)1.21-2.07)),并与缺血性卒中风险增加相关(未校正HR 1.83(95%置信区间(CI)1.52-2.22),校正后HR 1.56(95%置信区间(CI)1.27-1.91))。这些关联并未因使用口服避孕药、二甲双胍、抗雄激素药物、螺内酯或胰高血糖素样肽(GLP)-1类似物而改变。与对照相比,PCOS女性发生急性心肌梗死和缺血性卒中的相关风险增加。尽管绝对风险较低,这些发现提示在该人群中进行早期心血管风险评估和预防策略可能有益。

15妊娠血脂异常 (1篇)

临床研究 (1篇)

European journal of preventive cardiology IF 10.0 2025-8-4 PMID: 40758090
Significant lipid metabolism changes during pregnancy are essential for fetal development. However, when complicated by pre-existing cardiometabolic risk factors like obesity, hypertension, and diabetes, there is an increased risk for adverse maternal and fetal outcomes and future cardiovascular events. Despite the rising prevalence of maternal obesity and other co-morbidities, there continues to be a lack of clear guidelines for screening and treating dyslipidaemia during pregnancy. This review aims to highlight the physiological changes in lipid metabolism during pregnancy, explore the association between dyslipidaemia and adverse outcomes, summarize current treatment options, and identify research gaps pertaining to management of perinatal dyslipidaemia. Enhancing our understanding of dyslipidaemia in pregnancy is crucial for improving maternal and fetal health outcomes, guiding future offspring risk assessment, and informing therapy guidelines.
中文摘要:妊娠期显著的脂质代谢变化对胎儿发育至关重要。然而,当合并肥胖、高血压和糖尿病等既存的心血管代谢危险因素时,不良母胎结局及未来心血管事件的风险会增加。尽管孕产妇肥胖及其他合并症的患病率不断上升,但关于妊娠期血脂异常的筛查和治疗仍缺乏明确指南。本综述旨在强调妊娠期脂质代谢的生理变化,探讨血脂异常与不良结局之间的关联,总结当前治疗选择,并明确围产期血脂异常管理相关的研究空白。加深对妊娠期血脂异常的理解,对于改善母胎健康结局、指导未来子代风险评估以及为治疗指南提供依据至关重要。

16心脏外科/CABG (1篇)

临床研究 (1篇)

European journal of preventive cardiology IF 10.0 2025-6-12 PMID: 40504861
Higher mortality rates after coronary artery bypass grafting (CABG) have been reported in women than in men. We examined whether adherence to secondary prevention medications could explain these sex differences. We used data from 9857 participants (18% women) who underwent CABG between 1998 and 2021. Medication adherence for statins, beta-blockers, and renin-angiotensin-aldosterone system (RAAS) inhibitors was assessed using nationwide drug purchase registers. Multivariable-adjusted Cox regression models with a sex interaction term were used to analyze the association between adherence and all-cause mortality. Use of statins (90%), RAAS inhibitors (62%), and beta-blockers (93%) was similar in men and women immediately after CABG (P ≥ 0.57 for all). After 10 years, adherence remained high for statins (84%), beta-blockers (85%), and RAAS inhibitors (66%), with a non-significant trend towards greater adherence in women. Use of medications was associated with lower mortality in men and women, and particularly for statins [HR, 0.49; 95% confidence interval (CI), 0.41-0.59 for women; HR, 0.54; 95% CI: 0.50-0.59 for men; P for interaction 0.08]. Beta-blocker adherence was associated with a greater mortality benefit in women compared with men (HR, 0.66; 95% CI: 0.55-0.78 vs. HR, 0.82; 95% CI: 0.75-0.90; P for interaction 0.04). No major sex differences in medication adherence were observed during 10 years of follow-up. Use of beta-blockers was associated with lower risk of mortality in women compared with men. Future interventional trials should focus on the potential sex differences in efficacy of secondary prevention medication in CABG patients.
中文摘要:冠状动脉旁路移植术(CABG)后女性死亡率高于男性已有报道。我们探讨二级预防药物依从性能否解释这些性别差异。我们使用1998年至2021年间接受CABG的9857名参与者(18%为女性)的数据。通过全国药物购买登记评估他汀类、β受体阻滞剂和肾素-血管紧张素-醛固酮系统(RAAS)抑制剂的药物依从性。采用含性别交互项的多变量校正Cox回归模型分析依从性与全因死亡率之间的关联。CABG后即刻,他汀类(90%)、RAAS抑制剂(62%)和β受体阻滞剂(93%)的使用在男性和女性中相似(所有P ≥ 0.57)。10年后,他汀类(84%)、β受体阻滞剂(85%)和RAAS抑制剂(66%)的依从性仍然较高,女性依从性更高的趋势无统计学意义。药物使用与男性和女性较低死亡率相关,尤其是他汀类[女性HR 0.49;95%置信区间(CI)0.41-0.59;男性HR 0.54;95% CI 0.50-0.59;交互作用P=0.08]。与男性相比,β受体阻滞剂依从性在女性中与更大的死亡获益相关(女性HR 0.66;95% CI 0.55-0.78 vs 男性HR 0.82;95% CI 0.75-0.90;交互作用P=0.04)。在10年随访期间未观察到药物依从性的重大性别差异。与男性相比,使用β受体阻滞剂在女性中与更低的死亡风险相关。未来的干预试验应关注CABG患者中二级预防药物疗效可能存在的性别差异。

17脑损伤/卒中 (1篇)

基础研究 (1篇)

Nature neuroscience IF 20.3 2026-9-22 PMID: 42768215
Traumatic brain injury (TBI) accelerates bone healing and induces heterotopic ossification, raising the question of whether an injured brain benefits from bone. Here we reveal that dynamic compressive tibial axial loading (DCTAL), a model of tibial bone compression, increased survival and promoted motor and cognitive recovery after stroke and TBI in mice, as well as in pig TBI models. DCTAL reduced neuron loss, attenuated chronic inflammation and astrogliosis and stimulated neuronal regeneration after TBI. Deletion of the mechanosensory channel Piezo1 in osteocytes reversed these benefits, while serum from DCTAL mice recapitulated them. Osteocytes transduced mechanical signals to directly secrete factors such as IL-1R2, APOL11a and HSP70, while indirectly increasing serum levels of BDNF, PF4 and dopamine. These factors synergistically protected against TBI. Altogether, we establish a bone-brain axis in which bone endocrine function can be modulated by mechanical forces to enhance brain repair after injury.
中文摘要:创伤性脑损伤(TBI)可加速骨愈合并诱导异位骨化,这引发了一个问题:受伤的脑是否能从骨中获益。本研究发现,动态胫骨轴向压缩加载(DCTAL)——一种胫骨骨压缩模型——可提高小鼠卒中及TBI后的生存率,并促进其运动与认知恢复,在猪TBI模型中亦然。DCTAL可减少TBI后的神经元丢失,减轻慢性炎症和星形胶质细胞增生,并刺激神经元再生。敲除骨细胞中的机械感受通道Piezo1可逆转这些益处,而来自DCTAL小鼠的血清可重现这些益处。骨细胞转导机械信号,直接分泌IL-1R2、APOL11a和HSP70等因子,同时间接提高血清中BDNF、PF4和多巴胺水平。这些因子协同保护免受TBI。总之,我们确立了一条骨-脑轴,其中骨的内分泌功能可被机械力调控,以增强损伤后的脑修复。

18糖尿病心血管 (1篇)

临床研究 (1篇)

Diabetes care IF 22.6 2026-9-21 PMID: 42765974
We aimed to explore the heterogeneity of empagliflozin treatment effects on major adverse cardiovascular events (MACE), hospitalization for heart failure (HHF), and all-cause mortality (ACM) across sociodemographic and cardiovascular disease (CVD) subgroups of adults with type 2 diabetes (T2D). Using 2014-2020 Medicare claims data, we examined rates of MACE (e.g., composite myocardial infarction, stroke, all-cause mortality [ACM]), HHF, and ACM among propensity score-matched individuals aged ≥65 years with T2D initiating empagliflozin compared with those prescribed dipeptidyl peptidase-4 inhibitors (DPP4is) and those prescribed GLP-1 receptor agonists (GLP-1RAs). We calculated hazard ratios (HRs) and incidence rate differences (IRDs) overall and by age, sex, race or ethnicity, socioeconomic factors, and baseline CVD. Empagliflozin was associated with decreased risk of MACE (HR 0.77, 99.9% CI [0.69, 0.85]; IRD = -10.3 [-14.1, -6.4]); HHF (HR 0.72 [0.67, 0.79]; IRD = -18.3 [-22.9, -13.6]); and ACM (HR 0.66 [0.57, 0.76]; IRD = -8.6 [-11.4, -5.8]) compared with DPP4is. Effect heterogeneity by baseline CVD was present across all outcomes on the IRD scale but only for HHF on the HR scale. Empagliflozin was also associated with decreased risk of HHF (HR 0.88 [0.81, 0.95]; IRD = -6.9 [-10.8, -3.1]) versus GLP-1RAs, with effect heterogeneity by baseline CVD on the IRD scale. No effect heterogeneity was observed by sociodemographic factors, although a numeric trend suggested greater absolute benefit in patients aged ≥75 years compared with those aged 65-74 years. Empagliflozin reduced cardiovascular events across sociodemographic and CVD subgroups compared with both DPP4is and GLP-1RAs, with higher absolute benefits observed in those with prevalent CVD.
中文摘要:我们旨在探讨恩格列净对2型糖尿病(T2D)成人患者主要不良心血管事件(MACE)、心力衰竭住院(HHF)和全因死亡(ACM)的治疗效应在不同社会人口学和心血管疾病(CVD)亚组中的异质性。利用2014-2020年Medicare索赔数据,我们在倾向评分匹配的年龄≥65岁、启动恩格列净治疗的T2D患者中,与处方二肽基肽酶-4抑制剂(DPP4is)和处方GLP-1受体激动剂(GLP-1RAs)的患者相比,分析了MACE(例如,复合心肌梗死、卒中、全因死亡[ACM])、HHF和ACM的发生率。我们计算了总体以及按年龄、性别、种族或民族、社会经济因素和基线CVD分层的风险比(HRs)和发病率差异(IRDs)。与DPP4is相比,恩格列净与MACE风险降低相关(HR 0.77,99.9% CI [0.69, 0.85];IRD = -10.3 [-14.1, -6.4]);HHF(HR 0.72 [0.67, 0.79];IRD = -18.3 [-22.9, -13.6]);以及ACM(HR 0.66 [0.57, 0.76];IRD = -8.6 [-11.4, -5.8])。在IRD尺度上,所有结局均存在按基线CVD的效应异质性,但在HR尺度上仅HHF存在效应异质性。与GLP-1RAs相比,恩格列净也与HHF风险降低相关(HR 0.88 [0.81, 0.95];IRD = -6.9 [-10.8, -3.1]),在IRD尺度上存在按基线CVD的效应异质性。未观察到按社会人口学因素的效应异质性,尽管数值趋势提示年龄≥75岁患者比65-74岁患者有更大的绝对获益。与DPP4is和GLP-1RAs相比,恩格列净在社会人口学和CVD亚组中均降低了心血管事件,在患有CVD的患者中观察到更高的绝对获益。

19基础/转化 (1篇)

基础研究 (1篇)

Pharmacological research IF 12.2 2026-9-20 PMID: 42764062
Duchenne Muscular Dystrophy (DMD) is a severe genetic disorder characterized by progressive skeletal muscle degeneration, chronic inflammation, fibrosis, and mitochondrial dysfunction. Although gene- and cell-based therapies hold great promise, significant limitations still restrict their broad application, highlighting the need for complementary pharmacological approaches targeting secondary pathological mechanisms. Histone deacetylase (HDAC) inhibitors and Sirtuin 1 (SIRT1) activators represent promising therapeutic strategies, as HDAC8 is involved in cytoskeletal remodeling, whereas SIRT1 mainly regulates mitochondrial metabolism and energy homeostasis. In this study, we investigated the therapeutic efficacy of combining selective HDAC8 inhibition (PCI-34051) with SIRT1 activation (SRT2104) in a zebrafish model of DMD. Combined treatment significantly improved muscle structure and function, reduced inflammatory cell recruitment, and enhanced mitochondrial activity compared with single-drug administration. Importantly, comparable therapeutic efficacy was achieved using reduced doses of both compounds. Proteomic and acetylomic analyses revealed distinct but complementary molecular signatures induced by the two treatments. HDAC8 inhibition predominantly modulated pathways associated with cytoskeletal organization, epigenetic regulation, ribosome biogenesis, and muscle structural remodeling, whereas SIRT1 activation mainly affected mitochondrial function, oxidative metabolism, amino acid catabolism, and cellular bioenergetics. Overall, these findings demonstrate that combined HDAC8 inhibition and SIRT1 activation effectively ameliorate key pathological features of DMD in zebrafish and provide mechanistic insights into the complementary pathways targeted by the two compounds. This work supports the development of combinatorial epigenetic strategies as potential therapeutic approaches for DMD.
中文摘要:杜氏肌营养不良(DMD)是一种严重的遗传性疾病,其特征为进行性骨骼肌退化、慢性炎症、纤维化和线粒体功能障碍。尽管基因治疗和细胞治疗前景广阔,但显著局限仍限制其广泛应用,这凸显出需要针对继发性病理机制的补充性药物治疗策略。组蛋白去乙酰化酶(HDAC)抑制剂和Sirtuin 1(SIRT1)激活剂是有前景的治疗策略,因为HDAC8参与细胞骨架重塑,而SIRT1主要调节线粒体代谢和能量稳态。在本研究中,我们在DMD斑马鱼模型中研究了选择性HDAC8抑制(PCI-34051)与SIRT1激活(SRT2104)联合治疗的效果。与单药给药相比,联合治疗显著改善肌肉结构和功能,减少炎症细胞募集,并增强线粒体活性。重要的是,使用两种化合物的降低剂量即可达到相当的治疗效果。蛋白质组学和乙酰化组学分析显示,两种治疗诱导了不同但互补的分子特征。HDAC8抑制主要调节与细胞骨架组织、表观遗传调控、核糖体生物发生和肌肉结构重塑相关的通路,而SIRT1激活主要影响线粒体功能、氧化代谢、氨基酸分解代谢和细胞生物能量学。总体而言,这些发现表明,联合抑制HDAC8和激活SIRT1可有效改善斑马鱼DMD的关键病理特征,并提供了两种化合物所靶向互补通路的机制见解。这项工作支持将组合表观遗传策略开发为DMD的潜在治疗方法。

20铁过载/血色病 (1篇)

基础研究 (1篇)

Cell death & disease IF 12.2 2026-9-20 PMID: 42763343
A long-standing clinical conundrum is the pronounced phenotypic heterogeneity of hereditary hemochromatosis. Patients with identical HFE genotypes and similar degrees of iron overload can have vastly different clinical outcomes, ranging from being completely asymptomatic to developing severe cirrhosis, diabetes, or cardiomyopathy. This variability strongly implies the existence of genetic or environmental modifiers that dictate disease penetrance. Here, copper may be a compelling disease-modifying candidate, due to its intimately intertwined metabolism with iron. Indeed, profound iron loading in hemochromatosis mice (Hfe knockout) and hemochromatosis Huh7 hepatocytes does not cause overt toxicity. However, the addition of copper, even in trace amounts and harmless on its own, dramatically amplifies adverse effects to induce profound cell toxicity. We find that copper-provoked iron vulnerability is not driven by Fenton chemistry-driven ROS damage, but instead induces a cuproptotic-like mechanism, characterized by proteotoxic stress, loss of iron-sulfur cluster enzyme activity, and severe mitochondrial dysfunction. Remarkably, high-affinity copper chelation rescued Huh7 cells, whereas inhibition of other canonical cell death pathways did not. These findings spotlight copper as a critical modifier in iron overload toxicity, capable of converting largely compensated iron overload into severe cellular injury and death, thereby providing a mechanistic explanation for the phenotypic heterogeneity in hemochromatosis.
中文摘要:遗传性血色病的一个长期临床难题是其显著的表型异质性。具有相同HFE基因型且铁过载程度相似的患者,其临床结局可截然不同,从完全无症状到发生严重肝硬化、糖尿病或心肌病。这种变异性强烈提示存在决定疾病外显率的遗传或环境修饰因素。在此,铜可能是一个引人注目的疾病修饰候选因子,因为其代谢与铁密切交织。事实上,血色病小鼠(Hfe敲除)和血色病Huh7肝细胞中严重的铁负荷并未引起明显毒性。然而,加入铜,即使仅痕量且其本身无害,也会显著放大不良效应,诱导严重的细胞毒性。我们发现,铜所引发的铁易感性并非由Fenton化学驱动的ROS损伤所致,而是诱导了一种类似铜死亡的机制,其特征为蛋白质毒性应激、铁硫簇酶活性丧失以及严重的线粒体功能障碍。值得注意的是,高亲和力铜螯合可挽救Huh7细胞,而抑制其他经典细胞死亡通路则不能。这些发现凸显了铜在铁过载毒性中的关键修饰作用,能够将很大程度上已代偿的铁过载转化为严重的细胞损伤和死亡,从而为血色病的表型异质性提供了机制解释。

21心肺疾病 (1篇)

临床研究 (1篇)

Nature communications IF 18.1 2026-9-18 PMID: 42754610
Increasing wildfire activity in the US has made wildfire-specific fine particulate matter (PM2.5) an important and growing source of air pollution, yet its long-term health impacts and relative toxicity compared with non-wildfire PM2.5 remain unclear. Using a self-controlled design, we examine associations between 2-year average wildfire-specific and non-wildfire PM2.5 and cardiopulmonary hospitalization risks across 20 US states during 2006-2019. Per 1 µg/m3 increase, wildfire-specific PM2.5 is associated with significantly higher hospitalization risks for all cardiopulmonary diseases, with relative risks ranging from 10% for heart failure to 16% for asthma. In contrast, a 1-µg/m3 increase in non-wildfire PM2.5 is associated with smaller risk elevations, ranging from 4.7% for chronic obstructive pulmonary disease to 8.5% for hypertension. Stronger associations for both wildfire-specific and non-wildfire PM2.5 are observed among minorities, metropolitan residents, those with fewer years of education, and more deprived communities. Overall, at an equivalent concentration increase, long-term exposure to wildfire-specific PM2.5 poses greater cardiopulmonary hospitalization risks than non-wildfire PM2.5, underscoring wildfire smoke as a growing public health threat that requires targeted mitigation alongside conventional air quality control strategies.
中文摘要:美国日益增多的野火活动使野火特异性细颗粒物(PM2.5)成为重要且不断增长的大气污染来源,但其长期健康影响以及与野火无关PM2.5相比的相对毒性仍不清楚。我们采用自身对照设计,考察2006—2019年美国20个州2年平均野火特异性PM2.5和非野火PM2.5与心肺住院风险之间的关联。PM2.5每增加1微克/立方米,野火特异性PM2.5与所有心肺疾病住院风险显著升高相关,相对风险从心力衰竭的10%到哮喘的16%不等。相比之下,非野火PM2.5每增加1微克/立方米与较小的风险升高相关,从慢性阻塞性肺疾病的4.7%到高血压的8.5%不等。在少数族裔、大都市居民、受教育年限较少者以及更贫困社区中,野火特异性PM2.5和非野火PM2.5均观察到更强的关联。总体而言,在浓度增加相同的情况下,长期暴露于野火特异性PM2.5比非野火PM2.5带来更高的心肺住院风险,凸显野火烟雾是日益严重的公共卫生威胁,需要在常规空气质量控制策略之外采取有针对性的缓解措施。

22新生儿窒息 (1篇)

基础研究 (1篇)

Stroke IF 11.1 2026-9-17 PMID: 42751786
Metabolic and neurovascular disturbances contribute to brain injury after birth asphyxia. We previously showed that plasma feeding attenuated neuropathology after transient umbilical cord occlusion in piglets. This study explored the metabolic and molecular consequences of birth asphyxia and whether plasma feeding preserves metabolic homeostasis and brain barrier integrity. Piglets (n=89) delivered by cesarean section on gestational day 113 underwent umbilical cord occlusion (asphyxia) or remained nonasphyxiated (control). Asphyxia and control piglets were randomly assigned to receive formula reconstituted with either water (vehicle-treated group) or sow plasma (plasma-treated group). Animals were euthanized at 1 hour, 24 hours, or day 4 after insult. Cerebrospinal fluid metabolites were profiled by untargeted liquid chromatography-mass spectrometry metabolomics at 24 hours. Expression of metabolite transporters and structural components of the blood-brain barrier in the caudate nucleus and the blood-cerebrospinal fluid barrier at the choroid plexus was assessed by reverse transcription quantitative polymerase chain reaction and Western blotting. The CSF/plasma Na+ ratio was assessed, and cell-specific AQP4 expression was confirmed with RNAscope. Data were analyzed using linear and linear mixed-effects models. Birth asphyxia dysregulated the CSF metabolic profile, with reductions in multiple metabolites and increases in a smaller subset, consistent with impaired amino acid and lipid metabolism. This was accompanied by reduced expression of substrate transporters, including xCT, LAT1, ASCT2, FATP1, CAV1, and MCTs. In the caudate nucleus, expression of blood-brain barrier structural proteins and ion transporters, including Na+/K+-ATPase, was reduced, whereas the choroid plexus blood-CSF barrier remained largely preserved. Plasma feeding partially restored transporter expression at both brain interfaces and increased AQP4 and ion transporter expression at the blood-brain barrier by day 4. Increased VE-cadherin (vascular endothelial cadherin) and ZO-1 (zonula occludens-1) expression and elevated CSF Na+ concentrations suggested early modulation of the integrity of the 2 brain barriers. Plasma feeding preserves metabolic homeostasis and supports brain barrier integrity after birth asphyxia, highlighting plasma-derived factors as potential therapeutic targets to reduce neurodevelopmental impairment after perinatal asphyxia.
中文摘要:代谢和神经血管紊乱会加重新生儿窒息后的脑损伤。我们此前表明,在仔猪短暂脐带闭塞后,血浆喂养可减轻神经病理学改变。本研究探讨了出生窒息后的代谢与分子后果,以及血浆喂养是否能维持代谢稳态和脑屏障完整性。妊娠第113天经剖宫产分娩的仔猪(n=89)接受脐带闭塞(窒息)或保持非窒息状态(对照)。窒息和对照仔猪被随机分配接受用水(载体处理组)或母猪血浆(血浆处理组)配制的配方奶。动物在损伤后1小时、24小时或第4天实施安乐死。24小时时通过非靶向液相色谱-质谱代谢组学分析脑脊液代谢物。通过逆转录定量聚合酶链反应和蛋白免疫印迹评估尾状核中代谢物转运体及血脑屏障结构组分的表达,以及脉络丛处血-脑脊液屏障的这些指标。评估脑脊液/血浆Na+比值,并用RNAscope确认细胞特异性AQP4表达。数据采用线性模型和线性混合效应模型分析。出生窒息导致脑脊液代谢谱失调,多种代谢物减少,少数代谢物增加,与氨基酸和脂质代谢受损一致。这伴随底物转运体表达降低,包括xCT、LAT1、ASCT2、FATP1、CAV1和MCTs。在尾状核中,血脑屏障结构蛋白和离子转运体表达降低,包括Na+/K+-ATPase,而脉络丛血-脑脊液屏障大体保持完好。血浆喂养部分恢复了两个脑界面的转运体表达,并在第4天增加了血脑屏障中AQP4和离子转运体表达。VE-cadherin(血管内皮钙黏蛋白)和ZO-1(闭锁小带蛋白-1)表达增加以及脑脊液Na+浓度升高,提示两个脑屏障的完整性在早期受到调节。血浆喂养可维持代谢稳态并支持出生窒息后的脑屏障完整性,突出血浆来源因子作为潜在治疗靶点,以减少围产期窒息后的神经发育损害。

23动脉粥样硬化 (1篇)

基础研究 (1篇)

Signal transduction and targeted therapy IF 81.2 2026-9-17 PMID: 42749708
Atherosclerotic plaque rupture is a major cause of myocardial infarction and stroke, yet the mechanisms governing plaque stability remain incompletely understood. Endothelial activation can trigger endothelial-to-mesenchymal transition, a program linked to endothelial dysfunction and lesion vulnerability. Here we investigated whether transcriptional pause release and RNA polymerase II elongation constitute an early regulatory layer that promotes endothelial-to-mesenchymal transition and atherosclerosis. Analysis of human plaque single-cell transcriptomics indicated increased expression of super elongation complex components in endothelial cells with a transition signature. In primary human endothelial cell models, pharmacological inhibition of the super elongation complex attenuated the induction of mesenchymal markers. AFF4, pCDK9, and pSMAD2/3 showed physical interaction during endothelial transition. Genome-wide profiling of RNA polymerase II occupancy revealed reduced promoter-proximal pausing during early transition, accompanied by a rapid increase in nascent transcriptional elongation rates. Super elongation complex inhibition restored pausing and suppressed fast-responding transition-associated target genes. In a human cardiac organoid model, inhibition of the super elongation complex prevented EndMT-induced fibrillar collagen deposition and prevented the loss of beating rate. In a hyperlipidemic Pcsk9 gain-of-function mouse model, super elongation complex inhibition administered both prophylactically and therapeutically after established atherosclerosis reduced plaque burden and reduced features of plaque vulnerability. Finally, analysis of 1048 human plaque segments from the Athero-Express biobank showed significant associations between the elongation axis and multiple vulnerability-related plaque traits. Together, these findings identify rapid transcriptional elongation as a mechanistic driver of endothelial plasticity and features of plaque vulnerability and support targeting the elongation machinery as a potential strategy to reduce features of plaque vulnerability in atherosclerotic disease.
中文摘要:动脉粥样硬化斑块破裂是心肌梗死和卒中的主要原因,但决定斑块稳定性的机制仍未被完全理解。内皮激活可触发内皮-间充质转化,这一程序与内皮功能障碍和病变易损性相关。在此,我们研究了转录暂停释放和RNA聚合酶II延伸是否构成促进内皮-间充质转化和动脉粥样硬化的早期调控层。对人类斑块单细胞转录组学的分析表明,具有转化特征的内皮细胞中超级延伸复合物组分表达增加。在原代人内皮细胞模型中,药物抑制超级延伸复合物减弱了间充质标志物的诱导。AFF4、pCDK9和pSMAD2/3在内皮转化过程中表现出物理相互作用。对RNA聚合酶II占位的全基因组分析显示,早期转化期间启动子近端暂停减少,同时新生转录延伸速率迅速增加。抑制超级延伸复合物恢复了暂停,并抑制了快速响应的转化相关靶基因。在人心脏类器官模型中,抑制超级延伸复合物阻止了EndMT诱导的纤维状胶原沉积,并阻止了搏动频率的丧失。在高脂血症Pcsk9功能获得小鼠模型中,无论预防性给药还是在已形成动脉粥样硬化后进行治疗性给药,抑制超级延伸复合物均减少了斑块负荷,并减少了斑块易损性特征。最后,对来自Athero-Express生物样本库的1048个人类斑块片段进行分析显示,延伸轴与多种易损性相关斑块特征存在显著关联。总之,这些发现将快速转录延伸确定为内皮可塑性和斑块易损性特征的机制驱动因素,并支持将延伸机制作为减轻动脉粥样硬化疾病中斑块易损性特征的潜在策略。